 
Protocol J2A -MC-GZGI(a)  
 
 
A Phase [ADDRESS_272144] 
Obesity or Are Overweight with Weight -Related  Comorbidities  
 
[STUDY_ID_REMOVED] 
 
Approval Date: 27 -Sep-2021 
 
 
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
1Title Page
Confidential Information
The information contained in this document is confidential and is intended for the use of clinical investigators. It is the p roperty of 
Eli Lilly and Company or its subsidiaries and should not be copi[INVESTIGATOR_104441]3502970 , unless such persons are bound by a confidentiality agreement with Eli Lilly and Company or its 
subsidiaries . 
Note to Regulatory Authorities: This document may contain protected personal data and/or commercially confidential information 
exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public re lease. 
In the [LOCATION_002], this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or 
otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries .
Protocol Title: A Phase [ADDRESS_272145] Obesit y or Are Overweight with Weight -Related 
Com orbidi ties
Protocol Number: J2A-MC-GZGI
Amendment Number: a
Compound :LY3502970
Brief Title: Effect of LY3502970 versus Placebo in Participants Who Have Obesit y or Are 
Overweight
Study Phase: 2
Sponsor Name: [CONTACT_32868]: Indianapo lis, Indiana, [LOCATION_003] [ZIP_CODE]
Regulatory Agency Identifier Numbers
IND: [ADDRESS_272146]: 2021-002805 -88
Approval Date: Protocol Amendment (a) Electronically Signed and Approved by [CONTACT_41378].
Approval Date: 27-Sep-2021 GMT
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
2Medical Monitor Name [CONTACT_9352] [CONTACT_17055] .
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
3Protocol Amendment Summary of Changes Table
DOCUMENT HISTORY
Document Date
Original Protocol 21-Jun -2021
Amendment [a] 
This amendment is considered to be nonsubstant ial.
Overall Rationale for the Amendment:
The m ain rati onale of the am endment is to incorporate regulatory  agency  recommendations and 
correct typographical erro rs.
Section # and Name [CONTACT_23688]
1.3.Schedule of 
ActivitiesAdded visit window to Visit 801 .
Changed 3 sitting BP and PR 
measurement sto 2 sitting BP and PR 
measurement s.Correction of o versight in the original 
protocol
3. Objectives, 
Endpoints, and 
EstimandsRem oved Week 36 from the ABPM 
endpointsABPM is not collected at Week 36
4.1.1 .Overview of 
Study PeriodsChanged dose -escalatio n period up to 
Visit 12 instead of Visit 11Oversight in the original protocol
5.1.Exclusion Criteria Added that participants who are 
receiving strong CYP3A inducers
should be excluded (Exclusion 
Criterio n#52)Recommendation from regulatory agency
6.5.Dose Modification
7.1.[ADDRESS_272147] of strong CYP3A inducersRecommendation from regulatory agency
7.1.2 .QTc Stoppi[INVESTIGATOR_226347]
7.1.4 Restarting Study 
Drug after Interruption 
or Missed DosesChanged wording regarding 
restarting study drug through IWRSCorrection of mistake in the original protocol
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
4Section # and Name [CONTACT_23688]
8.1. Efficacy 
AssessmentsRem oved ABPM measurements and 
lipi[INVESTIGATOR_226348]
9.3.1. Statistical 
Analy sis: General 
ConsiderationsBMI stratum will be included inthe 
model for the analysis of body weightInclusion of discretized strata based on the 
continuous variable 
Added that additional supplemental 
estimand may be explored for the 
primary and secondary  efficacy 
endpointsRecommendation from r egulatory agency
Changed longitudinal logistic 
regression model to logistic 
regression model A simulation has shown that logistic 
regression with missing values imputed with 
multiple imputations can lead to smaller 
variance estimates than longitudinal logistic 
regression and the analysis was updated 
accordingly
9.3.3. Statistical 
Analy sis: Secondary  
Endpoint(s)/Estimand(s) 
Analy sisChanged longitudinal logistic 
regression to logistic regression with 
multiple imputationA simulation has shown that logistic 
regression with missing values imputed with 
multiple imputations can lead to smaller 
variance estimates than longitudinal logistic 
regression and the analysis was updated 
accordingly
Deletion of additional supplemental 
estimand analysisRecommendation from r egulat oryagency
10.11. Appendix 11 Local laboratory Testing Option: 
Central laboratory testing must be 
retained for: Visit 3, 10, and 15 
instead of Visit 3, 11, and 16.Correction o f oversight in the original 
protocol
Through out the prot ocol Minor editorial changes made 
throughout the protocolCorrection
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
5Table of Contents
1. Protocol Summary ...................................................................................................... [ADDRESS_272148] ivities (SoA) ...................................................................................... 12
2. Introduction .............................................................................................................. 18
2.1. Study  Rati onale .......................................................................................................... 18
2.2. Background ................................................................................................................ 18
2.3. Benefit/Risk Assessment ............................................................................................ [ADDRESS_272149] yle Considerat ions............................................................................................. 40
5.4. Screen Failures ........................................................................................................... 40
5.5. Criteria for Tem porarily  Delaying 
Enrollment/Rando mizat ion/Administrati on of  Study  Intervent ion 
of a Parti cipant ........................................................................................................... 41
6. Study Intervention(s) and Concomitant Therapy ................................................... 42
6.1. Study  Intervent ion(s) Administered ............................................................................ 43
6.2. Preparati on, Handling, Storage, and Accountabilit y.................................................... 43
6.3. Measures to Minimize Bias: Rando mizat ion and Blinding .......................................... 44
6.4. Study  Intervent ion Compliance ................................................................................... 44
6.5. Dose Modificat ion...................................................................................................... 45
6.6. Continued Access to Study  Intervent ion after the End of the 
Study .......................................................................................................................... 45
6.7. Treatment of Overdose ............................................................................................... 45
6.8. Concomitant Therapy .................................................................................................46
6.8.1. Management of Participants with Gastrointestinal Symptoms ..................................... 48
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal .................................................................................... 50
7.1. Discontinuati on of  Study  Intervent ion........................................................................ 50
7.1.1. Liver Chemistry  Stoppi[INVESTIGATOR_226349].............................................................................. 51
7.1.2. QTc Stoppi[INVESTIGATOR_2121] .................................................................................................51
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
67.1.3. Temporary  Discont inuat ion........................................................................................ 52
7.1.4. Restarti ng Study  Drug after Interruption or Missed Doses .......................................... 52
7.2. Parti cipant Discontinuation/Wit hdrawal fro m the Study ............................................. [ADDRESS_272150] to Follow -Up...................................................................................................... 53
8. Study Assessments and Procedures ......................................................................... 54
8.1. Efficacy Assessments .................................................................................................54
8.2. Safety Assessments .................................................................................................... 54
8.2.1. Physical Examinat ions................................................................................................ 54
8.2.2. Vital Signs.................................................................................................................. 55
8.2.3. Electro cardiograms ..................................................................................................... 55
8.2.4. Ambulatory  Blood Pressure Moni toring (ABPM) ....................................................... [ADDRESS_272151] .............................................................................. 63
8.4. Pharmacokinet ics........................................................................................................ 69
8.5. Pharmacodynamics ..................................................................................................... 69
8.6. Genet ics..................................................................................................................... 70
8.7. Biomarkers ................................................................................................................. 70
8.8. Immunogenicit y Assessments ..................................................................................... 70
8.9. Heal th Economics ....................................................................................................... 70
9. Statistical Considerations ......................................................................................... 71
9.1. Statistical Hypotheses .................................................................................................71
9.1.1. Multiplicity Adjustm ent.............................................................................................. 71
9.2. Analyses Sets ............................................................................................................. 71
9.3. Statistical Analyses ..................................................................................................... 71
9.3.1. General Considerations ............................................................................................... 71
9.3.2. Primary Endpo int(s)/Estimand(s) Analysis .................................................................73
9.3.3. Secondary  Endpo int(s)/Estimand(s) Analysis .............................................................. 73
9.3.4. Terti ary/Exploratory  Analysis ..................................................................................... 74
9.3.5. Other Safet y Analyses ................................................................................................ 74
9.3.6. Pharmacokinet ic/Pharmacodynamic Analyses ............................................................ 75
9.4. Interim Analysis ......................................................................................................... 75
9.5. Sample Si ze Determinat ion......................................................................................... 76
10. Supporting Documentation and Operational Considerations ................................ 77
10.1. Appendix 1: Regulatory , Ethical , and Study  Oversight 
Considerations ............................................................................................................ 77
10.1.1. Regulatory  and Ethi calConsiderat ions........................................................................ 77
10.1.2. Inform ed Consent Process .......................................................................................... 77
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
710.1.3. Data Protection ........................................................................................................... [ADDRESS_272152] igator Informat ion............................................................................................. 82
10.2. Appendix 2: Clinical Laboratory  Tests ........................................................................ 83
10.3. Appendix 3: Adverse Events and Serious Adverse Events: 
Definit ions and Procedures for Recording, Evaluating, Fo llow-
Up, and Reporting ...................................................................................................... [ADDRESS_272153] Complaint s............................................................................... 89
10.3.4. Recording and Fo llow-Up of AE and/or SAE and Product 
Com plaint s................................................................................................................. 89
10.3.5. Reporting of SAEs ...................................................................................................... 91
10.3.6. Regulatory  Reporting Requirements ........................................................................... 92
10.4. Appendix 4: Contraceptive and Barrier Guidance ....................................................... 93
10.4.1. Definit ions.................................................................................................................. 93
10.4.2. Contraception Guidance .............................................................................................. 94
10.5. Appendix 5: Liver Safet y: Suggested Actions and Follow -Up 
Assessments ............................................................................................................... 96
10.6. Appendix 6: [LOCATION_001] Heart Associat ion Funct ional 
Classificat ion of Heart Failure .................................................................................... 97
10.7. Appendix 7: Protocol GZGI Standardized Protocols for the 
Measurement of Height, Weight, Wais t Circumference and Vital 
Signs.......................................................................................................................... 98
10.8. Appendix 8: Diet and Physical Act ivity Suggest ions for Sites 
without Programs ..................................................................................................... [ADDRESS_272154] ivity...................................................................................................... 100
10.9. Appendix 9: Patient -Reported Outcomes .................................................................. 102
10.10. Appendix 10: Country -Specific Requirements .......................................................... 104
10.11. Appendix 11: Provisio ns for Changes in Study  Conduct during 
Except ional Circumstances ....................................................................................... 105
10.12. Appendix 12: Abbreviat ions and Definit ions............................................................ 109
11. References ............................................................................................................... 113
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
81. Protocol Summary
1.1. Synopsis
Protocol Title: A Phase [ADDRESS_272155] Obesit y or Are Overweight with Weight -Related 
Com orbidi ties
Brief Title: Effect of LY3502970 versus Placebo in Participants Who Have Obesit y or Are 
Overweight
Rationale :
LY3502970 is an oral non- pepti de glucagon -like peptide -1 (GLP -1)receptor agonist that is being 
developed as a daily  oral adjunct therapy  to di et and physical act ivity to improve weight 
management in adults who have obesit y or are overweight with weight -related comorbidit ies. 
Unlike the peptide GLP -1 receptor agoni stsapproved by  [CONTACT_226371], LY3502970 is a 
small mo lecule being developed for daily oral administration.
Study  J2A-MC-GZGI (GZGI) is a [ADDRESS_272156] one dose of LY3502970 is superior to 
placebo inpercent body  weight reduction . This study  is designed to inform the dose sel ection 
and dose escalat ion scheme for Phase 3 studi es.
Objectives and Endpoint s:
Objectives Endpoints 
Primary
To demonstrate that at least one dose level of QD oral 
LY3502970 is superior in percent body weight 
reductio n relative to placebo Percent change in body weight (kg) from 
baseline at Week 26
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
9Secondary
To compare the effect of QD LY3502970 versus 
placebo on body weightPercent change in body weight (kg) from 
baseline at Week 36
Change in body weight (kg) from baseline at 
Week 26 and Week 36
Percentage of study participants who achieve
o≥5% body weight (kg) reductio n
o≥10% body weight (kg) reductio n
  at Week 26 and Week 36
Change in BMI (kg/m2) from baseline at 
Week [ADDRESS_272157] circumference Change in waist circumference (cm) from 
baseline at Week 26 and Week 36
To assess safety and tolerability of study interventionsAEsoverall
AEs of special interest
Laborato ry parameters
Electrocardiogram
Vital signs
To assess the PK of LY3502970 and potential 
participant factors that may influence its PKPopulation PK parameters
Abbreviations: AEs= adverse events : BMI =body mass index; QD =once daily; PK =pharmacokinetics .
Brief Summary:
The purpose of this study  is to m easure the change in body  weight withoral daily doses of 
LY3502970 compared wit h placebo in parti cipants wi th obesi ty or overwei ght wi th weight -
related com orbidities.
Study  details include
●The study  durati on will be up to 40 weeks .
● The treatment duration will be up to 36 weeks.
Number of Participant s:
Approximately  350participants will be screened to achieve 270rando mly assigned to study  
intervent ion.An upper limit of 65% enrollment of women will be used to ensure a sufficiently 
large sample of men.
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
10Intervention Groups and Duration :
The durati on of  study parti cipat ion for each participant will be approximately [ADDRESS_272158] of an approximately 2 -week screening/lead -in period fo llowed by  a 36 -week 
treatm ent peri od. There will also be a 2 -week off-drug safet y follow-up period.
During the treatment period, doses will be escalated for all treatm ent groups. The dose escalation 
period will range fro m 0 to 16 weeks depending on dose group. LY3502970 or matching placebo 
will be administered daily  by [CONTACT_226372].
Data Monitoring Commi ttee: No
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
111.2. Schema
Abbreviations: LY =LY3502970 ; LY1 =LY 12 mg; LY2 =LY 24 mg; LY3 =LY 36 mg; LY4 =LY 45 mg

CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
121.3. Schedule of Activities (SoA)
The Schedule o f Activities described below should be fo llowed for all participants enrolled in Study  GZG I. However, for those 
participants whose participat ion in this study  is affected by  [CONTACT_31087] ,such as pandemics or natural disasters, please 
refer to Section 10.11 (Appendix 11) for addit ional guidance.
Study Period I
Screening/Lead -inStudy Period II
Treatment Period
For early terminations that occur before the last visit in treatment period, see the a ctivities listed 
for ETin this table. Shaded columns represent the dose escalation period Weeks 0- 16.Study 
Period 
III 
Safety 
Follow -
Up
Screening Lead
-In
Visit Number [ADDRESS_272159] End 
of TXP
Allowable Interval 
Tolerance (days)- ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 - ±3
Fasting Visit X X X X X X X X X X X X X X X X X X X
Administrative
Informed consent X
Inclusion and exclusion 
criteria review X X
Demographics X
Preexisting conditions 
and medical historyX X
Concomitant 
medicationsX X X X X X X X X X X X X X X X X X X X
Substance use (alcohol, 
caffeine, tobacco use)X
Adverse events (AEs) X X X X X X X X X X X X X X X X X X X X
Physical Evaluation
Height X
Weight X X X X X X X X X X X X X X X X X X X
Waist circumference X X X X X X X X X X X X
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
13Study Period I
Screening/Lead -inStudy Period II
Treatment Period
For early terminations that occur before the last visit in treatment period, see the a ctivities listed 
for ETin this table. Shaded columns represent the dose escalation period Weeks 0- 16.Study 
Period 
III 
Safety 
Follow -
Up
Screening Lead
-In
Visit Number [ADDRESS_272160] End 
of TXP
Allowable Interval 
Tolerance (days)- ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 - ±3
Fasting Visit X X X X X X X X X X X X X X X X X X X
Vital signs (2sitting BP
and PRmeasurements)X X X X X X X X X X X X X X X X X X X X
Vital signs include pulse rate, blood pressure, and temperature. Vital sign measurements should be collected after participant has been sitting for at 
least 5 minutes and before obtaining an ECG tracing and before collection of blood samples for laboratory testing ( see Section 10.7 ).
Physical examination X
Symptom -directed 
physical examinationX X X X X X X X X X X X X X X X X X
As indicated based on participant status and standard of care. May be performed by [CONTACT_81239].
12-Lead ECG X X X X X X X X X
Single central ECGs will be performed at screening and early termination. Central ECGs should be collected in triplicate at a ll other visits. ECG should be 
collected prior to collection of blood samples, including PK samples. ECG measurements should be obt ained per the instructions in Section 8.2.[ADDRESS_272161] ABPM 
measurementsX X
At the time participant visit data are uploaded by [CONTACT_779], the ABPM Data Validity Report will be generated and should be reviewed to ensure ≥70% of 
readings are valid. If <70% of re adings are valid, the 24 -hour monitoring session should be repeated within the visit window.
Participant Education 
Explain diet and physical 
activity planX X X X X
May be performed more frequently based on usual site practices and participant needs .

CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
14Study Period I
Screening/Lead -inStudy Period II
Treatment Period
For early terminations that occur before the last visit in treatment period, see the a ctivities listed 
for ETin this table. Shaded columns represent the dose escalation period Weeks 0- 16.Study 
Period 
III 
Safety 
Follow -
Up
Screening Lead
-In
Visit Number [ADDRESS_272162] End 
of TXP
Allowable Interval 
Tolerance (days)- ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 - ±[ADDRESS_272163] X X X X X
PGIS for Physical Activity X X X X X
Participant SurveyX X
The Participant Survey should be administered at early termination if it occurs before 26 weeks .
Clinician -Administered Assessments (Paper)
Patient Health 
Questionnaire -9 (PHQ -9)X X X X X X X
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
15Study Period I
Screening/Lead -inStudy Period II
Treatment Period
For early terminations that occur before the last visit in treatment period, see the a ctivities listed 
for ETin this table. Shaded columns represent the dose escalation period Weeks 0- 16.Study 
Period 
III 
Safety 
Follow -
Up
Screening Lead
-In
Visit Number [ADDRESS_272164] End 
of TXP
Allowable Interval 
Tolerance (days)- ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 - ±3
Fasting Visit X X X X X X X X X X X X X X X X X X X
C-SSRS 
screening/ baselineX
C-SSRS since last visit X X X X X X X X X X X X X X X X X X
Laboratory Tests and Sample Collections
Hematology X X X X X X
Hemoglobin A1c 
(HbA1c)X X X X X X
Clinical chemistry X X X X X X X X
Lipid panel X X X X X X X
Urinalysis X X X X X
Serum pregnancy X
Follicle -stimulating 
hormone (FSH)X
Collect serum estradiol, FSH, and LHin women whose menopausal status needs to be determined. For participants known to be either premenopausal 
or postmenopausal, these tests do not need to be collected.
Luteinizing hormone
(LH)X
Estradiol X
Glucagon X X
C-peptide X X
Calcitonin X X X X X X
Pancreatic amylase X X X X X X
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
16Study Period I
Screening/Lead -inStudy Period II
Treatment Period
For early terminations that occur before the last visit in treatment period, see the a ctivities listed 
for ETin this table. Shaded columns represent the dose escalation period Weeks 0- 16.Study 
Period 
III 
Safety 
Follow -
Up
Screening Lead
-In
Visit Number [ADDRESS_272165] End 
of TXP
Allowable Interval 
Tolerance (days)- ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 - ±3
Fasting Visit X X X X X X X X X X X X X X X X X X X
Lipase X X X X X X
HIV screening tests X
Hepatitis C Virus (HCV) 
screening testsX
Hepatitis B Virus (HBV) 
screening testsX
Pro-C3 X X X
High sensitivity CRP X X
Apo B and Apo C3 X X
Leptin X X
Cytokeratin 18 X X
eGFR (CKD -EPI) X X X X
Urinary 
albumin/creatinine ratio 
(UACR)X X X X
Pharmacokinetic (PK) 
samplePredose X X X X X
Postdose X X X X X
PK predose sample should be collected predose (~up to 1 hour predose).
PK postdose sample time windows: 3 -6 hours postdose (Week 4);6-12 hours postdose (Week 8), 1- 3 hours postdose (Week 16), 3-6 hours postdose 
(Week 26).
Participants may need to return to clinical site for additional PK -specific visits to provide postdose PK samples .

CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
17Study Period I
Screening/Lead -inStudy Period II
Treatment Period
For early terminations that occur before the last visit in treatment period, see the a ctivities listed 
for ETin this table. Shaded columns represent the dose escalation period Weeks 0- 16.Study 
Period 
III 
Safety 
Follow -
Up
Screening Lead
-In
Visit Number [ADDRESS_272166] End 
of TXP
Allowable Interval 
Tolerance (days)- ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 - ±3
Fasting Visit X X X X X X X X X X X X X X X X X X X
Stored Samples
Exploratory biomarker 
samples X X X X X
Randomization and Dosing 
IWRS X X X X X X X X X X X X X X X X X X X X
Randomization X
Dispense study 
intervention capsules X X X X X X X X X X X X X
One bottle of capsules is to be dispensed at Visit 3 and at Visit 4. Two bottles of capsules are to be 
dispensed at Visits 5-9 (during the rest of the dose escalation period). The site pharmacy should 
clearly label which bottle to take first. At Visits 10 -17, 4 bottles of capsules should be dispensed. 
Participant returns 
unused study drugX X X X X X X X X X X X X
Assess drug compliance X X X X X X X X X X X X X X
Abbreviations : ABPM = ambulatory blood pressure monitoring; AEs =adverse events; BP =blood pressure; C -SSRS =Columbia Suicide Severity Rating 
Scale; CKD -EPI=chronic kidney disease epi[INVESTIGATOR_623]; ECG =electrocardiogram; eGFR = estimated glomerular filtration rate ; ET=early termination; 
FSH =follicle -stimulating hormone; HbA1c =hemoglobin A1c; HBC =hepatitis B virus; HCV =hepatitis C virus; IWQOL -Lite- CT=Impact of Wei ght o n 
Quality  of Life -Lite Clinical Trials Version; IWRS =interactive web -response sy stems; PGIS for Physical Activity =Patient Global Impression of Status for 
Physical Activity; PHQ -9 = Patient Health Questionnaire -9; PK =pharmacokinetic; SF -36v2 acut e form =Short Form 36 Version 2 health survey; PR = pulse 
rate; TXP =treatment; UACR =urinary albumin creatinine ratio; Wks =week s
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
182. Introduction
2.1. Study Rationale
LY3502970 is an oral non- pepti de GLP -[ADDRESS_272167] (GLP -1 RA) that is being developed 
as a daily  oral adjunct therapy  to di et and physical activit yto improve wei ght management in 
adults who have obesit y or are overwei ght with weight related comorbidit ies. Unlike the peptide 
GLP -[ADDRESS_272168] sapproved by  [CONTACT_226373] -date, LY3502970 is a small mo lecule being 
developed for daily  oral administrati on.  
Study  J2A-MC-GZGI (GZGI )is a 36-week Phase 2, multicenter , randomized, double -blind, 
placebo -controlled study  designed to examine the efficacy  and safety  of 4dose l evels of Q D
administered LY [ADDRESS_272169] activit y for GLP -1receptor . To date, no off -
target toxicit y has been identified in the clinical studies.
The GLP -1 RAs are highly effective peptide drugs that mimic the incretin hormone GLP -1
(Werner et al. 2010; Lau et al. 2015; Scheen 2017) . The horm one is secreted fro m the intestine 
upon food consumpt ion, and its effects include augmented glucose -dependent insulin secret ion, 
prolonged sat iety, reduced glucagon release, and delayed gastric e mptying (Bayliss andStarling
1902; Baggio and Drucker 2007; Nauck et al. 1997) . The GLP -1RAs have demo nstrated 
beneficial effects on weight management (Frias et al. 2018; Newso meet al. 2019) . Furthermore, 
liraglutide and semaglut ide(SAXENDA®package in sert, 2014;WEGOVY™package insert, 
2021 )both injectable peptide GLP -[ADDRESS_272170] a benefit in major cardiovascular events (VICTOZA®
package insert , 2017 , OZEMPIC® package insert , 2017).
Obesit y is a chronic disease, and its increasing prevalence is a public healt h concern associated 
with rising incidence of T2D M, increased ri sk for prem ature death, and increased risk for some 
cancers (American Medical Associat ion [AMA] 2013; Council on Science and Public Healt h 
2013; Lauby -Secretan et al . 2016). There remains an unmet need in the pharmaco logic treatm ent 
of obesi ty for drugs that are safe, efficacious, and well tolerated. There are currently  only  a few 
FDA -approved medicationsfor long-term use for the treatment of obesit y that yield a placebo -
adjusted average weight loss between 3% and 7% (Srivastava and Apovian 2018; FDA 2020). 
Although moderate wei ght loss of 5% to 10% in individuals wit h obesit y/overwei ght has l ong 
been sho wn to yield significant metabo lic benefits ,including improvements in cho lesterol, BP, 
and glucose parameters (Goldstein 1992; Wing et al. 2011), greater weight loss can maximize 
these benefits and may  be requi red to realize clinically  meaningful improveme nts in other 
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
19weight-related comorbidit ies,such as sleep apnea, non alcoho licsteatohepatit is, and 
cardi ovascular di sease (Ryan and Yockey  2017). In addit ion to m oderate efficacy , som e centrally
acting weight -loss agents to date have had adverse neurocognit ive, psychiatric ,or cardi ovascular 
effects, further limit ing their applicat ion in clinical practice (Srivastava and Apovian 2018).
Weight l oss induced by  [CONTACT_34046] -1Rs , while appearing to be centrally mediated through a 
combinat ion of hormonal inputs to satiet ycenters (van Bloemendaal et al. 2014), has not been 
consistent ly associated with changes in mental healt h or with potential for addict ion in long-term 
studi es conducted to establish cardiovascular safety  in pat ients with diabetes (Marso et al. 2016a, 
2016 b, Gerstein et al. 2019).
The development program for LY3502970 is to demo nstrate that this oral non -peptide molecule 
has benefits on weight management and glucose control similar to that observed with injectable 
GLP -1 RA swith the convenience of an oral m edicati on.
The safet y, tolerabilit y, and PK/PDof LY3502970 has been evaluated in 2 Phase 1 clinical 
pharmaco logy studi es, J2A-MC-GZGA (GZGA )and J2A -MC-GZGC (GZGC ). Study  GZGA 
was a SAD and a 4-week MAD study  in healt hy volunteers that evaluated the safet y, tolerabili ty, 
PK, and PD of LY3502970 . Study  GZGC was a mul tiple dose study  in parti cipants wi th T2DM 
designed to evaluate the safet y, tolerabilit y, pharmacokinet ics, and pharmacodynamics of 
LY3502970 fo llowing [ADDRESS_272171] pharmacol ogy (Nauck et al. 2009; 
Dungan et al. 2014; Giorgino et al. 2015; Jendle et al. 2016; Nauck et al. 2016). All AEs were 
mild in severit y and consistent with other GLP -1 RA s;the inci dence of GI AEs decreased with 
continued dosing in the MAD, thus demonstrating tachyphylaxis to the GI AEs . The MAD 
showed that LY3502970 init ially delayed gastric empt ying, an effect that was greatly diminished 
with continued exposure similar to marketed GLP -[ADDRESS_272172] of GLP -1RAsis to increase HR, usually wit h either no change or a mild 
reducti on in BP (Lorenz et al. 2017). Changes in HR attenuate over time (Sun et al. 2015; Marso 
et al. 2016 b; Holman et al. 2017; Lorenz et al. 2017), and in lo ng-term cardi ovascular outcom es 
studi es, GLP -1RAshave been associated with reduced risk for major adverse cardiovascular 
events (Drucker et al. 2018). The m echanisms by [CONTACT_226374] -[ADDRESS_272173] stimulat ion of the sinoatrial node, although 
activat ion of the sympathet ic nervous system, or reduction of systemic vascular resistance has 
not been excluded (Bharucha et al . 2008; Mendis et al. 2012; Smit s et al . 2017). To further 
understand the potential effect of LY3502970 on BPandHR, ABPM will be utilized in this 
study .
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
20LY3502970 PK was studied across a range of doses administered as single doses or mult iple 
doses (28 doses) via a QD dosing regimen . LY3502970 PK appeared dose proportional over the 
dose range studied after a single and mult iple dosesfrom 0.[ADDRESS_272174] ivitywith or wi thout a stabl e dose of m etformin. Study  
GZGC included 5 dosing cohorts evaluating differe nt target doses and dose escalat ions. Dose 
escalat ions occurred weekly  to the target dose and then maintained at the target dose for the 
durati on of  the study . The foll owing were the dosing cohorts :
Cohort A: 3, 6, 12, and 24 mg
Cohort B: 3, 6, and 9 mg
Cohort C: 3, 6, 12, and 15 mg
Cohort D: 3, 6, 12, 21, and 27 mg
Cohort E: 3, 6, 9, 21, 36, and [ADDRESS_272175] 
been no clinically significant effects on ECG parameters or other laboratory  param eters noted to 
date.
2.3. Benefit/Risk Assessment
More detailed informat ion about the known and expected benefits and risks and reasonably 
expected AEs of LY3502970 may be found in the Invest igator’s Brochure andDevel opment 
Safety Update Report .
2.3.1. Risk Assessment
Study Intervention
The Sponsor has evaluate d the preclinical and clinical risks associated with LY3502970.
Nonclinical safet y of LY3502970 was evaluated in 6-month and 9-month repeat -dose toxico logy 
studi es in rats and m onkeys , respect ively . Monkey  doses were 0, 1.3 5, and 3 mg/kg/day and were 
administered via oral gavage QD at a volume o f 1mL/kg. Rat doses were 0, 5, 30, and 
200mg/kg/day given by [CONTACT_226375] a volume of 10 mL/kg. Important LY3502970 -
related findings in the mo nkey included vomiting, decreased body  weight,and decreased food 
consumption. Addit ional findings fro m the monkey  studi esinclude changes in CV parameters 
(such as increases in HR and decreased BP), and ECG changes (PR interval prolongation). The 
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
21No-observed -adverse -effect level ( NOAEL ) for target organ toxi city in the m onkey 9 -month 
toxicology study  was 3.0 mg/kg. The m onkey exposure m ultiples f or the LY3502970 45- mg 
dose were as follows : males=0.773 -fold; females =0.875 -fold.
The only clinically  relevant observat ion in the rat 6 -monthrepeat toxico logy study  was 
LY3502970 dose -related minimally higher total bilirubin in both sexes at ≥30mg/kg, and 
minimally  higher bile acid in both sexes at 200 mg/kg/day . These differences likely indicated a 
hepatobiliary  effect but l acked any correla tive microscopi c findings in the liver. The NOAEL for 
target organ toxicit y in the 6-month rat toxi cology study  was 200 mg/kg . The rat exposure 
multiples for the LY3502970 45 -mg dose were as follows: males=16.5-fold; females =31.1-
fold.
In Phase 1 Study  GZGA, mostfindings were associated wi th the pharmaco logy of LY3502970
andinclude
nausea
vomiting
loss of appet ite, and
increased HR.
Of note, there have not been any liver transaminase or bilirubin changes observed in any o f the 
Phase [ADDRESS_272176] been ident ified which would constitute undue risk to study 
participants. The safet y profile cont inues to be refined as more clinical safet y data beco me 
available. The benefit –risk profile cont inues to support further development of LY3502970.
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
223. Objectives , Endpoints ,and Estimands
Objectives Endpoints 
Primary
To demonstrate that at least one dose level of QD oral
LY3502970 is superior in percent body weight
reductio n relative to placebo Percent change in body weight (kg) from 
baseline atWeek [ADDRESS_272177] of QD LY3502970 versus 
placebo on body weightPercent change in body weight (kg) from 
baseline at Week 36
Change in body weight (kg) from baseline at
Week 26 and Week 36
Percentage of study participants who achieve
o≥5% body weight (kg) reductio n
o≥10% body weight (kg) reductio n
               at Week 26 and Week 36
Change in BMI (kg/m2) from baseline at 
Week [ADDRESS_272178] circumference Change in waist circumference (cm) from 
baseline at Week 26 and Week 36
To assess safety and tolerability of study interventionsAEsoverall
AEsof special interest
Laborato ry parameters
Electrocardiogram
Vital signs
To assess the PK of LY3502970 and potential 
participant factors that may influence its PKPopulation PK parameters
Exploratory
To assess the relationship between LY3502970 dose 
and/o r exposure and key efficacy and safety measures 
and potential participant factors that may influence 
these relationships Dose –response and concentration –response 
analy ses for key  efficacy and safety 
parameters
To compare the effect of QD LY3502970 versus 
placebo on body weight control Percentage of study participants who achieve
≥15% body weight (kg) reductio n
              at Week 26 and Week 36
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
23To compare the effect of QD LY3502970 versus 
placebo on BPChange f rom baseline in
oSystolic BP (mmHg) measured by 
[CONTACT_226376] (mmHg) measured by 
[CONTACT_226377] [ADDRESS_272179] of QD LY3502970 versus 
placebo on heart rate Change in heart rate from baseline measured 
by [CONTACT_226378] [ADDRESS_272180] of QD LY3502970 versus 
placebo on lipid parametersChange f rom baseline in fasting (mg/dL)
oTotal cholesterol
oHDL cholesterol
oLDL chole sterol
oVLDL cholesterol
oTriglycerides
                at Week [ADDRESS_272181] of QD LY3502970 versus 
placebo on glucose control Change in HbA1c (%)from baseline at Week 
26 and Week 36
Change in FBG (mg/dL ) from baseline at 
Week [ADDRESS_272182] of QD LY3502970 versus 
placebo on mechanisti c biomarkersChange in mechanistic biomarkers from 
baseline at Week 26 and Week 36
To evaluate the effects of QD LY3502970 versus 
placeb o on Patient -reported outcomes
Health -related quality of life
Participant experienceChange f rom baseline in SF -36v2 acute form 
domain and summary scores at We ek 26 and 
Week 36
Change f rom baseline in IWQOL -Lite-CT 
composite and total scores at Week 26 and 
Week 36
Actual and change from baseline in PGIS for 
Physical Activity at Week 26 and Week 36
Summary statistics of actual responses to 
Participant Survey at Week 26 
Abbreviations: ABPM =ambulatory blood pressure monitoring ; BMI=body mass index; BP=blood pressure ; 
FBG =fasting blood glucose; HbA1c =hemoglobin A1c; HDL =high-density lipoprotein cholesterol; IWQOL -Lite-
CT=Impact of Weight on Quality of Life -Lite Clinical Trials Version; LDL =low-density  lipoprotein cholesterol ;
PGIS =Patient Global Impression of Status for Physical Activity; PK=pharmacokinetics; QD =oncedaily ; SF-
36v2 =Short Form 36 Version 2 health survey acute form ; VLDL =very low -density  lipoprotein cholesterol .
Primary Estimand
The primary  clinical quest ion of interest is: What is thetreatm ent difference in percent change in 
body  weight a fter26 weeks of treatm ent in participants who meet the inclusio n criteria and 
woul d have com pleted the treatment period ?
The “efficacy” estimand i s described by  [CONTACT_941] f ollowing attributes:
Popul ation: parti cipants who meet the inclusio n criteri a.Further detail s can be found in 
Secti on5and Section 9.
Endpoint : percent change fro m baseline to 26 weeks in body  weight .
Treatment condit ion: the randomized treatment with allo wance for down -titration based 
on GI tol erabilit y.
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
24Theintercurrent event “ permanent discont inuat ionof study  drug” ishandled by [CONTACT_226379] ,and the potential outcome of interest is the response in the efficacy measurement if 
participants had adhered to the rando mized treatment. There are no other defined intercurrent 
events. Down -titration will not be considered as intercurrent events for the definit ion of est imand 
in this study .
Popul ation-level summary: difference in mean percent changes in body  weight between QD 
LY350 2970 and placebo.
Rationale for “efficacy” estimand : This Phase 2study  aims to study  the efficacy of LY3502970
under the ideal condit ion that all participants adhere to the randomized treatment.
Estimand(s) for Secondary Objective s
The same est imand for the primary objective will be used for the fo llowing efficacy endpo ints 
forthe secondary  object ives:
Difference between LY3502970 and placebo in
percent change in body  weight (kg) from baseline at Week 36
change in body  weight (kg) f rom baseline at Week 26 and Week 36
percentage of study  parti cipants who achieve ≥5% body  weight reducti on at Week 26 and 
Week 36
percentage of study  parti cipants who achieve ≥10% body  weight reducti on at Week 26 
and Week 36
change in BMI (kg/m2)from baseline at Week 26 and Week 36
change in waist circumference (cm)from baseline at Week [ADDRESS_272183] 1 dose of study drug , regardl ess of adherence to study  
drug.
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
254. Study Design
4.1. Overall Design
Study  GZGI i s a 36-week (primary endpoint at 26 weeks) , Phase 2, m ulticenter, randomized, 
doubl e-blind, placebo -controlled study  designed to examine the safet y and efficacy o f 4dose 
levels of QD LY [ADDRESS_272184] obesit y(BMI ≥
30kg/m2) or areoverwei ght (BMI ≥ 27 kg/m2and < 30 kg/m2) with at least 1weight -related 
comorbidi ty.
4.1.1. Overview of Study Periods
Screening Period
Visit [ADDRESS_272185] sign 
the ICF before the study  procedures are performed, as outline d in the SoA, Section 1.3. 
Screening procedures will be performed according to the SoA ( Secti on 1.3).
Visit [ADDRESS_272186] ivity.
ABPM :Between Visit 2 and Visit 3, the participant will undergo a baseline 24 -hour ambulatory 
blood pressure monitoring (ABPM)sessio n. Upon return of the ABPM device , the recordings 
must be transmitted to the core laboratory  and analyzed before the participant leaves the site. If 
the sessio n provi des technically satisfactory  resul ts (≥70% of readings are valid), this 
measurement will serve as the baseline value. If a technically satisfactory  resul t is not achi eved, 
the Invest igator should review the device setti ngs and placement and the participant’s activit y 
track in an attempt to correct any user error or device malfunctions. Another [ADDRESS_272187] ions. Lack of participat ion in 
ABPM collections at any  time is not considered a protocol deviat ion.
Of note, if the screening period between Visit 1 and Visit 3 (randomizat ion) takes less or more 
time than 2 weeks, it is not a protocol deviat ion.However, it is preferable that screening takes 
less than 1 month.
Randomization
Visit 3
At Visit 3, eligible participants, those who meet all applicable inclusio n criteria and none of the 
applicable exclusio n criteria, will perform all required study  procedures pri or to randomizat ion.
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
26Patient-reported outcomes quest ionnaires should be administered accordi ng to the SoA, as earl y 
as possible during the visit. Preferred administration order of these quest ionnaires i s
1.PGIS for Physical Act ivity
2.SF-[ADDRESS_272188] dose of study  drug will  be recorded on the electronic case report 
form (eCRF ). Beginning at randomizat ion, all part icipants will receive study drugs according to 
the randomized treatment arm for the duratio n of the 36-week treatm ent peri od (primary  
endpoint at 26 weeks) as per the SoA ( Secti on 1.3).
Treatment Period
During the treatm ent period, study drug will be returned per the SoA ( Section 1.3) and according 
to local requi rements. New supplies will be dispens ed as needed. Participants should be 
instructed to contact [CONTACT_226380].
Parti cipants shoul d also be advised about the appropriate course of act ion if study  drugs are not 
taken at the required time (late/missing doses). Study  parti cipants will be permitted to use 
concomitant medicat ions that they  requi re during the study , except certain excluded medicat ions 
that may  interfere wi th the assessment of efficacy  and safet y characteri stics of the study  
treatm ents.
Dose- Escalation Period (Visits 4-12)
For m aintenan ce doses of LY3502970, the init ial dose will be 2 or 3 mg followed by  [CONTACT_226381] .The dose will be increased until the maintenance dose is 
achieved ;see Section 6.1for dosing details andthe Treatment Group Dose Escalat ion Regime
table bel ow.
The m aintenance doses of LY3502970 will be continued for the remainder of the study . For
participants who experie nce intol erable GI symptoms or may need dose adjust ment for other 
reasons, the dose modificat ion procedures are described in Section 6.5.
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
27LY3502970 Treatment Group Dose Escalation Regimen
W 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 28 32 36
V 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
LY
13 3 3 3 3 3 3 3 6 6 6 6 6 6 6 6 12 12 12 12 12 12 12 12 12 12 12 12 12
LY
23 3 6 8 12 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24
LY
3-12 3 6 8 12 24 36 36 36 36 36 36 36 36 36 36 36 36 36 36 36 36 36 36 36 36 36 36 36
LY
3-23 3 3 6 6 6 12 12 12 24 24 24 36 36 36 36 36 36 36 36 36 36 36 36 36 36 36 36 36
LY
4-13 3 6 6 8 8 12 12 24 24 36 36 45 45 45 45 45 45 45 45 45 45 45 45 45 45 45 45 45
LY
4-22 2 3 3 6 6 12 12 24 24 36 36 45 45 45 45 45 45 45 45 45 45 45 45 45 45 45 45 45
Abbreviations: LY=LY3502970; LY1 =LY 12 mg; LY2 =LY 24 mg; LY3 =LY 36 mg; LY4 =LY 45 mg; V =Visit; W =week
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
28Visit [ADDRESS_272189] .
Maintenance Period (Visits 12-18)
During the m aintenance period, visits will occur approximately  every 3-4 weeks unt il Week 24 
and then 2 weeks from Weeks 24 to 26 (Primary Endpoint),and then every 2-4weeks (as per the 
SoA) until Week 36. Visit procedures should be conducted according to the SoA (Section 1.3).
ABPM: Within 1 week of Visit 15(Week 26), the parti cipant will undergo one [ADDRESS_272190] be 
transmitted to the core laboratory and analyzed before the participant leaves the site. If the 
session provides technically sat isfactory  resul ts (≥70% of readings are valid), this measurement 
will serve as the final value. If a technically sat isfactory  resul t is not achi eved, the Invest igator 
shoul d review the device settings and placement and the participant’s act ivity in an attempt to 
correct any  user error or device malfunct ions. Another 24 -hour ambulatory  monitoring sessi on 
shoul d be conducted (wi thin [ADDRESS_272191] ion),and this measurement will 
serve as the final value. If the second sessio n also provi des technically  unsati sfactory  resul ts, the 
data will be considered missing but will not be considered a protocol deviat ion.
Patient-Reported Outcomes: Patient-reported outcomes questionnaires should be administered at 
Visits 15and 18, as early as possible during the visit. Preferred administrati on order of these 
questionnaires is
1.PGIS for Physical Act ivity
2.SF-[ADDRESS_272192] , and
4.Parti cipant S urvey (Visit 15 only) .
Early Termin ation Visit
Parti cipants unable or unwilling to continue the study  for any  reason will  perform an ET of 
treatm ent visi t (Secti on 7.1). If the participant is dis continuing during an unscheduled visit or a 
scheduled visit, that visit should be performed as an ET visit. Procedures should be completed 
according to the SoA (Secti on 1.3). Participants who withdrawal fro m the study  after si gning the 
inform ed consent but who have not taken a dose of study  drug pri or to randomizat ion do not 
need to complete ET procedures.
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
29Patient-reported outcomes quest ionnaires shou ld be administered according to the SoA, as early 
as possible during the visit. Preferred administration order of these quest ionnaires i s
1.PGIS for Physical Act ivity
2.SF-[ADDRESS_272193] one dose of study  drug shoul dcomplete a safet y 
follow-up visit (Visit 801), according to the SoA (Section 1.3).
For parti cipants who discont inue from the study  early  (regardl ess of whether they  discontinue IP
at the sam e time or have discontinued IP at an earlier visit), an ET visit fo llowed by [CONTACT_941] s afety 
follow-up visit (Visit 801) should be completed as per the Schedule of Act ivities.
Parti cipants are also requi red to return any  remaining study  logs to the study  site at the end of 
this peri od.
4.2. Scientific Rationale for Study Design
Study  GZGI i s a Ph ase2 study  designed to examine the body weight -lowering efficacy  and 
safet y of LY3502970 QD (dose ranging fro m 12mgto 45mg) compared with placebo during the 
36-week treatment period ( with the primary end point at Week 26),in part icipants who have 
obesit y or are overwei ght wi th at least one weight-related comorbidity without di abetes. The 
primary  endpoint collection at Week 26 provides data that maybe co mpared with a Phase 2 
study (Study  GZGE) in participants with T2DMalso studying comparable doses and dose 
escalat ions of LY3502970 and being conducted at the same t ime.This will allow for selection of  
dose l evels and dose escalat ion schemes for future studies. The pl anned treatm ent durati on of  [ADDRESS_272194] ion of LY3502970 suggests that treatment with LY3502970 will result 
in continued weight loss bey ond a 6 -month peri od.
The effects of LY3502970 on other paramet ers such as circulating bio markers, lipi[INVESTIGATOR_805], and 
various safet y-related assessments will also be determined. The data from this trial will form the 
primary  basis to assess dose/exposure –response of LY3502970 efficacy for select ion of doses 
and the dose esca lation scheme to be included in Phase [ADDRESS_272195] benefit –risk characteri zations in this popul ation.
The pl acebo com parison will  provid e efficacy and safet y data to characterize the effects 
attributable to LY3502970.
Consistent with current guidelines for weight management, all participants will receive diet and 
physical act ivity counseling throughout the study . Clinical sites that have their own di etand 
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
30physical act ivity program s may  use those programs. However, for sites without specific diet and 
physical act ivity program s, a suggested di etand physical act ivity program  is provi dedin Section
10.8. In this section, the diet recommendat ions are based on the World Healt h Organization 
(WHO 2018) for every one and arebased on a Mediterranean Diet eating pattern.
Physical act ivity recommendat ions are based on WHO recommendat ions (WHO 20 20) and wi th 
the US Health and Human Services (HHS 20 20) recommendat ions. The primary efficacy 
measure, mean percent change in body  weight ,is an accepted Phase 2 end point for 
investigat ional drugs being developed for weight management (FDA 2007). In addit ion, the 
protocol  includes other parameters relevant to assessment of the effects of LY3502970 on safet y, 
BP, HR, lipi[INVESTIGATOR_805], PK parameters, and patient -reported outcomes.
Theprimary  object ive will be evaluated at 26 weeks because this period is considered adequate 
for evaluat ion of weight loss efficacy in a Phase 2 trial and sufficient to assess the dose –
exposure –response o f LY3502970 efficacy for selection of doses to be inc luded in Phase 3 
testing. The putative mechanism o f action of LY 3502970 suggests that treatment with 
LY3502970 will result in continued weight loss beyo ndthis treatm ent peri od; thus the treatment 
period of  thestudy  will cont inue an addit ional [ADDRESS_272196] benefit –risk 
characterizat ions in treatment of participants who have obesit y or are overweight.
To minimize the potential confounding e ffect of changes in conco mitant m edicati ons, 
participants will be permitted to use concomitant medicat ions that do not interfere with the 
assessment of efficacy  or saf ety characteristics of the study  treatm ents.
4.3. Justification for Dose
LY3502970 maintenancedoses of 12, 24, 36, and 45 mg administered orally QD were selected 
based on the fo llowing :
In the single and a 4- week mult iple dose study  in healthy vol unteers, GZGA, LY3502970 
doses through 24 mg were safe and tolerated fo llowing dose escalation .
In the 12- week study ,GZGC, in participants with T2D M, LY3502970 doses through 
45mg appear to be safe and well tolerated fo llowing dose escalat ion.Furtherm ore, 
LY3502970 doses through 45 mg appear to lower glucose and body  weight .
The selected dose levels and dose range will evaluate various titration schemes and 
support dose exposure– response analysis o f multiple safet y and efficacy measures to 
support select ion of dose(s) of LY3502970 with optimal benefit –risk ra tio for further 
clinical development.
High acute doses of GLP -[ADDRESS_272197] participant in the trial glo bally .
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
31A participant is considered to have co mpleted the study  if the part icipant has completed all 
periodsof the study  including the last vi sitor the last scheduled procedure shown in the SoA
(Secti on 1.3).
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
325. S tudy Population
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, is not permitted.
5.1. Inclusion Criteria
Parti cipants are eligible to be included in the study only if all o f the following criteria apply:
Age
1.Parti cipantsmust be 18or the l egal age of consent in the jurisdict ion in which the study is 
taking place to 75years of age inclusive, at the time of signing the informed consent
Type of Participant and Disease Characteristi cs
2.Have an HbA1c <6.5%
Weight
3.Have a BMI of
≥30kg/m2
≥27kg/m2and <30 kg/m2with at least 1 of the fo llowing weight -related 
comorbidi ties
ohypertensio n: on BP -lowering medicat ion or having sy stolic BP 
≥130 mmHg or diastolic BP ≥80 mmHg at screening
odyslipi[INVESTIGATOR_035]: on lipid -lowering medicat ion or having low -densit y 
lipoprotein (LDL) ≥160 mg/dL (4.1 mmo l/L) or triglycerides 
≥150 mg/dL (1.7 mmo l/L), or high- densit y lipoprotein (HDL) 
<40mg/dL (1.0 mmo l/L) for men or HDL <50 mg/dL 
(1.3mmo l/L) for wom en at screening
ocardi ovascular di sease: (for example, ischemic cardiovascular 
disease, [LOCATION_001] Heart Associat ion [NYHA] Funct ional 
Classificat ion Class I -II heart failure . See Secti on 10.6)
oobstructive sleep apnea (only in part icipants >30 years of age)
4.Have had a stable body  weight for the 3 months prior to randomizat ion (5%body weight 
gain and/or loss)
Sexand Contraceptive/Barrier Requirements
5.Male and/or female
Contraceptive use by [CONTACT_226382] d be consistent with local regulat ions regarding the 
methods of contraception for those participat ing in clinical studies.
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
33Women not of child bearing potenti al (for defini tions, see Sect ion 10.4) and men can 
participate in this study  considering the fo llowing:
a.Male parti cipants:
oMales who agree to use highly effective/effect ive methods of contraception may  
participate in this trial.
oPlease refer to Section 10.4 (Appendix 4)for definit ions and addit ional guidance 
related to contraception.
b.Female participants:
oWomen of childbearing potential (WOCBP) are excl uded from  thistrial.
oWomen not of childbea ring potenti al (WNOCBP) may participate in this trial.
oPlease refer to Appendix 4for definit ions and additional guidance related to 
contraception.
Note: Hormone replacement therapy  in postmenopausal women is allowed but women 
must be on stable therapy  for3 months pri or to screening/Visit 1.
Informed Consent
6.Capable of giving signed informed consent as described in Section 10.1 (Appendix 1 ),
which includes co mpliance wit h the requirements and restrictions listed in the ICFand in 
this protocol
5.2. Exclusion Criteria
Parti cipants are excl uded from  the study  if any of the following cri teria appl ies:
Medical Conditions
Diabetes Related
7.Have a ny pri or diagnosis of type 1 di abetes m ellitus (T1DM or T2DM , or rare forms of 
diabetes m ellitus
8.Have at least [ADDRESS_272198] ive of diabetes during screening, including 1 or 
more of HbA1c ≥6.5% (48 mmo l/mol), fasting serum  glucose ≥126 mg/dL (7.0 mmo l/L), 
or random  glucose ≥200 mg/dL (11.1 mmo l/L)
Obesity Related
9.Have a prior or planned surgic al treatm ent for obesi ty (excluding liposuct ion or 
abdo minoplast y, if performed >1 y ear pri or to screening)
10.Have obesi tyinduced by  [CONTACT_105411] (for example, Cushing’s 
syndro me) or diagnosed monogenet ic or syndromic forms of obesit y (forexample, 
Melanocorti n 4 Receptor deficiency or Prader –Willi Syndro me)
11.Have or plan to have endoscopic and/or device -based therapy  for obesi ty or have had 
device remo val wit hin the l ast 6 m onths pri or to screening including but not limited to
 mucosal ablat ion
 gastri c artery  embo lization
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
34 intragastri c balloon, and
 duodenal -jejunal endoluminal liner .
Other Medical
12.Have renal impairment measured as estimated glomerular filtrat ion rate ( eGFR)
<30mL/min/1.73 m2, calculated by  [INVESTIGATOR_19957] -Epi[INVESTIGATOR_82331] (CKD -EPI)
as determined by  [CONTACT_226383]
13. H ave a known clinically significant gastric empt ying abnormalit y (for example, severe 
gastroparesi s or gastri c outl et obstructi on), have undergone gastric by[CONTACT_6476] (bariatric) 
surgery  or restri ctive bariatric surgery (for example, Lap- Band®),or chroni cally take 
drugs that direct ly affect GI motilit y
14.Have a history of acute or chronic pancreat itis. A participant with a history of acute 
pancreat itis caused by [CONTACT_226384] a 
cholecystectomy to resolve the problem
15.Have a history  of significant active or unstable Major Depressive Disorder ( MDD )or 
other severe psychiatric disorder (for example, schizophrenia, bipo lar disorder, or other 
serious m ood or a nxiet y disorder) within the last 2 years
Note: Participants with MDD or generalized anxiety  disorder whose disease state is 
considered stable for the past [ADDRESS_272199] a Patient Health Questionnaire -9 (PHQ -9)score of 15 or more at Visit 1 or 3, prior 
to randomizat ion
18.On the C -SSRS at Vi sit 1or 3, prior to randomizatio n:
 a “yes” answer to Question 4 (Act ive Suicidal Ideation with Some Intent to Act, 
Without Specific Plan) on the “Suicidal Ideat ion” porti on of  the C -SSRS
or
 a “yes” answer to Question 5 (Act ive Suicidal Ideation with Specific Plan and 
Intent) on the “Suicidal Ideat ion” portion of the C -SSRS
or
 a “yes” answer to any  of the suici de-related behaviors (actual attempt, interrupted 
attem pt, aborted attempt, preparatory  act, or behavior) on the “Suicidal Behavior” 
porti on of  the C-SSRS
and
 the ideati on or behavior occurred within the past month .
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
3519. H ave poorly controlled hypertension ( that is, mean seated systolic BP 
160mmHgor mean seated diastolic BP 100mmHg)at screening, renal artery  
stenosi s, or evidence of labile BP including symptomat ic postural hypotension . 
Parti cipants on antihypertensive medicat ions must be on a stable dose for at least 
[ADDRESS_272200] an elevated resting pulse rate (PR) (>100 bpm) at screening and baseline
21. H ave any of the fo llowing cardi ovascular condi tions wi thin 3 mo nths prior to Screening :
acute my ocardial  infarct ion
cerebrovascular accident (stroke)
unstable angina, or
hospi [INVESTIGATOR_126145] (CHF) .
22.Ongo ing or history o f frequent intermittent or chronic tachyarrhyt hmia syndro mes (such 
as atri al fibrillat ion, supraventricular tachycardia, and posit ional orthostatic tachycardia 
syndr ome).
Note: Participants wi th history  of premature atri al contracti ons or prem ature 
ventri cular contractions may  be included.
23.Have a history  of NYHA Funct ional Classification III or IV CHF (see Section 10.7)
24.Have an electrocardi ogram  (ECG )considered by [CONTACT_226385] m ay interfere with the interpretation of changes in ECG 
intervals at screening
25.Have a personal or family history  of long QTsyndrom e, family history  of sudden 
death in a first -degree relative (parents, sibling s, or children) before the age of 
40years, or a personal history  of unexplained syncope within the last year. Use of 
prescri ption or over -the-counter medications known to significant ly pro long the 
QT or QTc i nterval at screening
26.Have a history  of clinically significant gallbladder disease . However, p articipants with 
cholecystectomy may be included in the study
27.Have signs and symptoms of any other liver disease other than nonalcoho lic fatty liver 
disease , or any  of the f ollowing, as determined by  [CONTACT_226386]
 ALT l evel >3.0X ULN for the reference range
 ALP l evel >1.5X ULN for the reference range, or
TBL >1.5X ULN for the reference range (except for cases of known 
Gilbert’s Syndro me)
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
3628.Have evidence of hypothy roidism  or hyperthy roidism  based on clinical evaluation 
and/or an abnormal thyro id-stimulat ing horm one that, in the opi[INVESTIGATOR_3078] n of the 
Invest igator, wo uld pose a risk to patient safet y. Subjects on a stable dose of 
thyroid replacement therapy  for at least the prior [ADDRESS_272201] a known self or family  history  (first-degree relat ive) of mult iple endocrine 
neopl asia ty pe2A or ty pe2B, thy roid C-cell hyperpl asia, or m edullary  thyroid 
carcino ma
30.Have a serum calcitonin level (at Visit 1) of
≥20ng/L, if eGFR ≥ 60 mL/min/1.73 m2or
≥35ng/L if eGFR < 60 mL/min/1.73 m2(as determined by [CONTACT_226387] 1)
31.Have evidence of a significant, uncontrolled endocrine abnormalit y (for example, 
thyrotoxi cosis or adrenal  crises), in the opi[INVESTIGATOR_3078] n of the Invest igator
32.Have a history  of an act ive or untreated malignancy or are in remissio n from a clinically  
significant malignancy  (other than basal or squamous cell skin cancer, in situ carcinomas 
of the cervix, or in situ prostate cancer) for less than [ADDRESS_272202] evidence of human immunodeficiency  virus ( HIV)and/or posit ive HIV 
antibodies historically or at screening
34.Evidence of hepat itis B and/or posit ive hepat itis B surface ant igen.
35.Hepati tis C as defined by [CONTACT_226388] C virus ( HCV )RNA or posi tive 
hepat itis C ant ibody  (anti-HCV). Parti cipants treated for hepat itis C (and 
diagnosed as cured) must have an RNA test at screening and also be RNA 
negat ive for at least [ADDRESS_272203] a history  of any other c ondition (such as known drug or alcoho l abuse, di agnosed 
eating disorder, or other psy chiatri c disorder) that, in the opi[INVESTIGATOR_3078] n of the Invest igator, may 
precl ude the parti cipant from  following and co mpleting the protocol
37.Have an average weekly alcoho l intakethat exceeds 21 units per week (males) 
and 14 units per week (females) [1 unit = 12 oz or 360 mL of beer; 5 oz or 
150mL of wine; 1.[ADDRESS_272204] illed spi[INVESTIGATOR_17040] s]
38.Have a history  of use of marijuana or tetrahy drocannabino l (THC -containing products 
within 3 mo nths of enrollment or unwillingness to abstain from marijuana or THC -
containing products use during the trial
Note : If a parti cipant has used cannabidio l oil during the past [ADDRESS_272205] had a transplanted organ (corneal transplants [keratoplasty] are allowed) or are 
awaiting an organ transplant
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
3740.Have had any  exposure to GLP -1 analogs, or other related compounds wit hin the 
prior 3months or any  prior history of hypersensi tivity/allergies to these 
medicat ions. Have known or suspected hy persensi tivity to tri al product(s), to 
select ive GLP -1 RAs or GIP/GLP -1 or GLP -1/Gcg dual receptor agonists.
Parti cipants who previ ously took GLP -[ADDRESS_272206] had a blood donation of [ADDRESS_272207] known 
hemoglo binopathy (for example, hemo lytic anemia, si ckle cell anemia ), or have a 
hemoglo bin value <11 g/dL (males) or <10 g/dL (females)
42. T riglycerides >500 mg/dL (5.7 mmo l/L). If the patient is on lipid -lowering 
therapi [INVESTIGATOR_014], doses m ustbe stable for [ADDRESS_272208] evidence of a significant, active autoimmune abnormalit y (for example, 
lupus or rheumatoid arthrit is) that, in the opi[INVESTIGATOR_66286], is likely to 
requi re concurrent treatment with s ystemic glucocorticoids in the next 9months
45.Have difficult y swallowing capsules
Prior/Concomitant Therapy
46.Unless otherwise specified, all conco mitant m edicati ons shoul d be at a stabl e dose 
for at least [ADDRESS_272209] received wit hin 3 months prior to screening chronic (>2 weeks) 
systemic glucocortico id therapy (excluding topi[INVESTIGATOR_2855], intraocular, intranasal, single 
intraarti cular inject ion, or inhaled preparations)
48.Have current treatment with or history  of treatm ent wi th (within 3 m onths pri or to 
screening) m edicat ions that may cause significant weight gain including, but not limited 
to, tricyclic ant idepressants, aty pi[INVESTIGATOR_226350], and m ood s tabilizers . However, 
participants at a stable dose (greater than 6months and with no expectation that the dose 
will change within the next y ear) and who are weight stable for the last [ADDRESS_272210] 6 months and wi th no expectati on of  changing wi thin the next y earinclude
imipramine
amitript yline
mirtazapi[INVESTIGATOR_050]
paroxetine
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
38phenelzine
chlorpromazine
thioridazine
clozapi[INVESTIGATOR_050]
olanzapi[INVESTIGATOR_050]
valpro ic acid and its derivat ives, and
lithium.
Note: Selective serotonin reuptake inhibitors other than paroxetine are permitted .
49.Have taken wit hin 3 months prior to screening medicat ions (prescribed or over the 
counter) or alternat ive remedies (including herbal/nutrit ional supplements) intended to 
prom ote weight loss
Examples include, but are not limited to :
Saxenda®(liraglut ide 3.0 mg) or other GLP -1RA
Xenical®/Alli®(orlistat)
Meri dia®(sibutramine)
Acutrim®(phenylpropano lamine)
Sanorex®(mazindo l)
Adip ex®or Lom airaTM (phentermine)
BELVIQ ®[lorcaserin]
QsymiaTM (phentermine/topi[INVESTIGATOR_81063])
Contrave®(naltrexone/bupropi[INVESTIGATOR_2394])
WegovyTM(semaglut ide 2.4 mg), and
other similar body  weight loss medicat ion, including OTC medicat ions, for 
example, allī®.
50.Use of met formin, or any  other glucose -lowering medicat ion, whether prescribed for 
polycyst ic ovarian syndrome or diabetes prevent ion,is not permitted
51.Are current ly taking a central nervous system stimulant ( for example , Ritalin-
SR) with the excepti on of  caffeinated beverages at scree ning
52. Are receiving strong CYP3A inhibitors or CYP3A inducers ordrugs that are P -
gp/BCRP substrates with narrow therapeutic index. Please see Section 6.8for 
details
53.Evidence of regular use of known drugs of abuse in the opi[INVESTIGATOR_3078] n of the Invest igator
Prior/Concurrent Clinical Study Experience
54.Are current lyenrolled in any other clinical study  involving an IPor any  other ty pe of 
medical research judged not to be scient ifically or medically co mpat ible with this study
55.Have part icipated, withinthe last [ADDRESS_272211] 6 m onths , whether on active drug or placebo, in a clinical 
study  that contained a GLP -1 RA
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
3956.Have previously completed or withdrawn fro m this study  or any  other study  invest igating 
LY3502970
Other Exclusions
57.Are women of child bearing potential
58. Are women acting as a surrogate, who are currently pregnant or breastfeeding, or who 
intend to becom e pregnant or to brea stfeed at any  time during the study  or wi thin [ADDRESS_272212] ly affiliated wit h this study  and/or thei r immediate 
families. Immediate family  is defined as a spouse, parent, child, or sibling, whether 
biological  or legally  adopted
60.Are emplo yees of Eli Lilly and Company (Lilly) or are emplo yees o f a third-party  
organi zation involved in the study ,which requires exclusio n of their emplo yees
61.Are, in the opi[INVESTIGATOR_3078] n of the Invest igator or Sponsor, unsuitable for inclusio n in the 
study
Exclusions Specifically for ABPM
The fo llowing addi tional exclusio ns apply only  to participat ionin ABPM co llections. A 
participant who qualifies for the study  based on the above inclusio n/exclusio n parameters but 
does not qualify for ABPM may  still parti cipate in the study . Not being able or willing to 
participate in ABPM procedures is not considere d a protocol deviat ion.
62.Parti cipants wi th hypertensio n shoul d have well -controll ed BP (<140/90), regardless of 
antihypertensive treatment. Participants receiving treatment for hy pertensi on shoul d be 
on a stabl e ant ihypertensive regimen for at least 3 months prior to screening
Note: If the Invest igator anticipates a need to add ant ihypertensive medicat ion during the 
course of the study , the participant shoul d not be included in the ABPM procedures.
63.Parti cipant works rotati on shifts or works during the h ours of 2200 to 0700
64.Parti cipant performs strenuous manual labor that cannot be avoided during the 
monitoring peri od
65.Parti cipant has a nondominant arm circumference of >55 cm at Vi sit 1
66.Parti cipant i s unable to obtain a valid baseline ABPM reading
67.Chronic use of nonsteroidal anti -inflammatory  agents or cy clooxygenase -2 (COX -2) 
inhibitors, as well as other agents, prescript ion or over -the-counter, known to affect BP, 
are permitted; however, use of these agents on an as needed basis (PRN) during the 48 -
hour p eriod immediately prior to or during each 24 -hour ABPM recording is prohibited. 
Examples include, but are not limited to ,decongestants (pseudoephedrine, ephedrine, 
phenylephrine, naphazoline, and oxymetazoline) and mult i-symptom  cold remedies
68.Male parti cipants m ust abstain fro m use of phosphodi esterase ty pe 5 (PDE -5) inhibitors 
(that is, tadal afil, vardenafil, and sildenafil) or y ohimbine (herbal aphrodisiac) during the 
48-hour peri od immediately  prior to or during each 24 -hour ABPM recording, since these 
medicat ions m ay confound the BP measurements.
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
405.3. Lifestyle Considerations
Throughout the study , parti cipants m ay undergo medi cal assessments and review of compliance 
with requi rements before continuing in the study . Parti cipants will report to the clinical re search 
site for safet y assessments and will remain in the clinic unt il all procedures for that visit are 
complete and the Invest igator has deemed it safe to release the participant fro m the clinic.
Per the SoA (Section 1.3), personnel will provide diet and physical activit y counseling and will 
encourage the participants to be compliant with diet and physical activ ityrecommendat ions.
Prescri ption or OTC medicat ions that promote weight loss are exclusio nary if used wi thin 
3months pri or to screening or between screening and rando mizat ion. These m edicat ions are al so 
not allowed at any  time during the treatment per iod. If started after randomization, the 
medicat ions should be immediately wit hdrawn. Participants who refuse to withdraw the weight 
loss medicati ons m ust be di scont inued fro m study  drug.
Throughout the study , parti cipants m ay undergo medi cal assessments and review of compliance 
with requirements before continuing in the study .
Meals/Diet –Participants shoul d follow the di et and physical act ivityrecommendat ions 
provi ded by [CONTACT_226389] 10.8 (Appendix 8).
For certain assessments, the participants will be required to come to the site in a fasting state, 
after an overnight fast (except for water) of at least 8 hours when clinical laboratory  assessments 
and/or weig ht measures are performed as specified in the SoA (Section 1.3).
Caffeine, Alcohol , and Tobacco –Participants will be allowed to maintain their regular caffeine 
consumption throughout the study  period.
Alcoho l will not be permitted at least [ADDRESS_272213] consume no m ore than 10 cigarettes or equivalent per day .
Physical Activity –Participan ts will  be advised to increase their regular levels o f physical 
activit y during the study .Parti cipants will be advised to avoid strenuous physical act ivitywithin 
24 hours prior to each study  site visi tif possible . When certain study  procedures are i n progress 
at the site, participants may be required to remain supi[INVESTIGATOR_226351].
Blood Donation –Study part icipants should be instructed not to donate blood or blood products 
during the study  and f or 8 weeks fo llowing the study .
5.4. Screen Failures
A screen failure occurs when a participant who consent sto parti cipate in the clinical studyisnot 
subsequent ly rando mly assigned to study  interventio n. A minimal set of screen failure 
inform ation is required to ensure transparent reporting of screen failure participant s to m eet the 
Conso lidated Standards of Reporting Trials (CONSORT) publishing requi rements and to 
respond to queries from regulatory  authori ties. Minimal information includes demography , 
screen failure details, eligibilit y criteria, and any  SAE.
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
41If, in the opi[INVESTIGATOR_3078] n of the Investigator, an ineligible lab test result is the result of an error or 
extenuat ing circumstance, then that parameter can be retested once without the participant 
having to be rescreened.
5.5. Criteria for Temporarily Delaying 
Enrollment/Randomization/Administration of Study Intervention of 
a Participant
Not applicable
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
426. Study Intervention (s) and Concomitant Therapy
Study  intervent ion is defined as an y invest igational intervent ion(s), m arketed product(s), 
placebo ,or medical device (s)intended to be administered to /used by a study  parti cipant 
according to the study  protoc ol.
All participant s will take one capsule orally  each day . All capsules are the same size ,and pl acebo 
capsules match LY3502970 capsules. Therefore, participants will not know whether they are 
receiving act ive LY3502970 or placebo.
LY3502970 will be supplied in weekly  bottles wi th 10 capsules per bottle. Bottles contain 10 
capsules to account for visit windows and prevent ing participant s from missing doses even if it 
delays the dose escalat ion. Participants should return unused capsu les.
Disposition of Study Drug Bottles
Visit Number of Bottles of 
Capsules to be Dispensed
3 1
4 1
5-9* 2
10-17 4
*Visits [ADDRESS_272214]. 
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
436.1. Study Intervention(s) Administered
ARM Name [CONTACT_36940]3502970 Placebo
Intervention 
NameLY3502970 Placebo
Type Drug
Dose 
FormulationCapsule Capsule
Unit Dose 
Strength(s)2 mg capsule LY
3mg capsule LY
6 mg capsule LY
8mg capsule LY
12mg capsule LY
24mg capsule LY
36mg capsule LY
45mg capsule LYCapsule of LY -placebo 
to match
Route of 
AdministrationOral Oral
Use Experimental Placebo
Abbreviation: LY=LY3502970
6.2. Preparation , Handling , Storage , and Accountability
The Investigator or designee must confirm appropriate storage conditions have 
been maintained during transit for all study  intervent ion received and any 
discrepancies are reported and resolved before use of the study  intervent ion.
Only participants enro lled in the study  may receive study  intervent ion. Only 
authori zed study  personnel may supply , prepare, or administer study  intervent ion. 
All study  intervent ion must be stored in a secure, environmentally controlled, and 
monitored (m anual  or automated) area in acco rdance wi th the l abeled storage 
condi tions wi th access limited to the Investigator and authorized study  personnel .
The Investigator or authori zed study  personnel are responsible for study  
intervent ion accountabilit y, reconciliat ion, and record maintenance (that is, 
recei pt, reconciliat ion, and final disposit ion records).
Further gui dance and information for the final disposit ion of unused study  
intervent ions are provided in the study  training m aterials.
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
44The study  site must store the study  drug in a l ocked and secure environment. The study  drug 
capsules may be stored at room temperature. Study drug in each participat ing country will be 
labeled according to the coun try’s regulatory  requirem ents.
6.3. Measures to Minimize Bias: Randomization and Blinding
All partic ipants will be centrally  assigned to randomized study  intervent ion using an IWRS. 
Before the study  is initiated, the l og-in informat ion and di rections for the IWRS will be provided 
to each site.
Parti cipants will be randomly assigned to study  intervent ion in a rando mizat ion rati o of 
5:5:5:3:3:3:[ADDRESS_272215] acebo capsules look like study  
drug capsules tomaintain blinding .
Stratificat ion will be by [CONTACT_44207] (≤35, >35kg/m2at Visit 1) and by [CONTACT_4321].
Blinding will be maintained throughout the conduct of the study  as described in the separate 
blinding plan.
Emergency  codes will be available to the Investigator and pharmacy . A code, whi ch reveals the 
study  interventi on [group] for a specific study  partici pant, m ay be opened during the study  only  
if the participant’s well -being requires knowledge of the partici pant’s treatm ent assi gnment.
If a participant’s study  treatment assi gnment is unblinded, the participant must be discontinued 
from the study , unless the Invest igator obtains specific approval fro m a Lilly clinical research 
physician /clinical  research scien tist(CRP /CRS )for the study  parti cipant to continue in the study . 
During the study , emergency unblinding should occur only by  [CONTACT_226390]’s 
emergency code.
In case of an emergency , the Investigator has the sole responsibilit y of determ ining if unblinding 
of a parti cipant’s treatment assignment is warranted for medical management of the event. The 
participant’s safet y must always be the first consideration in making such a determinat ion. 
Where feasible and when timing of the emergent sit uation permits, the Invest igator should 
attem pt to contact [CONTACT_226391] a participant’s treatment 
assignment. If the Investigator decides that unblinding is warranted, it is the responsibilit y of the 
Invest igator to prompt ly document the deci sion and rati onale and notify  Lilly  as soon as 
possible.
6.4. Study Intervention Compliance
Parti cipant com pliance wi th study  drug will be assessed at each visit. Compliance will be 
assessed by  [CONTACT_226392] (capsules). Study  drug 
compliance will  be determined by [CONTACT_716]:
Study  drug administration data will be recorded by [CONTACT_226393].
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
45The parti cipants will be instructed to return any  unused study  drug and/or em pty 
vials at the next visit to the study  site for the purpose of performing drug 
accountabilit y.
In addit ion to the assessment of a participant’s compliance wit h the study  drug administration, 
other aspects of compliance with the study  treatm ents will  be assessed at each visit based on the 
participant’s adherence to the visit schedule, complet ion of study ,study  drug administrati on logs, 
and any  other parameters the Invest igator considers necessary .
Parti cipants consi dered to be poorly c ompliant wi th their medicat ion and/or the study  procedures 
will receive addit ional training and instruction, as required, and will be reminded of the 
importance of co mplying wit h the protocol. Addit ional  unscheduled visit s may be scheduled if 
study  site pe rsonnel determine that a participant requires addit ional training for the study  drug 
preparati on and inject ion techniques.
6.5. Dose Modification
If a participant does not tolerate a specific dose level for 1 week (for example, due to moderate -
to-severe nausea, vomiting, or diarrhea) and the Investigator does not believe that the participant 
will tol erate the dose with further exposure, then the Invest igator may reduce the dose to the next 
lower target dose per the instructions below.
To m aintain blinding, the IWRS web site is set up to instruct which bottle of capsules to give the 
participants . It will also manage the dose escalat ion.
LY1 (3/6/12 mg):A participant who does not tolerate the 3 mg dose will need to 
discontinue study  drug. If the parti cipant does not tolerate either the 6 mg or 12 mg doses, 
then the participant will remain on the 3 mg dose (6 mg will not be a maintenance dose).
LY2, LY3 -1, LY3 -2, LY4 -1, and LY4 -2:A participant who does not tolerate the first 
dose l evel, ei ther 3mg or 2 mg, will n eed to discont inue study  drug. Parti cipants who do 
not tol erate ei ther the 6 m g or 8 mg dose level will also need to discont inue study  drug; 
neither the 6 mg nor 8mg doses will be a maintenance dose. If a parti cipant does not 
tolerate a dose l evel above 1 2 mg, then the dose should be dropped to the next 
maintenance dose l evel (12 mg, 24 mg, or 36 mg). If this dose is tolerated for 2 weeks, 
the dose should be increased per original protocol dose escalat ion unt il the maintenance
dose i s achieved. However, if this dose escalat ion is not tolerated, the dose should be 
reduced to the next lower target dose that was tolerated (for example, 12 mg, 24 mg, or 
36mg). The participant will remain at that dose level for the duration of the study .
6.6. Continued Access to Study Intervention after the End of the Study
LY3502970 will not be made available to participants after conclusion o f the study .
6.7. Treatment of Overdose
For thi s study , any total  dose estimated from where the participant is in the dose escalation 
regimen or treatment -maintenance regimen within a 48 -hour time period that is g reater than 
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
46100mgwill be considered an overdose and should be reported per criteria described in Sect ion 
10.3.[ADDRESS_272216] igator should
contact [CONTACT_226394]
evaluate the participant to determine, in consultat ion wit h the medical mo nitor, whether 
study  interventi on shoul d be interrupted or whether the dose should be reduced
closely monitor the parti cipant for any  AE/SAE and laboratory  abnorm alities for at l east 
1 week. Based on the known AE profile o f LY3502970, the f ollowing are the possible 
AEs related to an overdose:
osevere GI events that lead to dehy dration and require medical intervent ion
oCV abnorm alities,such as increase in HR, decrease in BP, and 
supraventricular arrhy thmias/cardiac conduct ion disorders , and
ohypoglycemia
 implement medical intervent ion/monitoring according to the clinical presentation
 obtain a plasma sample for PK analysis as soon as possible fro m the date of the last 
dose of study  intervent ion if requested by [CONTACT_1689] (determined on a case-
by-case basis)
 docum ent the quanti ty of the excess dose as well as the duration of the overdose in the 
CRF.
6.8. Concomitant Therapy
Allowed conco mitant m edicati ons shoul d be taken according to label direct ions.Medicat ions 
that may be affected by  [CONTACT_226395] d be separated from study drug 
administration by [CONTACT_2669] 2 -4 hours .
Any medicat ion or vaccine (including over -the-counter or prescript ion medicines, vitamins, 
and/or herbal supplements or other specific categ ories of interest) that the participant is receiving 
at the time of enrollment or receives during the study  must be recorded along wit h
 reason for use
dates of administration including start and end dates , and
dosage information ,including dose and frequen cy for concomi tant therapy  of 
special interest .
The m edical  monitor shoul d be contact[CONTACT_17064] .
Parti cipants cannot be taking strong CYP3A inhibitors or strong CYP 3A inducers and drugs that 
are sensit ive P -gp/BCRP substrates with a narrow therapeut ic index. Tobe eligible for screening 
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
47into this study , those drugs need to be washed out for at least [ADDRESS_272217] of strong CYP3A4 inhibitors and strong CYP3A inducers , which 
are listed below:
boceprevir
cobicistat
danoprevir and ritonavir
elvitegravir and ritonavir
grapefruit juice
indinavir and ritonavir
itraconazo le
ketoconazo le
lopi[INVESTIGATOR_5326] r and ri tonavir
paritaprevi r and ri tonavir and o mbitasvir and/or dasabuvir
posaconazole
ritonavi r
saquinavir and ritonavir
telaprevir
tipranavi r and ri tonavir
telithromycin
troleando mycin
voriconazo le
clarithromycin
nefazo done
nelfinavir
apalutamide
carbamazepi[INVESTIGATOR_050]
enzalutamide
mitotane
phenytoin
rifampin , and
St. John’s wort .
Tobe eligible for screening into this study, participants taking the following anti-fungal agents
ketoconazo le
itraconazo le
voriconazo le, and
posaconazole
shoul d discont inue taking these medicat ions for at least 2 weeks prior to screening. However, if 
the participant is unable to wash out these drugs, then if appropriate, the participant could switch 
to
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
48miconazo le
clotrimazol e or
fluconazo le.
For participants taking clarit hromycin or telit hromycin, azithro mycin may be subst ituted 2 weeks 
prior to beginning screening. Participants who chronically use these drugs should be excluded.
Parti cipants taking sensi tive P-gp substrates are excluded fro m being screened for thi s study .
Examples of sensit ive P-gp substrates are
digoxin
fexofenadine
loperamide
quinidine
talino lol, and
vinblast ine.
Parti cipants taking sensit ive BCRP substrates are excluded fro m being screened for this 
study .
Examples of sensit ive BCRP substrates are
coum estrol
daidzein
genistein
prazosin, and
sulfasalazine.
Initial doses of LY3502970 may  delay  gastri c emptying and have the potential to transient ly 
impact the rate of absorption of conco mitantly administered oral medicinal products. LY3502970 
shoul d be used wi th cauti on in part icipants receiving oral medicinal products that require rapid 
gastrointestinal absorption fo llowing the init ial doses of LY3502970 as exposure to oral 
medicat ions m ay be increased.
6.8.1. Management of Participants wit h Gastrointestinal Symptoms
In the Phase [ADDRESS_272218] commo nly reported TEAEs for parti cipants receiving 
LY3502970 were nausea and vo miting diarrhea. To mit igate GI symptoms and manage 
participants wi th intolerable GI AEs, the Investigator should
Advise parti cipants to eat smaller meals, for example, splitt ing 3 daily meals into 4, 
or more sm aller m eals, and to stop eating when they  feel full. Also, participants may  
be informed that lower -fat meals coul d be better tolerated.
Prescribe symptomat ic med ication (f or example, ant iemetic or antidiarrheal 
medicat ion) per local country  availabilit y and individual participant needs. Use of 
symptom atic medicat ion shoul d be captured as concomitant medicat ion in the eCRF.
Temporarily  interrupt study  drug (omi t 1 to 3 doses). The data related to temporary  
interrupti on of  study  treatm ent shoul d be documented i n source documents and 
entered on the eCRF.
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
49After the interruption, restart at the same dose with the pa rticipant taking medicat ion 
to alleviate their GI sympt oms.
If intolerable GI symptoms or events persist despi[INVESTIGATOR_10902], see Section 6.5.
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
507. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal
Discontinuati on of  specific sites or of the study  as a who le ishandled as part of Appendix 1.
7.1. Discontinuation of Study Intervention
In rare instances, it may be necessary  for a parti cipant to perm anent ly discont inue study  
intervention. If study  intervent ion is perm anent ly discontinued, the participant will remain in the 
study  to be evaluated for all planned efficacy and safet y measures . See the SoA for data to be 
collected at the time of discont inuat ion of study  intervent ion and follow-up and for any  further 
evaluat ions that need to be completed.
Possible reasons leading to permanent discontinuatio n of invest igational product include
Parti cipant decisio n
othe participant or the participant’s designee (for example, parents or legal guardian) 
requests to discont inue invest igational product
Invest igator decision
othe Invest igator decides that the pa rticipant shoul d be discont inued fro m the 
study  medicat ion
Any non-study medication for wei ght loss is given for more than 1 week
Parti cipants will be discont inued fro m the invest igational product in the fo llowing 
circumstances:
oDiagnosis of cirrhosis after randomizat ion
oPancreat itis or pancreatic cancer
oDiagnosis of medullary thyro id cancer (MTC) after randomizat ion
oDiagnosis of an active or untreated malignancy  (other than basal  or squam ous 
cell skin cancer, in situ carcino mas of the cervix, or in situ prostate cancer) after 
rando mizat ion
oAny TEAE, SAE, or clinically significant laboratory  value for which the 
Invest igator believes that permanent study  drug discontinuat ion is the 
appropriate measure to be taken
oA female part icipant beco mes pregnant , and
oDiagnosis of T1DM or latent autoimmune diabetes in adults .
If the participant develops any exclusio n criteria during the course of the study , the 
Invest igator should call the Sponsor to determine whether discont inuat ion of study  drug 
is necessary
Significant non compliance with the protocol .
Ifstudy  drug i s permanently discont inued, the participant should remain in the study  if possible. 
The parti cipant shoul dcontinue part icipation in the study, attend all visit s, and undergo most 
protocol  procedures.
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
51Parti cipants discont inuing from the invest igational product prematurely  for any reason shoul d 
complete AE and other fo llow-up procedures per Section 1.3(Schedule of Act ivities), Section
10.3 (Adverse Events and Serious Adverse Events), and Section 8.2(Safety Assessments) of the 
protocol .
7.1.1. Liver Chemistry Stoppi[INVESTIGATOR_226352] d be interrupted or discont inued if one or more of these condit ions occur:
Elevation Exception
ALT or AST >[ADDRESS_272219] >[ADDRESS_272220] >[ADDRESS_272221] and either TBL >[ADDRESS_272222] or 
INR >1.5 In parti cipants wi th Gilbert’s 
syndro me, doubling of direct 
bilirubin should be used for drug 
interrupti on/discont inuat ion 
decisio ns rather than TBL >2X
ULN
ALT or AST >[ADDRESS_272223] with the appearance of 
fatigue, nausea, vo miting, right upper quadrant pain 
or tenderness, fever, rash, and/or eosinophilia (>5%)
ALP >3X ULN, when the source of increased ALP is 
the liver
ALP >2.5X ULN and TBL > 2X ULN In parti cipants wi th Gilbert’s 
syndro me, doubling of direct 
bilirubin should be used for drug 
interrupti on/discont inuat ion 
decisio ns rather than TBL >2X
ULN
ALP >2.5X ULN with the appearance of fatigue, 
nausea, vo miting, right upper quadrant pain or 
tenderness, fever, rash, a nd/or eosinophilia (>5%)
Source: FDA Guidance for Industry: Drug-Induced Liver Injury: Premarketing Clinical Evaluation, July [ADDRESS_272224] results return to baseline and if a self -limit ed non -drug 
etiology is identified.
7.1.2. QTc Stoppi[INVESTIGATOR_226353]’s formula(QTcF) of an ECG tri plicate is >500 
ms or there is >[ADDRESS_272225] igator or qualified designee will determine if the participant can continue in the study 
and if any  change in participant management is needed.
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
527.1.3. Temporary Discontinuation
After rando mizat ion, the Investigator may interrupt study drug, for example, due to an AE ( for 
example , nausea and vomit ing), or a clinically  significant l aboratory  value. If study  drug 
interrupti on is due to an AE, the event is to be followed and documented. Every  effort sh ould be 
made by  [CONTACT_226396], as soon as i t is safe to do so ( see Secti on 7.1.4 for restarting study  drug). 
The dates of study  drug interrupti on and restart must be documented. The data related to 
interrupti on of  study  treatm ent will  be docum ented in source documents and entered on the 
eCRF. Participant noncom pliance shoul d not be recorded as interruption of study  drug on the 
eCRF.
7.1.4. Restarting Study Drug after Interruption or Missed Doses
If the number of consecut ive missed doses is ≤7, the treatment can be restarted at the same dose, 
if the drug was well tolerated pri or to di scontinuat ion.
Parti cipants who have missed >7 days of study  drug will need to restart the study  drug at the 
8mg dose (LY3502970 treatment groups 2, 3, 4 -1, 4-2) and dose -escalate according to the 
protocol , including if the participants were in the early  part of the dose escalat ion and were 
taking doses less than [ADDRESS_272226] missed >7 days of study  drug in the LY 1 
treatm ent group will need to restart drug at 6 mg. To maintain blinding o f the Investigator and 
participant, these changes may be made through the IWRS web site and IWRS will provide 
dispensing information. Dose reductions may occur at unscheduled visit s.
7.2. Participant Discontinuation/ Withdrawal from the Study
A participant may withdraw from  the study
●at any  time at his/her own request
●at the request of his/her designee (for example, parents or legal guardian)
●at the discretion of the Investigator for safet y, behavioral, co mpliance, or 
administrative reasons
●if enro llment in any  other clinical  study  involving an invest igational product or 
enrollment in any other type o f medical research judged not to be scient ifically or 
medically co mpat ible with this study , and
●if the participant , for any  reason, requi res treatm entwith another therapeutic agent 
that has been demo nstrated to be effect ive for treatment of the study  indicat ion, 
discontinuat ion from the study  drug occurs pri or to introduction of the new agent .
Discontinuati on is expected to be uncommo n.
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
53At the time of discont inuing from the study , if possible, an early discont inuat ion visit should be 
conducted, as shown in the SoA. See SoA for data to be collected at the time of study  
discontinuat ion and fo llow-up and for any  further evaluat ions that need to be complete d.The 
participant will be permanent ly discont inued fro m both the study  interventi on and the study  at 
that time.
If the participant withdraws consent for disclos ure of  future inform ation, the Sponsor may retain 
and cont inue to use any data collected before such a withdrawal o f consent .If a participant
withdraws fro m the study , he/she may  request destructi on of  any sam ples taken and not tested ,
and the Investigator must document this in the site study records .
7.2.1. Discontinuation of Inadvertently Enrolled Parti cipants
If the Sponsor or Invest igator ident ifies a participant who did not meet enrollment criteria and 
was inadvertently enrolled, then the participant shoul d be di scontinued from study  treatm ent 
unless there are extenuat ing circumstances that make it medically advisable for the participant to 
continue on study  treatm ent. If the I nvest igator and the Lilly CRP /CRS agree i t is medically 
appropriate to cont inue, the Investigator must obtain documented approval fro m the Lilly 
CRP/CRS to allow the inadvertent ly enro lled participant to continue in the study with or without 
treatm ent wi th invest igational product. Safet y follow-up shoul d be perform ed as outlined in 
Secti on1.3(SoA), Secti on8.2(Safety Assessments) , and Section 8.3.(Adverse Events, Serious 
Adverse Events, and Product Complaints) of the protocol.
7.3. Lost to Follow -Up
A participant will be considered lost to follow -up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contact[CONTACT_17066]. Si te personnel or desi gnee are 
expected to make diligent attempts to contact [CONTACT_10971] a scheduled visit 
or were otherwise unable to be fo llowed up by [CONTACT_779].
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
548. Study Assessments and Procedures
Study  procedures and their timing are summarized in the SoA.
Immediate safet y concerns shoul d be discussed wit h the Sponsor immediately 
upon occurrence or awareness to determine if the participant should continue 
or discontinue study  intervent ion.
Adherence to the study  design requi rements, including those specified in the 
SoA, i sessent ial and requi red for study conduct.
All screening evaluat ions must be com pleted and reviewed to confirm that
potenti al participant s meet all  eligibili ty criteria. The Invest igator will 
maintain a screening log to record details o f all participant s screened and to 
confirm eligibilit y or record reasons for sc reening failure, as applicable.
8.1. Efficacy Assessments
Primary:
The primary  efficacy measure ispercent change in body  weight from  baseline at Week 26 .
Secondary:
The fo llowing s econdary  efficacy measures will be collected at the times shown in the SoA.
Body  weight (see Section 10.7 for measurement procedure)
BMI (see Section 10.7 for measurement procedure ), and
Waist circumference (see Section 10.7 for measurement procedure) .
Exploratory:
Percentage of study  partici pants who achieve ≥15% body  weig ht reduction
HbA1c as determined by [CONTACT_12115]
FBG as determined by [CONTACT_12115]
Mechanist ic biomarkers
Patient-reported outcomes (see Sect ion 10.9 for details)
oSF-36v2 acute form dom ain and summary  scores
oIWQOL -Lite-CT com posite and total  scores
oPGIS for Physical Act ivity, and
oSummary  statistics of actual responses to Participant Survey .
8.2. Safety Assessments
Planned time po ints for all safet y assessments are provided in the SoA.
8.2.1. Physical Examinations
A co mplete physical examinat ion will include, at a minimum, assessments of the cardi ovascular, 
respi [INVESTIGATOR_696] , gastrointestinal ,and neurol ogicalsystems. Height and weight will also be measured 
and recorded as per the SoA ( Section 1.3).Refer to Section 10.7 for further details on weight 
measurements.
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
55A brief physical examinat ion will include, at a minimum, assessments of the skin, lungs, 
cardi ovascular system , and abdom en (liver and spleen).
Invest igators should pay special attention to clinical signs related to previous serious illnesses.
8.2.2. Vital Signs
For each participant, vi tal signs m easurements shoul d be conducted according to the 
Schedule of Act ivities (Section 1.3) and fo llowing the study -specific recommendations 
included in Section 10.7.
Any clinically  significant findings from vital signs measurement that res ult in a di agnosis and
that occur after the participant receives the first dose of study  intervent ion shoul d be reported to
Lilly or i ts desi gnee as an AE via eCRF.
8.2.3. Electrocardiograms
For each participant, 12 -lead ECGs should be co llected according to Section 1.3.
All digital single and triplicate ECGs will be obtained using centrally provided ECG 
machines and will be electronically transmitted to a designated central  ECG l aboratory .
12-lead ECGs should be obtained after the participant has rested in a supi[INVESTIGATOR_226354] [ADDRESS_272227] ion of more ECGs than expected at a particular time point is allowed when needed to 
ensure high -qualit y records.
Electrocardiograms will initially be interpreted by  a qualified physician (the Invest igator or 
qualified designee) at the site as soon after the time of ECG collection as possible, and ideally  
while the pa rticipant is still present, to determine whether the participant meets entr y criteria and 
for immediate participant management, should any clinically  relevant findings be identified. Any 
clinically significant findings fro m ECGs that result in a diagnosis and that occur after the 
participant receives the first dose of the invest igational treatment should be reported to Lilly or 
its designee as an AE. The Invest igator (or qualified designee) is responsible for determining if 
any change in participant management is needed andmust docum ent his/her review of the ECG 
printed at the ti me of evaluat ion.
After enro llment, if a clinically significant increase in the QT/QTc interval fro m baseline or 
other clinically significant quantitative or qualitat ive change fro m baseline is identified, the 
participant will be assessed by [CONTACT_226397] (for example, palpi[INVESTIGATOR_53895], near 
syncope, and syncope) and to determine whether the participant can continue in the study . The 
Invest igator or qualified designee is responsible fo r determining if any change in participant
management is need ed and m ust docum ent his/her review of the ECG printed at the time of 
evaluat ion from at least 1 of the replicate ECGs from each time point.
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
56The central ECG laboratory  will perf orm a basic quali ty control  check (for example, 
demographics and study  details) of the di gital ECG and then store the ECGs in a database. At a 
future time, the stored ECG data may be over -read by  a cardi ologist at the central ECG 
laboratory  for further eval uation of  machine -read measurements or to meet regulatory  
requi rements.
The m achine -read ECG intervals and HR may be used for data analysis and report -writing 
purposes, unless a cardio logist over -reading of the ECGs is conducted prior to complet ion of the 
final study  report (in which case, the over -read data would be used).
Any trea tment-emergent clinically significant ECG finding result ing in a diagnosis shoul d be 
reported as an AE in the eCRF.
8.2.4. Ambulatory B lood Pressure Monitoring (ABPM)
Ambulatory Monitoring Device
An ambulatory  monitoring device that uses an inflatable cuff attached to a portable device worn 
around the waist will be used to collect mult iple BP and HR readings over a [ADDRESS_272228] variat ions over time, and to compute other distribution 
patterns.
Study Procedures
Parti cipants who give consent and meet all eligibility  requi rements will  receive edu cation about 
ABPM and will be trained in its use at Visit 2. Ambulatory  monitoring of HR and BP will be 
perform ed at Visi t 2 (Week -1), and Visit 1 5(Week 26: primary endpoint ). It will not be 
considered a protocol deviat ion if a parti cipant does not meet all ABPM eligibilit y requirements 
or refuses to participate in ABPM procedures.
Use of the ABPM Device
The ABPM device will be attached to the nondominant arm, and part icipants will be instructed to 
wear the monitor for a 24- to 27 -hour period. Participant s will also be instructed to keep track of 
daily  activi ties throughout the testing period and not to engage in strenuous activit y.
Ambulatory  blood pressure measurements:
Shoul d be co llected on a ty pi[INVESTIGATOR_226355] -day, not on a non -working day
Will be recorded every 30 minutes during dayt ime hours (0700 to 2200 hours)
Will be recorded every  60 minutes during nighttime hours (2200 to 0700) .
A 24 -hour sessio n of ambulatory  monitoring produces technically  acceptable measurements if 
≥70% of  the readings are valid.
If a technically  satisfactory  resul t is not achi eved, the Invest igator should review the device 
settings and placement and the participant’s act ivity track in an attem pt to correct any  user error 
or device malfunct ions. Another 24- hour ambulatory  monitoring sessio n shoul d be conducted 
prior to Visit 3 ,and this measurement will serve as the baseline value. If the second sessio n also 
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
57provi des technically  unsati sfactory  resul ts, the participant should not undergo any  further ABPM 
measures.
8.2.5. Clinical Safety Labo ratory Tests
●See Secti on 10.2 (Appendix 2 )for the list of clinical laboratory tests to be 
perform ed and the So A for the timing and frequency.
●TheInvestigator must review the laboratory  resul ts, docum ent this review, and 
report any clinically relevant changes occurring during the study as an AE . The 
laboratory  resul ts must be retained wit h source documents unless a Source 
Docum ent Agreement or com parable document cites an electronic location that 
accommodates the expected retention duration. Clinically significant abnormal 
laboratory  findings are those which are not associated with the underlying disease, 
unless judged by [CONTACT_226398] ’s condi tion.
●All laboratory  tests wi th values considered clinically  significantly abnorm al 
during participat ion in the study or within [ADDRESS_272229] dose of study  
intervent ion shoul d be repeated until the values return to normal or baseline or are 
no longer consi dered clinically  significant by  [CONTACT_226399].
○If such values do not return to normal/baseline wit hin a peri od of  time judged 
reasonable by [CONTACT_737], the etiology  shoul d be ident ified and the 
Sponsor notified.
○All protocol -requi red laboratory  assessments, as defined in Appendix 2, must 
be conducted in accordance with the SoA , standard collect ion requirements , 
and laboratory  manual .
●If laboratory  values fro m non-protocol -specified laboratory  assessments 
perform ed at an Invest igator -designated l ocal laboratory  requi re a change in 
participant m anagement or are considered clinically  significant by  [CONTACT_24342] 
(for example , SAE or AE or dose modificat ion), then report the informat ion as an 
AE.
8.2.6. Pregnancy Testing
Female participants will undergo a serum pregnancy  test at screening
8.2.7. Suicidal Ideation and Behavior Risk Monitoring
Parti cipants who have obesit y or are overwei ght are at increased risk for depressio n (Luppi[INVESTIGATOR_226356]. 2010). Depressi on can increase the risk for suicidal ideat ion and behavior. Therefore, study  
participants will be screened at trial entry  and m onitored during the study  for depressi on, suicidal  
ideat ion, and behavior.
Participants shoul d be m onitored appropriately  and observed closely for suicidal ideation and 
behavior or any  other unusual changes in behavior, especially at the beginning and end of the 
course of treatment, or at the time of dose changes, either increases or decreases. Considerat ion 
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
58shoul d be given to discont inuing the study medicatio n in who experience signs of suicidal 
ideat ion or behavior, fo llowing a ri sk assessment.
Baseline and treatment -emergent assessment of depressio n, suicidal ideat ion, and behav ior will 
be monitored during the study  using the C -SSRS and PHQ -9 (Section [IP_ADDRESS] ).
8.2.8. Safety Monitoring
Lilly will periodically  review evolving aggregate safet y data wi thin the study  by [CONTACT_82393]. The study  team  will review safet y reports in a blinded fashio n (for applicable blinded 
study  period) according to the schedule provided in the Trial -Level  Safety  Review plan. Lilly  
will also review SAEs within t ime frames mandated by  [CONTACT_221056]. The Lilly 
CRP /CRS will, as appropriate, consult with the functionally independent Global Pat ient Safet y 
therapeuti c area physician or clinical scient ist.Safety  monitoring will include review of hepat ic, 
pancreat ic, cardiovascular, thy roid C-cell function, and renal safet y data. The hepat ic safet y 
monitoring plan is provided below; for additional informat ion, please see also Secti on10.5.
Close Hepatic Monitoring
Laboratory  tests (Secti on 10.5), including ALT, AST, ALP, total bilirubin, direct bilirubin, 
gamma- glutamyl transferase, and creat ine kinase, should be repeated within 48 to 72 hours to 
confirm the abnormalit y and to determine if it is increasing or decreasing, if 1 or more of these 
condi tions occur:
If a participant with baseline results 
of…develops the following elevations
ALT or AST <1.5X ULN ALT or AST ≥3X ULN
ALP <1.5X ULN ALP ≥2X ULN 
TBL <1.5X ULN TBL ≥2X ULN (except for participants with 
Gilbert’s syndrome)
ALT or AST ≥1.5X ULN ALT or AST ≥2X baseline 
ALP ≥1.5X ULN ALP ≥2X baseline 
TBL ≥1.5X ULN TBL ≥1.5X baseline (except for participants 
with Gilbert’s syndro me)
If the abnormalit y persists or worsens, clinical and laboratory  monitoring, and evaluat ion for 
possible causes of abnormal liver tests should be init iated by  [CONTACT_226400] -designated m edical mo nitor. A t a minimum, this evaluat ion shoul d include physical 
examinat ion and a thorough medical history , including symptom s, recent illnesses (for example, 
heart failure, systemic infect ion, hypotension, or seizures), recent travel, history  of concomi tant 
medicat ions (including over -the-counter), herbal and dietary  supplements, and history  of alcohol  
drinking and other substance abuse.
Initially, m onitoring of  symptoms and hepat ic biochemical tests should be done at a frequency o f 
1 to 3 times weekly , based on the participant’s clinical condit ion and hepat ic biochemical tests. 
Subsequently, the frequency  of monitoring m ay be l owered to once every  1 to 2 weeks, if the 
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
59participant’s clinical condit ion and l ab resul ts stabilize. Moni toring of ALT, AST, ALP, and 
TBL sho uld cont inue unt il levels normalize or return to approximate baseline levels.
Comprehensive Hepatic Evaluation
A co mprehensive evaluat ion shoul d be perform ed to search for possible causes of liver injury  if 
1 or m ore of these condit ions occur:
If a participant with baseline results of… develops the following elevations:
ALT or AST <1.5X ULN ALT or AST ≥3X ULN with hepat ic 
signs/symptom s*, or
ALT or AST ≥5X ULN 
ALP <1.5X ULN ALP ≥3X ULN 
TBL <1.5X ULN TBL ≥2X ULN (except for participants with 
Gilbert’s syndrome) 
ALT or AST ≥1.5X ULN ALT or AST ≥2X baseline wit h hepat ic 
signs/symptom s*, or
ALT or AST ≥3X baseline 
ALP ≥1.5X ULN ALP ≥2X baseline 
TBL ≥1.5X ULN TBL ≥2X baseline (except for participants with 
Gilbert’s syndrome) 
*Hepatic signs/symptoms are severe fat igue, nausea, vomit ing, j aundice, ri ght upper quadrant 
abdo minal pain, fever, rash, and/or eosinophilia >5%.
At a minimum, this evaluat ion should inc lude physical examinat ion and a thorough medical 
history , as outlined above, as well as tests for prothrombin t ime (PT -INR; tests for viral 
hepat itisA, B, C, or E; tests for autoimmune hepatit is; and an abdo minal imaging study  (for 
example, ultrasound or computed tomography scan).
Based on the participant’s history  and ini tial resul ts, further testing should be considered in 
consultation wit h the Lilly -designated m edical m onitor, including tests for hepatit is D virus, 
cytomegalovirus, Epstein -Barr virus, a cetaminophen levels, acetaminophen protein adducts, 
urine toxico logy screen, Wilso n’s disease, blood alcohol levels, urinary ethyl glucuronide, and 
blood phosphat idylethano l. Based on the circumstances and the Invest igator’s assessment of the 
participant’s clinical condit ion, the Investigator should consider referring the participant for a 
hepatol ogist or gastroenterologist consultation, magnet ic resonance cho langiopancreatography , 
endoscopi c retrograde cholangiopancreatography , cardi ac echocardi ogram , or a liver biopsy.
Additional Hepatic Data Collection (Hepatic Safety CRF) in Study Participants Who Have 
Abnormal Liver Tests during the Study
Addit ional hepatic safet y data collect ion in hepat ic safet y CRFs shoul d be performed in study  
participants who meet 1 or more of the fo llowing 5 condi tions:
1.Elevat ion of serum ALT to ≥5X ULN on 2 or more consecutive blood tests (if baseline 
ALT <1.5X ULN)
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
60In parti cipants wi th baseline ALT ≥1.5X ULN, the thresho ld is ALT ≥3X baseline on 
2 or m ore consecut ive tests
2.Elevat ed TBL to ≥2X ULN (if baseline TBL <1.5X ULN) (except for cases of known 
Gilbert’s syndrome)
In parti cipants wi th baseline TBL ≥1.5X ULN, the thresho ld should be 
TBL ≥2X baseline
3.Elevat ion of serum ALP to ≥2X ULN on 2 or more consecutive blood tests (if ba seline 
ALP <1.5X ULN)
In parti cipants wi th baseline ALP ≥1.5X ULN, the thresho ld is ALP ≥2X baseline on 
2 or m ore consecut ive blood tests
4.Hepati c event consi dered to be an SAE
5.Discontinuati on of  study  drug due to a hepati c event
Note: The interval be tween the [ADDRESS_272230] Complaints
The definit ions of the fo llowing events can be found in Appendix 3:
Adverse events (AEs)
Serious adverse events (SAEs) , and
Product complaints (PCs) .
These events will be reported by  [CONTACT_17071] (or, when appropriate, by  a caregiver, surrogate, 
or the participant ’s legally authori zed representative).
The Investigator and any qualified designees are responsible for detecting , documenting, and 
recording events that meet these definit ions and remain responsible for fo llowing up events that 
are seri ous, considered related to the study  intervent ion or study  procedures, or that caused the 
participant to di scont inue the study  interventionor the study  (see Section 7).
Care will be taken not to introduce bias when detecting events. Open -ended and non -leading 
verbal quest ioning of the parti cipant is the preferred method to inquire about event occurrences.
After the init ial report, the I nvest igator is required to proactively fo llow each participant at 
subsequent visits/contacts. All SAEs and AEs o f speci al interest will be follow ed until 
resol ution, stabilization, the event is otherwise explained, or the participant is lost to fo llow-up 
(as defined in Sect ion7.3). For PCs, the Investigator is responsible for ensuring that fo llow-up 
includes any supplemental invest igations as indicated to elucidate the nature and/or causalit y. 
Further informat ion on fo llow-up procedures i s provi ded in Section 10.3.
8.3.1. Timing and Mechanism for Collecting Events
Thistable describes the timing, deadlines ,and m echanism for collect ing events.
Event Collection 
StartCollection 
StopTiming for 
Reporting to Sponsor 
or DesigneeMechanism for 
ReportingBack -Up 
Method of 
Reporting
Adverse Event
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
61Event Collection 
StartCollection 
StopTiming for 
Reporting to Sponsor 
or DesigneeMechanism for 
ReportingBack -Up 
Method of 
Reporting
AE Start of drug Participation in 
study has endedShould be recorded in 
the eCRF as soon as 
possible. The Sponsor 
will periodically 
evaluate safety data in 
the eCRFAE eCRF N/A
Serious Adverse Event
SAE and SAE 
updates –prior 
to start of study 
interventio n 
anddeemed 
reasonably 
possibly related 
with study 
proceduresSigning of 
the ICFStart of 
interventio nWithin 24 hours of 
awarenessSAE eCRF SAE paper 
form
SAE and SAE 
updates –after 
start of study 
interventio nStart of 
interventio nParticipation in 
study has endedWithin 24 hours of 
awarenessSAE eCRF SAE paper 
form
SAE* –after 
participant’s 
study 
participation has 
ended andthe 
Investigator 
becomes awareAfter 
participant’s 
study 
participation 
has endedN/A Promptly SAE paper form N/A
Pregnancy
Pregnancy in 
female 
participants and 
female partners 
of male 
participantsAfter the 
start of study 
interventio n90 days or [ADDRESS_272231] participant 
visitWithin 24 hours (see 
Section 8.3.2 )Pregnancy paper 
formSAE paper 
form
Product Complaints
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
62Event Collection 
StartCollection 
StopTiming for 
Reporting to Sponsor 
or DesigneeMechanism for 
ReportingBack -Up 
Method of 
Reporting
PCassociated 
with an SAE or 
might have led 
to an SAEStart of study 
interventio nEnd of study 
interventio nWithin [ADDRESS_272232] Complaint 
formN/A
PC not 
associated with 
an SAEStart of study 
interventio nEnd of study 
interventio nWithin [ADDRESS_272233] Complaint 
formN/A
Updated PC 
information— — As soon as possible 
upon site awarenessOriginally 
completed Product 
Complaint form 
with all changes 
signed and dated by 
[CONTACT_226401]/A
PC (if 
Investigator 
becomes aware)Participation 
in study has 
endedN/A Promptly Product Complaint 
form
*Serious adverse events should not be reported unless the Investigator deems them to be possibly related to study 
treatment or study participation .
8.3.2. Pregnancy
Collection of Pregnancy Information
Male participants w ith partners who become pregnant
●The Investigator will attempt to collect pregnancy informat ion on any male 
participant’s female partner who beco mes pregnant while the male participant is 
in this study . This applies only  to m ale parti cipants who receive study  drug.
●After obtaining the necessary  signed informed consent from the pregnant female 
partner direct ly, the Investigator will record pregnancy informat ion on the 
appropriate form and submit it to the S ponsor within 24 hours of learning o f the 
partner’s pregnancy. The female partner will also be fo llowed to determine the 
outcom e of the pregnancy . Informati on on the status of the mother and child will 
be forwarded to the Sponsor. Generally, the fo llow-up will be no longer than [ADDRESS_272234] imated delivery date. Any terminat ion of the pregnancy 
will be reported regardl ess of gestati onal age, fetal status (presence or absence of 
anomalies),or indication for the procedure.
Female participants who become pregnant
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
63●The Investigator will co llect pregnancy informat ion on any female participant 
who beco mes pregnant while part icipating in this study . The init ial inform ation 
will be recorded on the appropriate form and submitted to the S ponsor within 24 
hours of learning of a participant ’s pregnancy.
●The parti cipant will be fo llowed to determine the outcome of the pregnancy . The 
Invest igator will co llect fo llow-up inform ation on the participant and the neonate ,
and the information will be forwarded to the Sponsor. Generally, follow-up will 
not be required for longer than 6 to 8 weeks bey ond the estimated delivery  date. 
Any terminat ion of pregnancy  will be reported, regardl ess of gestati onal age, fetal 
status (presence or absence of anomalies) ,or indication for the procedure.
●While pregnancy  itself is not considered to be an AE or SAE, any  pregnancy  
complicat ion or el ective terminat ion of a pregnancy  for m edical  reasons will be 
reported as an AE or SAE.
● A spontaneous abortion (occurring at <20 weeks gestational age) or stil l birth 
(occurring at ≥20 weeks gestational age) is always considered to be an SAE and 
will be reported as such.
●Any post studypregnancy -related SAE considered reasonably  related to the study  
intervent ion by [CONTACT_226402]8.3.[ADDRESS_272235] igator is not obligated to actively seek this 
inform ation in former study  parti cipants, he or she may learn o f an SAE through 
spontaneous reporting.
●Any female part icipant who becomes pregnant while participat ing in the study  
will discont inue study  intervent ion.If the participant is discont inued from the 
study , follow the standard di scont inuation process and cont inue direct ly to the 
follow-up phase. The fo llow-up on the pregnancy  outcome shoul d continue 
independent of intervent ion or study  discontinuat ion.
8.3.3. Adverse Events of Special Interest
The fo llowing are AEs of special interest and will be adjudicated by  [CONTACT_15731] :
pancreat itis
major adverse cardiovascular events
drug-induced liver injury ,and
deaths.
The fo llowing are addi tional AEs of special  interest for thi s program  that will  not be adj udicated 
by [CONTACT_226403]:
hypoglycemia (Level 2 and 3)
thyroid malignancies and C -cell hyperpl asia
supraventricular arrhy thmias and cardiac conductive disorders
hepatobiliary  disorders
severe GI AEs
acute renal events, and
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
64depressio n, suicidal ideat ion, orbehavior monitoring.
Sites shoul d collect addi tional details and data regarding these safet y topi[INVESTIGATOR_1102], as instructed on the 
applicable eCRFs, and detailed below.
[IP_ADDRESS]. Hypoglycemia
Upon ICF signing, all participants will be educated about signs and symptoms of hypoglycemia 
and how to treat hy poglycemia. Parti cipants will be asked to con tact si te personnel if they 
experience any of these symptoms.
Hypoglycemia may  be identified by [CONTACT_105418] 
(whether confirmed or unconfirm ed by [CONTACT_105419]) or by  [CONTACT_226404].
All participants who develop incident diabetes during the study  will be provi ded wi th 
glucometers. Parti cipants wi thout di abetes m ay, at the Invest igator’s discret ion, be gi ven 
glucometers to assist in the evaluat ion of reported symptoms consistent with hypoglycemia. 
Parti cipants receiving gl ucometers will be provided a diary to record relevant information (for 
example, glucose values and symptoms).
Parti cipants who devel op incident diabetes during the study  may be started on allowed glucose -
lowering m edicati ons. In the event that participants subsequent ly develop persistent or recurrent 
unexplained hypoglycemia during the treatment period, participants will be asked to reduce the 
dose of LY3502970.
All hypoglycemic epi[INVESTIGATOR_226357]. If a 
hypoglycemic event meets severe criteria (see definit ion below), it should be recorded as serious 
on the AE and SAE eCRFs and reported t o Lilly  as an SAE.
Invest igators should use the fo llowing definit ions and criteria when diagnosing and categorizing 
an epi[INVESTIGATOR_105397] (the BG values in this sect ion refer to values 
determined by a laboratory  or Internati onal Federati on of  Clinical  Chemistry  and Laboratory  
Medicine blood -equivalent glucose meters and strips) in accordance with the 2020 American 
Diabetes Association posit ion statem ent on glycemic targets (ADA 2020). Level [ADDRESS_272236]:
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
65Level 1 hypoglycemia:
Glucose <70 mg/dL (3.9 mmol/L) and ≥54mg/dL (3.0 mmol/L): Level [ADDRESS_272237] -acting carbohydrates. Prov iders should 
continue to counsel participants to treat hypoglycemia at this glucose alert value.
Level 2 hypoglycemia:
Glucose <54 mg/dL (3.0 mmol/L): This isalso referred to as documented or BG -confirmed 
hypoglycemia with glucose <54 mg/dL (3.0 mmo l/L). This glucose threshold is clinically 
relevant regardless of the presence of absence of symptoms of hypoglycemia.
Level 3 hypoglycemia:
Severe hypoglycemia (in adults): A severe event characterized by [CONTACT_226405]/or 
physical status requiring assistance for treatment of hypoglycemia. For example, p articipants
hadaltered mentalstatus and could not assist in their own care, or were semiconscious or 
unconscious, or experienced comawithorwithout seizures, andthe assistance of another 
person w as needed to actively  administer carbohydrate, glucagon, or other resuscitative
actions. Glucose measurements may not be available during such an event, but neurological 
recovery attributable to the restoration of glucose concentration tonormal isconsidered
sufficient evidence that the event was induced by [CONTACT_226406].
The determinat ion of a hypoglycemic event as an epi[INVESTIGATOR_66677], as 
defined above, is made by [CONTACT_226407] a 
participant simply having received assistance.
If a hypoglycemic event meets the criteria of severe hypoglycemia, the Invest igator 
must record the event as serious on the AE CRF and report it to Lilly as an SAE.
Nocturnal hypoglycemia :
Nocturnal hypoglycemia is a hypoglycemia event (including severe hypoglycemia) that 
occurs at night and presumably during sleep.
To avoid duplicate reporting, all consecutive BG values <70 mg/dL (3.9mmo l/L) occurring 
within a 1- hour period may be considered to be a single hypoglycemic event (Weinberg et
al.2010; Danne et al. 2013).
[IP_ADDRESS]. Pancreatitis
Diagnosis of Acute Pancreatitis
Acute pancreat itis is an AE of interest in all studies with LY3502970, including this study. The 
diagnosis of acute pancreat itis requires 2 of the fo llowing 3 features (Banks and Freeman 2006;
Koizumi 2006):
abdo minal pain, characterist ic of acute pancreat itis (that i s, epi [CONTACT_24365] c pain radiat ing 
to the back, often associated with nausea and vo miting)
serum  amylase (total, pancreat ic, or both) and/or lipase ≥3X ULN, and
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
66characterist ic findings of acute pancreat itis on CT scan or MRI.
If acute pancreat itis is suspected, the Investigator should ensure that the fo llowing steps are 
taken:
obtain appropriate laboratory  tests, including pancreatic amylase (p -amylase) and 
lipase, and
perform  imaging studies, such as abdo minal CT scan wit h or without contrast, or 
abdo minal MRI.
Note :Abdo minal ultrasound may be used as an alternat ive method only if CT and 
MRI cannot be performed.
evaluate for possible causes of acute pancreatit is, including alcoho l use, gallstone/gall 
bladder disease, hypertriglyceridemia, and conco mitant m edicati ons.
Discontinuation for Acute Pancreatitis
If acute pancreat itis is suspected by  [CONTACT_737], the participant must temporarily discont inue 
use of the study  drug. Afterwards, if the case is confirmed as acute pancreat itis by [CONTACT_226408], st udy drug must be permanent ly discont inued; the participant may 
continue in the study . If the case is not confirmed, then the participant can restart study  drug, if 
the Invest igator deems as clinically appropriate, as described in the Section 6.5.
Case Adjudication and Data Entry
An independent CEC will adjudicate all suspected cases o f acute pancreatit is. Relevant data fro m 
participants wi th acute pancr eatitis will  be entered into a specifically designed eCRF page. The 
adjudicat ion commit tee representative will enter the results of adjudicat ion in a corresponding 
eCRF page.
Asymptomatic Elevation of Pancreatic Amylase and/or Lipase
Serial measures of pancreat ic enzymes have limit ed clinical value for predicting epi[INVESTIGATOR_226358] (Nauck et al . 2017; Steinberg et al. 2017a, 
2017b). Therefore, further diagnostic fo llow-up of  cases o f asymptom atic elevati on of  pancreat ic 
enzymes (lipase and/or p- amylase ≥3X ULN) is not mandated but may  be perform ed based on 
the Invest igator’s clinical judgment and assessment of the participant’s overall clinical condit ion.
[IP_ADDRESS]. Thyroid Malignancies and C -Cell Hyperplas ia
Individuals with personal or family history  of MTC and/or MEN -2 will be excluded from the 
study . Parti cipants who are diagnosed with MTC and/or MEN -[ADDRESS_272238].
The assessment of thy roid saf ety during the tri al will include reporting of any  case of  thyroid 
malignancy (including MTC, papi[INVESTIGATOR_226359] a, and others) and measurements of calcitonin. 
These data will be captured in specific eCRFs. The purpose of calciton in measurements is to 
assess the potential of LY3502970 to affect thy roid C-cell funct ion, which may indicate 
development of C -cell hyperpl asia and neopl asms.
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
[IP_ADDRESS].1. Calcitonin Measurements
If an increased calcitonin value (see definit ions below) is observed in a participant who has been 
administered a medicat ion that is known to increase serum calcitonin, then this medicat ion 
shoul d be stopped, and calcitonin levels should be measured after an appropriate washout period.
For participants who require addit ional en docrine assessment because of increased calcitonin 
concentration as defined in this sect ion, data from the fo llow-up assessment will be co llected in 
the specific sect ion of the eCRF.
Calcitonin Measurements in Participants with eGFR ≥60 mL/min/1.73 m2
A significant increase in calcitonin for participants with eGFR ≥60mL/min/1.73 m2is defined 
below. If a participant ’s laboratory  resul ts meet these cri teria, these clinically  significant 
laboratory  resul ts shoul d be recorded as an AE.
Serum calcitonin value ≥20 ng/L and <35 ng/L AND ≥50% increase from the screening 
value. These participants will be asked to repeat the measurement within 1 month. If thi s 
repeat val ue is increasing ( ≥10% increase), the study  drug shoul d be stopped, and the 
participants encouraged to undergo addit ional endocrine assessment and longer -term 
follow-up by  [CONTACT_226409].
Serum calcitonin value ≥35 ng/L AND ≥50% over the screening value . In these 
participants, study  drug shoul d be stopped, and the participants recommended to 
immediately  undergo addi tional endocrine assessments and longer -term follow-up by  [CONTACT_134110].
Calcitonin Measurement in Participants with eGFR <60 mL/min/1.73 m2
A significant increase in calcitonin for parti cipants with eGFR <60 mL/min/1.73 m2is defined as 
a serum calcitonin value ≥35 ng/L AND ≥50% over the screening value. If a participant ’s labs 
meet these criteria, these clinically  significant l abs shoul d be recorded as an AE.
In these participants, study  drug shoul d be di scontinued (after first confirming the value) and the 
participants recommended to immediately  undergo addi tional endocrine assessments and longer-
term follow-up by  [CONTACT_226410] t hyroid.
[IP_ADDRESS]. Major Adverse Cardiovascular Events
Nonfatal  cardi ovascular AEs will be adjudicated by  a commi ttee of  physicians external to Lilly 
with cardi ology expertise. This committee will be blinded to treatment assignment. The nonfatal 
cardi ovascular AEs to be adjudicated include
myocardial  infarct ion
hospi [INVESTIGATOR_34069]
hospi [INVESTIGATOR_226360]
coronary  intervent ions (such as coronary  artery  by[CONTACT_226411]), and
cerebrovascular events, including cerebrovascular accident (stroke) and transient 
ischemic attack.
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
[IP_ADDRESS]. Deaths
All deaths will be adjudicated by  a commi ttee of  physicians external to Lilly . This commi ttee 
will be blinded to treatment assignment.
[IP_ADDRESS]. Supraventricular Arrhythmias and Cardiac Conducti on Disorders
Treatment -emergent cardiac conduction disorders will be further evaluated. Participants who 
develop any event from these groups of disorders should undergo an ECG, which should be 
submitted to the central reading center. Additional diagnostic tests to determine exact diagnosis 
shoul d be perform ed, as needed. The specific diagnosis will be recorded as an AE. Events that 
meet criteria for serious conditions as described in Section 10.3 (Appendix 3)must be reported 
as SAEs.
[IP_ADDRESS]. Hepatobiliary Disorders
All events of TE biliary  colic, chol ecyst itis, cholelithi asis, orother suspected events related to 
acute gallbladder disease should be evaluated and addit ional diagnost ic tests performed, as 
needed. In cases of elevated liver laboratory  tests, hepat ic monitoring shoul d be ini tiated as 
outlined in Sect ion8.2.8 .
[IP_ADDRESS]. Severe Gastrointestinal Adverse Events 
LY3502970 may cause severe GI AEs, such as nausea, vo miting, and diarrhea. Informat ion 
about severe GI AEs as well as anti emetic /antidiarrheal  use will be collected in the eCRF/AE 
and Conco mitant Medi cations forms, respectively. For detailed informat ion concerning the 
management of GI AEs, please refer to Section 6.8.1 .
[IP_ADDRESS]. Acute Renal Events
Rena l safety  will be assessed based on repeated renal funct ional assessment as well as 
assessment of AEs suggest ive o f acute renal failure or worsening of preexist ing chronic renal 
failure. Gastrointestinal AEs have been reported wit h LY3502970, including naus ea, di arrhea, 
and vo miting. This is consistent with other GLP -1Rs (Aroda and Ratner 2011). These events 
may lead to dehy dration, which could cause a deterioration in renal funct ion, including acute 
renal failure. Participants should be advised to notify Investigators in case of severe nausea, 
frequent vomit ing, or symptoms of dehydrat ion.
[IP_ADDRESS]. Depression, Suicidal Ideation, or Behavior Monitoring
Parti cipants will be m onitored f or depressi on and sui cidal i deati on or behavior through AE 
collect ion and by [CONTACT_226412] e C-SSRS and the PHQ -[ADDRESS_272239] igator at the time o f each visit ,and appropriate actions as 
described below should be taken.
Columbia Suici deSeverit y Rating Scale (C -SSRS) is a scale that captures the occurrence, 
severit y, and frequency  of suicidal ideation and behavior during the assessment period via a 
questionnaire. The scale was developed by [CONTACT_226413] 
(TASA) for the purpose of being counterpart to the Columbia Classificat ion Algorithm o f 
Suicide Assessment (C -CASA) categorization of suicidal events. For this study, the C -SSRS i s 
adapted for the assessment of the ideat ion and behavior categories only. The Intensit y of Ideati on 
and Lethalit y of Behavior sect ions are removed.
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
69The PHQ -[ADDRESS_272240] ionnaire, which is used as a diagnostic instrument for commo n menta l 
disorders. The PHQ -9 consists of 9 items each scored on a scale of 0 =“not at all” to 3 =“nearly 
every day” with a recall period of “the last 2 weeks.” Major depression is diagnosed if [ADDRESS_272241] “more than half the days” in the 
past [ADDRESS_272242] igator 
it is necessary  for the safet y of the parti cipant or if the participant had any  of the f ollowing:
a PHQ -9 score ≥15
C-SSRS responses of
oA “yes” answer to Question 4 (Active Suicidal Ideation with So me Intent to Act, 
Without Specific Plan) on the “Suicidal Ideat ion” porti on of  the C -SSRS
or
oA “yes” answer to Question 5 (Act ive Suicidal Ideation with Specific Plan and 
Intent) on the “Suicidal Ideat ion” portion of the C -SSRS
or
oA “yes” answer to any  of the suici de-related behaviors (actual at tempt, interrupted 
attem pt, aborted attempt, preparatory  act, or behavior) on the “Suicidal Behavior” 
porti on of  the C -SSRS .
8.4. Pharmacokinetics
Bloodsamples will be collected from all rando mized participants in accordance with schedule 
provi ded in Sect ion 1.3and at ET for measurement of plasma concentrati ons of LY3502970. 
Participants may  need to return to the clinical site for PK -specific visits to provide postdose PK 
samples dependent on the time window of PK sampling. Only  samples from  parti cipants 
assigned to treatment with LY3502970 will be analyzed for drug concentration.
Date and time o f each sample and the most recent LY3502970 dose prior to PK blood draw must 
be recorded. Drug concentration information that would unblind the study  will not be reported to 
study  sites or blinded personnel while the study  is blinded.
Samples will  be analyzed at a l aboratory  approved by  [CONTACT_226414] a facilit y 
designated by  [CONTACT_1034]. Concentrations of LY3502970 will be assayed using a validated 
liquid chro matography  mass spectrom etry method. Analyses of samples collected from 
participants who received placebo are not planned. Bioanaly tical samples collected to measure IP 
concentrations will be retained for a maximum o f [ADDRESS_272243] ion and handling of blood samples will be provided by [CONTACT_1034].
8.5. Pharmaco dynamics
Efficacy measures will be used as indicators of pharmacodynamic response.
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
708.6. Genetics
Not applicable
8.7. Biomarkers
In addit ion to the planned bio marker research as indicated in the SoA, biomarker research on 
stored nonpharmacogenet ic samples may be performed to address questions of relevance to drug 
disposi tion, target engagem ent, pharm acodynamics, mechanism of act ion, variabilit y of 
participant response (including safet y), and clinical outcome. Sample co llection is incorporated 
into clinical  studi esto enable examinat ion of these questions through measurement of 
biomolecules including proteins, lipi[INVESTIGATOR_805], and other cellular elements.
Serum  and plasma samples for nonpharmacogenetic bio marker research will be co llected at the 
times specified in the SoA (Section 1.3) where local regulat ions allow.
Samples may be used for research on the drug targets, disease process, variable response to 
LY3502970, pa thways associ ated wi th diabetes mellitus and related clinical traits or 
complicat ions, including nonalcoho lic steatohepatitis or obesit y, mechanism  of action of 
LY3502970, and/or research method, or for validating diagnostic tools or assay(s) related to 
diabetes m ellitus, rel ated clinical traits, or complications.
All samples will be coded with the participant number. These samples and any data generated 
can be linked back to the participant only by [CONTACT_41417].
Samples will  be retained at a facilit y selected by  [CONTACT_82395] a m aximum  [ADDRESS_272244] igation of variable response that may 
not be observed unt il later in the development of LY3502970 or after LY3502970 becomes 
commercially  available.
8.8. Immunogenicity Assessments
Not applicable
8.9. Health Economic s
Not applicable
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
719. Statistical Considerations
9.1. Statistical Hypotheses
The study  hypothesis for the primary object ive is that at least one dose level of QD oral doses of 
LY3502970 is superior in percent reduction from baseline inbody  weight relative to placebo at 
Week 26, in participants without diabetes who have obesit y or are overweight with at least one 
weight-related comorbidit y.
9.1.1. Multiplicity Adjustment
Treatment comparisons will be performed for the primary  object ive at the f ull significance level 
of 0.05. No m ultiplicity adjustm ents will be m ade for the analysis of secondary  and expl oratory  
objectives.
9.2. Analyses Sets
For the purposes of analysis, the fo llowing analyses popul ations and datasets are defined:
Participant Analysis
PopulationDescription
Entered Participants All participants who sign informed consent .
Randomized All participants who are randomly assigned a study drug. 
Efficacy Analysis Set (EAS) Data obtained during the treatment period from a llrandomized participants 
who are exposed to at least 1 dose of study drug. Excludes data after 
permanent discontinuation of study drug. Participants will be included in the 
treatment group to which they were randomly assigned. 
Full Analy sis Set (FAS) Data obtained during the treatment period from a llrandomized participants 
who are exposed to at least 1 dose of study drug, regardless of adherence to 
study drug. Participants will be included in the treatment group to which they 
were randomly assigned. 
Safety Analysis Set (SS) Data obtained during the treatment period plus safety follow -up from all 
randomized participants who are exposed to at least [ADDRESS_272245] been assigned .
9.3. Statistical Analyses
9.3.1. General Considerations
Statistical analysis o f this study  will be the responsibilit y of Lilly or i ts desi gnee. Any  change to 
the data analysis methods described in the protocol will require an a mendment ONLY if it 
changes a principal feature of the protocol. Any other change to the data analysis methods 
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
72described in the protocol, and the just ificat ion for making the change, will be described in the 
SAP or the CSR. Addit ional exploratory  analyses of data will be conducted, as deemed 
appropriate.
Unless otherwise noted, all tests of treatment effects will be conducted at a 2 -sided alpha level o f 
0.05, and CIs will be calculated at 95%, [ADDRESS_272246] non -missing measurement at or before randomization visit (prior to 
first dosing of study  drug) unless otherwise specified.
The primary  estimand (a precise def inition of the treatment effect to be estimated) of interest in 
comparing efficacy of LY3502970 doses with placebo is the “efficacy est imand” (Section3).
The primary  efficacy  assessment, gui ded by [CONTACT_941] “efficacy  estimand ,” will be conducted using the 
EAS (Secti on 9.2).To estimate the “efficacy est imand ,” when change from baseline is included 
as a response variable of analysis models, the participants will be included in the analysis only if 
a baseline and at least 1 postbaseline measurement are available. A restricted maximum 
likelihood -based MMRM analysis will be used to analyze continuous longitudinal variables. All 
the longitudinal observat ions at each scheduled postbaseline visit will be included in the analysis. 
The m odel for the analysis of the primary  efficacy  endpoint of percent change from baseline in 
body  weight will include the fixed class effects of treatment (placebo, LY1, LY2, LY3 -1, LY3-2, 
LY4-1,LY4-2), strat a, visit, and treatm ent-by-visit interacti on, as well as the continuous, fixed 
covari ate of  baseline value o f body  weight . For all the an alyses, the BMI stratum (≤35kg/m2, 
>35 kg/ m2) and sex ( female, male) will be included in the model as strata. An unstructured 
covari ance structure will be used to model the within -participant errors. Significance tests will be 
based on LS means and Ty pe III tests. SAS PROC MIXED will be used to perform the analysis. 
If this analysis fails to converge, the fo llowing covari ance structures will be tested in order:
Toeplitz with heterogeneit y
Autoregressive with heterogeneit y
Com pound symmetry  with heterogeneous variances
Toeplitz
Autoregressive , and
Com pound symmetry  without heterogeneous variances .
The first covariance structure that converges will be used. The Kenward -Roger approximat ion 
will be used to estimate deno minator degrees of freedom.
Addit ional supplemental  estimand smay be explored for the primary  and secondary efficacy  
endpo ints.
Unless specified otherwise, safet y assessments will be guided by  [CONTACT_226415]350 [ADDRESS_272247] errors derived from the analysis models will also be displayed for the change 
from baseline measurements. Treatment comparisons will be displayed showing the treatment 
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
73difference LS means and the 95% CIs for the treatment differences, along with the p- values for 
the treatment comparisons.
For categorical measures, summary  stati stics will include sample size, frequency, and 
percentages. A logist ic regressio n model with missing valuesimputed will be used t o examine 
the treatment difference in binary efficacy outcomes . Fisher’s exact test or Pearson’s chi -square 
test will be used for treatment comparisons in other categorical outcomes.
Other stati stical methods may be used, as appropriate, and details will b e described in the SAP.
9.3.2. Primary Endpoint (s)/Estimand(s) Analysis
The primary  efficacy  assessment, gui ded by [CONTACT_941] “efficacy  estimand ,” will be conducted using the 
EAS for the primary  endpoint (percent change from baseline in body weight at Week 26).
For the “efficacy est imand ,” the hy potheti cal strategy  is used to handle the intercurrent events 
(permanent discontinuation o f study  drug), so only data collected before the occurrence of any  
intercurrent events will be used in the MMRM analysis (Sect ion9.3.1 ) through which the 
potenti al efficacy measures (after the intercurrent events) had participants had not intercurrent 
events will be implicit ly imputed.
The primary  efficacy  com parison will  be based on the contrast between each treatment group of 
LY3502970 and placebo at Week 26 (Visit 1 5) from the MMRM analysis of percen t change 
from baseline in body  weight using the EAS (Section 9.2). The analysis model and select ion of 
covari ance structure is described in Sect ion 9.3.[ADDRESS_272248] ical power, the evaluat ion of the primary  endpoint for LY 3(36 m g) and LY 4(45 
mg)will be made by  [CONTACT_76435] 2dose escalat ion regimens, that is, combine LY 3-[ADDRESS_272249] ive at the full significance level 
of 0.05.
9.3.3. Secondary Endpoint (s)/Estimand(s) Analysis
The fo llowing secondary  study  endpo ints will be analyzed on the EAS:
Difference between LY3502970 and placebo in
percent change in body  weight from  baseline at Week 36
change in body  weight (kg) from baseline at Week 26 and Week 36
percentage of study  parti cipants who achieve ≥5% body  weight reducti on at Week 26 and 
Week 36
percentage of study  parti cipants who achieve ≥10% body  weight reducti on at Week 26 
and Week 36
change in BMI (kg/m2)from baseline at Week 26 and Week 36
change in waist circumference fro m baseline at Week [ADDRESS_272250] circumference will be analyzed by  [CONTACT_226416] “efficacy 
estimand” as described in Sect ion 9.3.1 .
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
74Treatment comparisons for the percentage of participants with ≥5% and ≥10% body  weight loss 
will be analyzed using a logist ic regressio n with missing values imputed by  [CONTACT_226417], 
which will be describe d in greater detail in the SAP . 
9.3.4. Tertiary/Exploratory Analysis
A Bayesian dose –response model for percent change in body  weight from  baseline to the [ADDRESS_272251] ics will be provided for 
incidence of TEAEs, SAEs, study  discontinuati on due to AEs, study  drug di scontinuati on due to 
AEs, deaths, and other CV endpo ints. Counts and proportions of participants experiencing AEs 
will be reported for each treatment group, and Fisher’s exact test will be used to compare the 
treatm ent groups.
[IP_ADDRESS]. Adverse Event of Special Interest
Summaries and analyses for incidence of Adverse Events of Special Interest (AESI )will be 
provi ded by [CONTACT_3148]. The details of analysis o f AESI (as defined in Sect ion 8.3) will be 
provi ded in the SAP.
[IP_ADDRESS]. Other Adverse Event Assessments
Gastrointestinal Events
Summaries and analyses for incidence and severit y of nausea, vo miting, and diarrhea will be 
provi ded by [CONTACT_91014].
Hypoglycemia Events
Hypoglycemic events will be analyzed. Incidence and rate of hypoglycemia will be reported. 
Some analyses m ay be conducted excluding data after introducing another antihyperglycemic 
therapy .
[IP_ADDRESS]. Central Laboratory Measures, Vital Signs, Electrocardiograms and A mbula tory 
Blood Pressure Monitoring (ABPM)
Actual  and change from  baseline to postbaseline values of central laboratory  measures, vital 
signs, selected ECG param eters andABPM parameters will be summarized at each scheduled 
visit. The analysis model to make co mpar isons among treatm ent groups rel ative to continuous 
change from baseline values assessed over time will be an MMRM similar to the primary  
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
75efficacy  analysis and wit h baseline measurement as a covariate. An unstructured covariance 
structure will model relat ionship of within-participant errors. ABPM parameters will be analyzed 
using analysis o f variance (ANCOVA) which will include baseline measurement as a covariate. 
The percentages of participants with TEabnormal, high, or low measures (including laboratory , 
vital, ECG param eters ,and ABPM parameters ) will be summarized and co mpared between 
treatm ent groups using Fisher’s exact test.
9.3.6. Pharmacokinetic/Pharmacodynamic Analyses
LY3502970 concentration data will be summarized and analyzed using a populat ion PK 
approach via nonlinear mixed -effects m odeling. The relationships between LY3 502970 dose 
and/or concentration and selected efficacy, tolerabilit y, and safet y endpo ints may be 
characterized. Addit ionally, the impact of intrinsic and extrinsic factors, such as age, w eight, 
gender, and renal funct ion on PK and/or PD parameters, may be examined as needed. Addit ional 
analyses may be conducted if they are deemed appropriate.
[IP_ADDRESS]. Subgroup Analyses
Subgroup analyses of the primary  endpoint will be made to assess consistency o f the treatm ent
effect across the fo llowing subgroups using the efficacy estimand:
Age group: < 65 versus ≥ 65 y ears
Sex: female versus male
BMI stratum ( ≤35kg/m2, >35kg/m2)
Pre-diabetes status(HbA1c <5.7% versus ≥5.7%)
Race
Ethnicit y, and
Country /region.
If the number of participants is too small (less than [10%]) within a subgroup, then the subgroup 
categori es may be redefined prior to unblinding the study . Further details on the statistical 
analysis will be provi ded in the SAP.
Analyses for percent change from baseline in body wei ghtwill be perform ed using an MMRM 
model that includes the sam e fixed effects given for the primary  analysis model plus factors of 
subgroup, [ADDRESS_272252] ion of treatment, visit ,and subgroup. The interaction of subgroup and 
treatm ent at the primary  endpoint (Week 26) will be evaluated to assess the treatment by 
[CONTACT_226418]. Addit ional subg roup analyses m ay also be performed.
9.4. Interim Analys is
An interim efficacy and safet y assessment after all participants complete Visit 1 2(Week 16) of 
the treatment period may be conducted to provide inform ation for dose escalation schemes and 
clinical trial material  packaging for future studi es.If conducted, an internal AC will be formed to 
review the interim analyses for the safet y and efficacy  reports in an unblinded manner. 
Addit ional interim analyses m ay be conducted. Details on the timing of the i nterim analyses, 
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
76operati onal support, and unblinding will be specified in the AC charter and in the study  
unblinding plan. Informat ion that m ay unblind the study  during the analyses will not be reported 
to study  sites or blinded study  team  members before t he study has been unblinded for the final 
data base lock. Study  sites will receive informat ion about interim results only if deemed 
necessary  for the safet y of the participants. The trial will not be stopped based on the superiorit y 
of LY3502970 versus pla cebo. Therefore, there will be no inflat ion of the ty pe [ADDRESS_272253] ion of the SAP or in a separate 
unblinding plan document. The SAP will des cribe the planned interim analyses in greater detail.
9.5. Sample Size Determination
Approximately 270participants will be randomly  assigned to study  drug in a rando mizat ion rati o 
of 5:5:5:3 :3:3:3, including 50participants per treatment group to placebo, LY1 andLY2 group s, 
and 30participants per group to LY 3-1, LY3- 2, LY4-1, and LY4-2 groups .
The sample size calculat ion is based on the primary efficacy estimand and its end point (percent 
change from baseline to Week 26 in body  weight ). Assuming a nSD of  6%, a 2 -sided alpha level 
of 0.05, 40completers for one LY350 2970treatm ent group and 40completers for the placebo 
group can provide approximately >90% power to detect a treatment difference of -5% between 
the LY3 502970 treatment group and placebo ( LY3502 970–Placebo) in percen tchange fro m 
baseline in body  weight at Week 26. Assuming a 20% dropout rate for placebo , LY1, LY2, and a 
higher dropoutrate for LY3 and LY 4, 50participants per group shoul d be rando mized for each 
of placebo, LY1, LY2 ,and60 parti cipants per group shoul d be rando mized for each of LY3 and 
LY4.
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
7710. Supporting Documentation and Operational Considerations
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations
10.1.1. Regulatory and Ethical Considerations
●This study  will be c onducted in accordance wit h the protocol and with the 
following:
○Consensus ethical principles derived from international guidelines including 
the Decl aration of Helsinki and CIOMS International Ethical Guidelines
○Applicable ICH GCP Guidelines , and
○Applicable laws and regulations .
● The protocol, protocol amendments, ICF, Investigator Brochure, and other 
relevant docum ents ( for example , advertisements) must be submitted to an 
IRB/IEC by  [CONTACT_226419]/IEC before 
the study is init iated.
●Any amendments to the protocol will require IRB/IEC approval before 
implementation of changes made to the study  design, except for changes 
necessary  to eliminate an immediate hazard to study  parti cipants.
●Protocol s and any substa ntial amendments to the protocol will require healt h 
authori ty approval  prior to ini tiation except for changes necessary  to eliminate an 
immediate hazard to study  parti cipants .
●The Investigator will be responsible for the fo llowing:
○Provi ding wri tten summaries o f the status of the study  to the IRB/IEC 
annually or more frequently in accordance with the requirements, policies, and 
procedures established by [CONTACT_1201]/IEC
○Notifying the IRB/IEC of SAEs or other si gnificant safet y findings as required 
by [CONTACT_1744] /IEC procedures , and
○Provi ding oversight of study  conduct for parti cipants under thei r responsibilit y 
and adherence to requirements of 21 CFR, ICH guidelines, the IRB/IEC, 
European regulat ion 536/2014 for clinical studies (if applicable), and all other 
applicable local regulat ions.
●Invest igator sites are compensated for participat ion in the study as detailed in the 
clinical trialagreement .
10.1.2. Informed Consent Process
●The Investigator or his/her representative will explain the nature of the study , 
inclu ding the risks and benefit s,to the participant or his/her l egally  authori zed 
representative and answer all questi ons regarding the study .
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
78●Parti cipants m ust be inform ed that thei r parti cipat ion is vo luntary. Partici pants or 
their legally authori zed repre sentative swill be required to sign a statement of 
inform ed consent that meets the requirements of 21 CFR 50, local regulat ions, 
ICH guidelines, privacy  and data protecti on requi rements, where applicable, and 
the IRB/IEC or study center.
●The m edical  record m ust include a statem ent that wri tten inform ed consent was 
obtained before the participant was enter ed in the study  and the date the written 
consent was obtained. The authorized person obtaining the informed consent must 
also sign the IC F.
●Parti cipants m ust be reconsented to the most current version of the ICF(s) during 
their parti cipat ion in the study .
●A copy  of the ICF(s) m ust be provi ded to the participant or the participant’s 
legally authorized representati veand is kept on file.
10.1.3. Data Protection
●Parti cipants will be assigned a unique ident ifier by [CONTACT_1034]. Any participant 
records ,datasets , ortissue samples that are transferred to the Sponsor will contain 
the identifier only; participant names or any  informat ion which would make the 
participant i dentifiable will not be transferred.
●The parti cipant must be inform ed that hi s/her personal  study -related data will  be 
used by [CONTACT_1034] i n accordance with local data protection law. The level o f 
disclosure m ust al so be explained to the parti cipant who will be required to give 
consent for his/her data to be used as described in the informed consent .
●The parti cipant must be inform ed that hi s/her m edical  records m ay be examined 
by [CONTACT_17080] y Assurance auditors or other authorized personnel appo inted by  
[CONTACT_1034], by [CONTACT_6667]/IEC members, and by [CONTACT_226420].
●The Sponsor has processes in place to ensure data protection, informat ion 
securit y, and data integri ty. These processes include appropriate contingency 
plan(s) for appropri ate and timely response in the event of a data security  breach.
10.1.4. Dissemination of Clini cal Study Data
Report Preparation
An Invest igator will sign the final CSR for this study, indicat ing agreement that, to the best of his 
or her knowledge, the report accurately  describes the conduct and results of the study .
Public Access to Reports and Data
Reports
The Sponsor will disclo se a summary of study  information, including tabular study results, on 
publicly available websites where required by  [CONTACT_17087].
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
79Data
The Sponsor provides access to all individual participant data collected d uring the trial, after 
anonymizat ion, wi th the excepti on of  PK or genetic data. Data are available to request [ADDRESS_272254].com .
Publications/Publication Policy
The publicat ion policy is described in the letters of agreement between the Sponsor and the 
Invest igators and inst itutions.
10.1.5. Data Quality Assurance
●All participant data relat ing to the study  will be recorded on printed or electronic 
CRF sunless transmitted to the Sponsor or designee electronically ( for example , 
laboratory  data). The Invest igator is responsible for verifying that data entries are 
accurate and correct by  [CONTACT_134123].
●The Investigator must maintain accurate documentation (source data) that 
supports the informat ion entered in the CRF.
●The Investigator must permit study -related m onitoring, audi ts, IRB/IEC review, 
and regulatory  agency inspe ctions and provide direct a ccess to source data 
docum ents.
●Moni toring details describing strategy  (for example , risk-based init iatives in 
operati ons and qualit y,such as risk m anagement and mit igation strategi es and 
analyt ical risk- based mo nitoring), met hods, responsibilit ies,and requi rements, 
including handling of nonco mpliance issues and monitoring techniques ,are 
provi ded in the monitoring plan.
●The Sponsor or designee is responsible for the data management of this study  
includin g qualit y checking of the data.
●The Sponsor assum es accountabilit y for acti ons delegated to other individuals ( for 
example , contract research organizat ions).
●Study  monitors will perform  ongoing source data verification to confirm that data 
entered into the CRF by [CONTACT_32861], com plete, and 
verifiable fro m source docum ents; that the safet y and ri ghts of  parti cipants are 
being protected; and that the study  is being conducted in accordance with the 
currently approved protocol and any other study  agreem ents, ICH GCP, and all 
applicable regu latory  requi rements.
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
80●Records and documents, including signed ICFs, pertaining to the conduct of this 
study  must be retained by  [CONTACT_226421] a 
longer retention period. No records may be destroyed during the retention period 
without the wri tten approval  of the Sponsor. No records may be transferred to 
another location or party  without written n otificat ion to the Sponsor .
●In addit ion, Sponsor or its representati ves will periodi cally check a sample of the 
participant data recorded against source documents at the study  site. The study  
may be audited by [CONTACT_226422], and/or regul atory  agencies at 
any time. Invest igators will be given notice before an audit occurs.
Data Capture System
The Investigator is responsible for ensuring the accuracy , com pleteness, l egibili ty, and timeliness 
of the data reported to the Sponsor.
Data collect ed via the Sponsor -provided data capture sy stem will be stored at athird part y.The 
Invest igator will have continuous access to the data during the study  and unt il deco mmissio ning 
of the data capture sy stem .Prior to decommissio ning, the I nvest igator will receive an archival 
copy  of pertinent data for retention.
Data m anaged by  a central  vendor, such as laboratory  test data, will be stored electronically  in 
the central  vendor’s database system ,and electronic transfers will be provi ded to the Investigator 
for review and retent ion. Data will subsequent ly be transferred fro m the central  vendor to the 
Sponsor data warehouse.
Data from co mplaint forms submitted to Sponsor will be encoded and stored in the global 
product complaint management sy stem .
10.1.6. Source Docum ents
●Source documents provide evidence for the existence of the participant and 
substant iate the integrity  of the data collected. Source documents are filed at the 
Invest igator’s site.
●Data reported on the CRF or entered in the eCRF that are transcribe d from source 
docum ents m ust be consistent with the source documents or the discrepancies 
must be explained. The Invest igator may need to request previous medical records 
or transfer records, depending on the study . Also, current medical records must be 
available.
●Definit ion of what constitutes source data can be found in 10.1.5 .
10.1.7. Study and Site Start and Closure
[IP_ADDRESS]. First Act of Rec ruitment
The study  start date is the date on which the clinical study  will be open for recruit ment of 
participants.
The first act of recruitme nt is the first participant to enter screening .
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
8110.1.7.2. Study or Site Termination
The Sponsor designee reserves the right to close the study site or terminate the study at any time 
for any  reason at the sol e discret ion of the Sponsor. Study  sites will be cl osed upon study  
completion. A study  site is considered cl osed when all required documents and study  supplies 
have been co llected and a study -site closure visi t has been perform ed.
The Investigator may  initiate study -site closure at any time, provided there is r easonable cause 
and sufficient notice is given in advance of the intended terminat ion.
Reasons for the early closure of a study  site by [CONTACT_226423]:
For study  terminat ion:
●Discontinuati on of  further stud y intervent ion developm ent
For si te terminati on:
●Failure of the Invest igator to comply wit h the protocol, the requirements of the 
IRB/IEC or local healt h authorit ies, the Sponsor's procedures, or GCP guidelines
●Inadequate recruit ment (evaluated after a reasonable amount of time) of 
participants by  [CONTACT_24342] , and
●Total  number of participants included earlier than expected .
If the study  is prem aturely  terminated or suspended, the Sponsor shall prompt ly inform the 
Invest igators, the IECs/IRBs, the regulatory  authori ties, and any contract research 
organi zation(s) used in the study  of the reason for terminat ion or suspensio n, as specified by [CONTACT_226424]. The Invest igator shall pro mptly inform the participantand 
shoul d assure appropri ate participant therapy  and/or fo llow-up .
[IP_ADDRESS]. Discontinuation of the Study
The study  will be di scontinued if Lilly or its designee judges it necessary  for m edical, safet y, 
regul atory , or other reasons consistent with applicable law s, regul ations, and GCP.
A safet y invest igation will be triggered to determine if the study  shoul d be terminated early  
based on the fo llowing cri teria:
Three study  participants develop the same TEAE or SAE considered possibly  or 
probably  related to the study drug that is severe or medically significant, but not 
immediately  life-threatening; or where hospi[INVESTIGATOR_5186] n or prolongat ion of 
hospi [INVESTIGATOR_215293]; or is disabling; or limit s self -care act ivities of daily 
living 
OR
Two study  parti cipants deve lop any  TEAE or SAE ,regardless of attribut ion to 
study  drug that has life -threatening consequences or requires urgent intervention
OR
Death of any study  parti cipant at any  time rel ated to AE that i s consi dered 
possibly  or probably rel ated to study  drug.
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
8210.1.8. P ublication Policy
In accordance with the Sponsor’s publicat ion policy ,the resul ts of this study  will be submitted 
for publicat ion by a peer -reviewed journal.
10.1.9. Investigator Information
Researchers withappropri ateeducation, training, andexperience, asdetermined by[CONTACT_1034],
willparticipate asInvest igators inthisclinical trial.
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
8310.2. Appendix 2: Clinical Laboratory Tests
●The tests detailed in the table below will be performed by [CONTACT_19690] .
●Local  laboratory  resul ts are only  required in the event that the central laboratory  
resul ts are not available in t ime for either study  intervent ion administration and/or 
response evaluat ion. If a local sample is required, it is important that the sample 
for central  analysis is obtained at the same time. Addi tionally , if the l ocal 
laboratory  resul ts are used to m ake ei ther a study  intervent ion decisio n or 
response evaluat ion, the results must be recorded .
●In circumstances where the Sponsor approves local laboratory  testing in lieu o f 
central  laboratory  testing (in the table below), the local laboratory  must be 
qualified in accordance wit h applicable local regulations.
●Protocol -specific requirements for inclusio n or exclusio n ofparticipants are 
detailed in Section 5ofthe protocol.
●Addit ional tests may be performed at any  time during the study  as determined 
necessary  by [CONTACT_226425].
●Invest igators must document their review of the laboratory  safety resul ts.
Clinical Laboratory Tests Comments 
Hematology Assay ed by [CONTACT_11007] -designated laboratory
Hemoglobin
Hematocrit
Erythrocy te count (RBCs -red blood cells)
Mean cell volume 
Mean cell hemoglobin
Mean cell hemoglobin concentration 
Leukocytes (WBCs -white blood cells) 
Differential
  Neutrophils, segmented
  Lymphocy tes
  Monocytes
  Eosinophils
  Basophils
Platelets
Cell morphology ( RBCs and WBCs)
Clinical Chemistry Assay ed by [CONTACT_11007] -designated laboratory
Sodium
Potassium
Chloride
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
84Bicarbonate
Total bilirubin
Direct bilirubin
Alkaline phosphatase (ALP)
Alanine aminotransferase (ALT)
Aspartate aminotransferase (AST)
Gamma -glutamyl transferase (GGT)
Blood urea nitrogen (BUN)
Creatinine 
Creatine kinase (CK)
Uric acid
Total protein
Albumin
Calcium
Phospho rus
Glucose
Lipase
Amylase
Calcitonin
Lipid Panel Assay ed by [CONTACT_11007] -designated laboratory
High -density lipoprotein cholesterol (HDL -C)
Low-density  lipoprotein cholesterol (LDL -C)
Very  low-density  lipoprotein cholesterol 
(VLDL -C)
Total cholesterol 
Triglycerides
Urinalysis Assay ed by [CONTACT_11007] -designated laboratory
Specific gravity
pH
Protein
Glucose
Ketones
Bilirubin
Urobilinogen
Blood
Nitrite
Urine leukocyte esterase
Microscopic examination of sediment (if 
appropriate)
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
85Hormones ( Female)
Serum pregnancy Assay ed by [CONTACT_11007] -designated laboratory 
Follicle -stimulating hormone (FSH) Assay ed by [CONTACT_11007] -designated laboratory 
Estradiol
Urine Chemistry Assay ed by [CONTACT_11007] -designated laboratory
Albumin
Creatinine
Calculations Generated by [CONTACT_11007] -designated 
laborato ry
eGFR (CKD -EPI) 
Urinary  albumin/creatinine ratio (UACR)
Pharmacokinetic Samples –LY3502970
ConcentrationAssay ed by [CONTACT_11007] -designated laboratory. 
Results will not be provided to the 
investigative sites
Exploratory Samples Assay ed by [CONTACT_11007] -designated laboratory. 
Results will not be provided to the 
investigative sites
Explo ratory  storage samples: 
Serum
Plasma (EDTA)
  Plasma (P800)
Whole blood (EDTA) 
Hypersensitivity Tests Laborato ry assessments should be 
performed if the participant 
experiences generalized urticaria or if 
anaphy laxis is suspected
Collect sample after the participant 
has been stabilized, and within 1 to 2 
hours of the event; however, 
samples may be obtained as late as 
[ADDRESS_272255] the time at 
which the sample was collected
Obtain a follow -up sample at 
the next regularly scheduled 
visit or after 4 weeks, 
whichever is later
LY3502970 concentrations (PK) Assay ed by [CONTACT_11007] -designated laboratory. 
Results will not be provided to the 
investigative sites
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
86Tryptase Assay ed by [CONTACT_11007] -designated 
laborato ry. Results will not be 
provided to the investigative sites.
Note :If a tryptase sample is obtained 
more than 2 hours after the event (that 
is, within 2 to 12 hours) or is not 
obtained because more than [ADDRESS_272256] Will be performed if a validated assay 
is available.
Assay ed by [CONTACT_11007] -designated 
laborato ry. Results will not be 
provided to the investigative sites.
Note: The basophil activation test is an 
in vitro cell -based assay that only 
requires a serum sample. It is a surrogate 
assay  for drug -specific IgE, but is not 
specific for IgE
Complement (C3, C3a, and C5a) Assay ed by [CONTACT_11007] -designated laboratory. 
Results will not be provided to the 
investigative sites
Cytokine panel (IL‐6, IL‐1 β, and IL‐10) Assay ed by [CONTACT_11007] -designated laboratory. 
Results will not be provided to the 
investigative sites
Abbreviations: CKD -EPI=Chronic Kidney Disease Epi[INVESTIGATOR_623]; EDTA =ethylenediaminetetraacetic acid; 
eGFR =estimated glomerular filtration rate; HbA1c =hemoglobin A1c; HDL =high-density lipoprotein 
cholesterol; IgE = immunoglobulin E; IL = interleukin ; LDL =low-density  lipoprotein cholesterol; 
PK=pharmacokinetic, RBC =red blood cells; UACR =urine albumin/creatinine ration; VLDL =very low -
density  lipoprotein cholesterol; WBC =white blood cells.
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
8710.3. Appendix 3: Adverse Events and Serious Adverse Events : Definitions 
andProcedures for Recording, Evaluating, Follow-U p, and 
Reporting
10.3.1. Definition of AE
AE Definition
An AE is any  untoward m edical occurrence in a participant administered a 
pharmaceutical product and which does not necessarily have a causal relat ionship with 
the study intervent ion. An AE can therefore be any unfavo rable and unintended sign 
(including an abnormal laboratory finding), symptom, or disease (new or exacerbated)
temporally  associ ated wi th the use of a m edicinal (investigat ional) product, whether or 
not rel ated to the m edicinal (investigational) product.
Events Meeting the AE Definition
1.Any abnormal laboratory  test resul ts (hematol ogy, clinical chemistry , or uri nalysis) or 
other safet y assessments ( for example , ECG, radi ological scans, and vital signs 
measurements), including those that worsen from baseline, considered clinically 
significant in the medical and scientific judgment of the Invest igator ( that is, not 
related to progression of underlying disease).
2.Exacerbat ion of a chronic or int ermittent pre existing condi tion,including eit her an 
increase in frequency and/or intensit y of the condi tion.
3.New condit ion detected or diagnosed after study  intervent ion administration even 
though it may have been present before the start of the study .
4.Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.
5.Signs, symptoms, or the clinical sequelae of a suspected overdose of either study  
intervent ion or a concomitant medicat ion. Overdose per se will not be reported as an 
AE/SAE un less it is an intentional overdose taken with possible suicidal/self -harming 
intent. Such overdose sshoul d be reported regardless of sequelae.
6.Lack of efficacy or failure of expected pharmaco logical act ion per se will not be 
reported as an AE or SAE. Such instances will be captured in the efficacy assessments. 
However, the signs, symptoms, and/or clinical sequelae result ing fro m lack of efficacy 
will be reported as AE or SAE if they fulfill the definit ion of an AE or SAE.
Events NOT Meeting the AE Defini tion
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments that are associated with the underlying disease, unless judged by [CONTACT_226426]’s condit ion.
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
88The disease/disorder being studied or expected progressio n, signs, or symptom s of the 
disease/disorder being studied, unless more severe than expected for the participant’s 
condi tion.
Medical or surgical procedure ( for example , endoscopy  and appendectomy): the
condi tion that l eads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admissio n to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of pre exist ingdisease(s) or condi tion(s) present or
detected at the start of the study  that do not worsen.
10.3.2. Definition of SAE
An SAE is defined as any untoward medical occurrence that, at any dose , meets one or 
more of the criteria listed :
a.Results in death
b.Is life -threatening
The term  life-threatening in the definit ion of serious refers to an event in which the participant 
was at risk of death at the time of the event. It does not refer to an event, which hypothetically 
might have caused death, if it were more severe.
c.Requires inpatient hospi[INVESTIGATOR_1081]
In general, hospi[INVESTIGATOR_226361] (usually invo lving at least an overnight stay ) for observat ion and/or 
treatm ent that woul d not have been appropriate in the physician’s office or outpatient 
setting. Co mplications that occur during hospi[INVESTIGATOR_1084]. If a co mplication 
prolongs hospi[INVESTIGATOR_226362], the event is serious. When 
in doubt as to whether hospi[INVESTIGATOR_226363] , the AE shoul d be 
considered serious.
Hospi[INVESTIGATOR_17048] a pre exist ingcondi tion that di d not worsen 
from baseline is not considered an AE.
d.Results in persistent disability/incapa city
The term disabili ty means a substant ial disrupt ion of a person’s abilit y to conduct 
norm al life f unctions.
This definit ion is not intended to include experiences of relat ively minor medical 
significance ,such as unco mplicated headache, nausea, vo miting, diarrhea, influenza, 
and accidental trauma ( for example , sprained ankle) ,which may interfere wit h or 
prevent every day life f unctions but do not constitute a substant ial disruption.
e.Is a congenital anomaly/birth defect
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
89Abnorm al pregnancy outcom es (for example , spontaneous abortion, fetal death, 
stillbirth, congenital ano malies, and ectopi c pregnancy) are considered SAEs.
f.Other situations:
Medical or scient ific judgment should be exercised by [CONTACT_226427] ,such as important medical 
events that may  not be immediately life- threatening or resul t in death or hospi[INVESTIGATOR_226364] m ay jeopardi ze the parti cipant or m ay require medical or surgical intervent ion to 
prevent one of the other out comes listed in the above definit ion. These events should 
usually be considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency room or at home for allergic bronchospasm, blood dyscrasias ,or 
conv ulsions that do not resul t in hospi [INVESTIGATOR_3094], or development of drug dependency or 
drug abuse.
10.3.3. Definition of Product Complaints
Product Complaint
7.A product complaint is any written, electronic, or oral communicat ion that alleges 
deficiencies related to the identi ty, quali ty, durability , reliabilit y, safet y, effect iveness , 
orperformance of a study intervention. When the abilit y to use the study  intervent ion 
safely is impacted, the fo llowing are al so product com plaints:
8.Deficiencies in labeling informat ion, and
9.Use errors for device or drug-device combination products due to ergonomic design 
elements of the product.
10.Product complaints related to study  interventions used in clinical trials are collected to
ensure the safet y of parti cipants, m onitor quali ty, and to facili tate process and product 
improvements.
11.Invest igators will instruct participants to contact [CONTACT_11010] a product complaint or problem wit h the study  intervention so that the situation can 
be assessed.
12.An eve nt may meet the definit ion of both a product complaint and an AE/SAE. In such 
cases, it should be reported as both a product complaint and as an AE/SAE.
10.3.4. Recording and Follow -Up of AE and/or SAE and Product Complaints
AE,SAE ,and Product Complaint Recording
When an AE/SAE /product com plaint occurs, i t is the responsibilit y of the Invest igator 
to revi ew all  documentati on (for example , hospi [INVESTIGATOR_1088], laboratory  reports, 
and diagnostics reports) related to the event.
The Investigator will th en record all relevant AE/SAE /product com plaint informat ion 
in the part icipant’s medical records, in accordance with the Invest igator’s normal 
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
90clinical practice. AE/SAE information is reported on the appropriate (e)CRF page ,and 
product complaint informat ion is reported on the Product Complaint Form.
Note: An event may meet the definit ion of both a product complaint and an AE/SAE. 
In such cases, it should be reported as both a product complaint and as an AE/SAE.
It is notacceptable for the Invest igator to send photocopi[INVESTIGATOR_10914]’s medical 
records to Sponsor or designee in lieu of co mpletion of the (e)CRF page for AE/SAE 
and the Product Complaint Form for product complaints .
There m ay be instances when copi[INVESTIGATOR_226365] . In thi s case, all part icipant identifiers, with the exception o f 
the participant number, will be redacted on the copi[INVESTIGATOR_17051] n to Sponsor or designee .
The Investigator w ill attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical informat ion. Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.
Assessment of Intensity
The Investigator will make an assessment of intensit y for each AE and SAE reported during 
the study  and assign it to one of the fo llowing categori es:
Mild: A type of adverse event that is usually  transient and m ay requi re only  minimal  
treatm ent or therapeutic i ntervent ion. The event does not generally interfere wit h usual 
activit ies o f daily living.
Moderate: A type of AEs that is usually  alleviated wi th addi tional specific therapeut ic 
intervent ion. The event interferes wit h usual activit ies of daily living, cau sing 
discomfort but poses no significant or permanent risk of harm to the research 
participant.
Severe: A type of AEs that interrupts usual act ivities of daily living, or significantly 
affects clinical status, or may require intensive therapeutic intervent ion. An AE that i s 
assessed as severe should not be confused with anSAE. Severe is a category  utilized 
for rati ng the intensit y of an event; and both AEs and SAEs can be assessed as severe.
An event is defined as “serious”when i t meets at least one of the predefined outcomes 
as described in the definit ion of an SAE, NOT when it is rated as severe.
Assessment of Causality
The Investigator is obligated to assess the relat ionship between study  intervent ion and 
each occurrence of each AE/SAE. The Invest igator will use clinical judgment to 
determine the relat ionship .
A “reasonable possibilit y”of a rel ationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relat ionship, rather than a relat ionship cannot be 
ruled out.
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
91Alternative causes, such as underlying disease(s), concomitant therapy , and other ri sk 
factors, as well as the temporal relationship of the event to study  intervent ion 
administration ,will be considered and invest igated.
The Investigator will also consult th e IB in his/her assessment.
For each AE/SAE, the Invest igator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causalit y.
There m ay be si tuations in which an SAE has occurred and the Investigator has 
minimal informat ion to include in the init ial report to Sponsor or designee . However, i t 
is very important that the Invest igator always make an assessment of causalit y for 
every event before the init ial transmissio n of the SAE data to Sponsor or designee .
The Investigator may  change his/her opi[INVESTIGATOR_226366] y in light of fo llow-up 
inform ation and send a nSAE follow -up report wi th the updated causalit y assessment.
The causalit y assessment is one of the cri teria used when determining regulatory  
reporting re quirements.
Follow -Up of AEs and SAEs
The Investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluat ions as medically indicated or as requested by [CONTACT_226428]/or causalit y of the AE or SAE as fully as possible. 
This m ay include addit ional laboratory  tests or investigations, histopathological 
examinat ions, or consultation with other health care professio nals.
If a participant dies dur ing participation in the study or during a recognized fo llow-up 
period,the Investigator will provide Sponsor or designee with a copy  of any 
post-mortem findi ngs including histopathology .
10.3.5. Reporting of SAEs
SAE Reporting via an Electronic Data Collection Tool
The primary  mechanism  for reporting an SAE will be the electronic data collect ion 
tool.
If the electronic system is unavailable, then the site will use the SAE paper form  (see 
next section) toreport the event within 24 hours.
The site will enter the SAE data into the electronic sy stem  as soon as i t becom es 
available.
After the study  is com pleted at a given site, the electronic data collect ion tool  will be 
taken off -line to prevent the entry  of new data or changes to exist ing data.
If a site receives a report of a new SAE fro m a study  parti cipant or receives updated 
data on a previously reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this informatio n on an SAE paper form (see next 
section) or to the SAE coordi nator by [CONTACT_756].
Contacts for SAE reporting can be found in study  training m aterials.
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
92SAE Reporting via Paper Form
Facsimile transmissio n of the SAE paper form is the preferred method to transmit this 
inform ation to the SAE coordinator .
Initial notificati on via telephone does not replace the need for the Invest igator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
Contacts for SAE reporting can be found in study  training m aterials.
10.3.6. Regulatory Reporti ng Requirements
SAE Regulatory Reporting
Prom pt notificat ion by [CONTACT_208555] a nSAE is essent ial so 
that legal obligat ions and ethical responsibilit ies toward the safet y of 
participants and the safet y of a study  intervent ion under clinical invest igation 
are met.
●The Sponsor has a legal responsibilit y to notify  both the l ocal regulatory  
authori ty and other regul atory  agencies about the safet y of a study  intervention 
under clinical invest igation. The Sponsor will co mply wit h country -specific 
regul atory  requi rements rel ating to safet y reporting to the regulatory  authori ty, 
IRB/IEC , and Investigators.
●An Invest igator who receives an Investigator safety report de scribing a nSAE 
or other specific safet y informat ion (for example , summary  or list ing of SAEs) 
from the Sponsor will review and then file it along with the Invest igator’s 
Brochure and will notify the IRB/IEC, if appropriate according to local 
requi rements.
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
9310.4. Appendix 4: Contraceptive and Barrier Guidance
10.4.1. Definitions
Word/Phrase Definition
Women of 
childbearing 
potentialFema les are considered a woman of child bearing potential if
they have had at least one cycle of menses, or
they have Tanner [ADDRESS_272257] development.
Any amount of spotting should be considered menarche. If Tanner Staging of 
breasts is performed as part of study procedures, please refer to the Reproductive, 
Pregnancy and Pediatrics Safety Committee Safety Guidance for Children in 
Clinical Trial regarding Tanner Staging.
Women not of 
child bearing
potentialFema les are considered women not of child bearing potential if
they have a congenital anomaly ,such as Mullerian agenesis
they are infertile due to surgical sterilization, or
they are postmenopausal .
Examples of surgical sterilization include hysterectomy, bilateral oophorectomy, 
and tubal ligation.
Postmenopausal
stateThe post menopausal state should be defined as
1.A woman at any age at least 6 weeks postsurgical bilateral oophorectomy 
with or without hysterectomy, confirmed by [CONTACT_31083]; or
2.A woman at least [ADDRESS_272258] 
uterus, not on hormone therapy*, who has had cessation of menses for at 
least 12 consecutive months without an alternative me dical cause, AND
With a FSH >40 mIU/mL; or
3.A woman [ADDRESS_272259] 55 years of age with a diagnosis of menopause prior to 
starting hormone replacement therapy .
* Women should not be taking medications during amenorrhea ,such as oral 
contraceptives, hormones, gonadotropin -releasing hormone, anti -estrogens, 
selective estrogen receptor modulators, or chemotherapy that could induce 
transient amenorrhea.
Reproductive 
toxicology 
studiesEmbryo-fetal studies are toxicity studies in pregnant animals designed to identify 
abnor malities in the development of fetuses, which could indicate potential for 
teratogenicity in humans. The relevant dosing period is durin g organogenesis.
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
9410.4.2. Contraception Guidance
Women of child bearing potenti al are excl uded f rom parti cipat ion in this trial.
The table below describes contraception guidance for men.
Topic Guidance
For all men should refrain from sperm donation for the 
duration of the study and for [ADDRESS_272260] participant visit
Contraception for men with partners of 
childbearing potential either remain abstinent (if this is their 
preferred and usual lifestyl e), or
must use condoms during intercourse for 
the duration of the study, and
for90 days or [ADDRESS_272261] 
participant visit
Contraception for men in exclusively same sex 
relationships, as their preferred and usual lifestyleAre not required to use contraception
Examples of highly effective, effective , and unacceptable methods of contraception can be found below.
Methods Examples
Highly effective contraception combination oral contraceptive pi[INVESTIGATOR_31076]-pi[INVESTIGATOR_4382]
implanted contraceptives
injectable c ontraceptives
contraceptive patch (only women <198 
pounds or 90 kg)
total abstinence
vasectomy (if only sexual partner)
fallopi[INVESTIGATOR_31077] (if confirmed by 
[CONTACT_31084][INVESTIGATOR_8913])
combined contraceptive vaginal ring, or
intrauterine devices .
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
95Effective contraception male or female condoms with spermicide
diaphragms with spermicide or cervical 
sponges
barrier method with use of a spermicide
ocondom with spermicide
o diaphragm with spermicide, or
ofemale condom with spermicide .
Note: The barrier m ethod must include use of a 
spermicide ( that is, condom with spermicide, 
diaphragm with spermicide, female condom with 
spermicide) to be considered effective.
Ineffective forms of contraceptionspermicide alone
immunocontraceptives
periodic abstinence
fertility awareness (calendar method, 
temperature method, combination of 
above 2, cervical mucus, and 
symptothermal)
withdrawal
post coital douche , and
lactational amenorrhea .
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
9610.5. Appendix 5: Liver Safety: Suggested Actions and Follow -Up 
Assessments
Hepatic Evaluation Testing
See 8.2.[ADDRESS_272262] bilirubin
Erythrocytes (RBCs -red bl ood cells) Alkaline phosphatase (ALP)
Leukocy tes (WBCs -white blood cells) Alanine aminotransferase (ALT)
Different ial: Aspartate aminotransferase (AST)
  Neutrophils, segmented Gamma -glutamyl  transferase (GGT)
  Lymphocytes Creatine kinase (CK)
  Mo nocy tes Other Chemistry
  Basophils Acetaminophen
  Eosinophils Acetaminophen protein adducts
Platelets Alkaline phosphatase isoenzymes
Cell morpho logy (RBC and WBC) Cerul oplasmin
CoagulationCopper
Ethyl alcoho l (EtOH)
Prothrombin t ime, INR (PT -INR) Haptogl obin
SerologyImmunoglobulin IgA (quantitative)
Hepati tis A vi rus (HAV) testi ng: Immunoglobulin IgG (quantitative)
  HAV total ant ibody Immunoglobulin IgM (quant itative)
  HAV IgM antibody Phosphat idylethano l (PEth)
Hepati tis B virustesting: Urine Chemistry
  Hepatit is B surface ant igen (HBsAg) Drug screen
  Hepatit is B surface ant ibody  (anti-HBs) Ethyl glucuroni de (EtG)
  Hepatit is B core total ant ibody  (anti-HBc)Other Serology
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
97  Hepatit is B core IgM antibody Anti-nuclear ant ibody  (ANA)
  Hepatit is B core IgG antibody Anti-smooth muscle antibody  (ASMA)a
  HBV DNAdAnti-actin ant ibodyb
Hepatis C virus (HCV) testing: Epstein -Barr virus (EBV) testing:
  HCV antibody   EBV antibody
  HCV RNAd  EBV DNAd
Hepati tis D vi rus (HDV) testi ng: Cytomegalovirus (CMV) testing:
  HDV antibody   CMV antibody
Hepati tis E virus (HEV) testing:   CMV DNAd
  HEV IgG antibody Herpes simplex virus (HSV) testing:
  HEV IgM antibody   HSV (Ty pe 1 and 2) ant ibody  
  HEV RNA d   HSV (Ty pe 1 and 2) DNA d
Microbiology c Liver ki dney  microsom al type 1 (LKM -1) antibody
Culture:
  Blo od
  Urine
Abbreviations: Ig = immunoglobulin; INR = international normalized ratio.
aNot required if anti -actin antibody is tested.
bNot required if anti -smooth muscle antibody (ASMA) is tested.
cAssay ed ONLY by [CONTACT_1697] -designated local laboratory; no central testing ava ilable.
dReflex /confirmation dependent on regulatory requirements, testing availability, or both
10.6. Appendix 6: [LOCATION_001] Heart Association Functional Classification 
of Heart Failure
Class Symptomatology 
I No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, 
palpi[INVESTIGATOR_226367] n, dy spnea.
II Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in 
fatigue, palpi[INVESTIGATOR_332], dyspnea.
III Marked limitation of physical activity. Comfort able at rest. Less than ordinary activity causes 
fatigue, palpi[INVESTIGATOR_332], or dyspnea.
IV Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. 
If any physical activity is undertaken, discomfort increases.
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
9810.7. Appendix 7: Protocol G ZGIStandardized Protocols for the 
Measurement of Height, Weight, Waist Circumference and Vital 
Signs
The fo llowing inform ation has been adapted fro m standardized physical measurement protocols 
for the WHO’s STEPwise approach to Surveillance (STEPS) (WHO 2017).
Measuring Height
Step 1. Ask the participant to remove their footwear and any headgear (light headgear worn for 
religious reasons can remain, but this should be worn by [CONTACT_226429] t is m easured).
Step 2. Ask the participant to stand on the calibrated height measuring board (stadio meter) or 
against a wall wit h their feet together and their knees straight with their heels against the 
backboard, the stadio meter, or the wall.
Step 3. Ask the parti cipant to l ook s traight ahead wi thout til ting thei r head up.
Step 4. Ask the participant to breathe in and stand tall. Measure and record the participant’s 
height in cent imeters to [ADDRESS_272263].
Measuring Weight
Body  weight m easurements shoul d be done in a consistent manner using a calibrated 
electroni c scale capable of measuring weight in kilograms to [ADDRESS_272264].
All weights for a given participant should be measured using the same scale, whenever 
possible, at approximately the same time in the mo rning after evacuat ion of bladder 
contents .
Body  weight m ust be m easured in fasting state. If the participant is not fast ing, the 
participant shoul d be called in for a new visit within the visit window to have the fast ing 
body  weight m easured.
Step 1. Ask the participant to empt y their pockets, rem ove thei r footwear, outerwear (coat, 
jacket, etc.), and any  headgear (li ght headgear worn for religious reasons can remain, but this 
shoul d be worn by  [CONTACT_226430] t when weight i smeasured).
Step 2 . Make sure the scale is placed on a firm, flat, even surface (not on carpet, on a slopi[INVESTIGATOR_126154], or a rough, uneven surface).
Step [ADDRESS_272265] Circumference
Waist circumference should be measured in the horizontal plane and at the midpoint 
between the lower margin o f the last palpable rib and the top of the iliac crest .
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
99Measurements should be taken at the end of a normal expi[INVESTIGATOR_134067] a non- stretchable 
measuring tape. The tape should lie flat against the skin without compressing the soft 
tissue.
The waist circumferen ce shoul d be m easured twi ce, rounded to the nearest 0.5 cm. The 
measuring tape should be removed between the 2 measurements. Both measurements will 
be recorded in the eCRF. If the difference between the 2 measurements exceeds 1 cm, 
this set of m easurements shoul d be discarded and the 2 measurements repeated.
Step 1 : Ask the participant to wear litt le clothing (if available, garments could also be used).
Step 2 : Ask the participant to stand with their feet close together, arms at their side, body weight 
evenly distributed.
Step 3 : Ask the participant to relax and measure the participant’s waist circumference.
Vital Sign Measurements
Vital sign m easurements ( BPand HR, measured by  [CONTACT_117682]) shoul d be taken before 
obtaining an ECG tracing and before collect ionof blood sam ples for l aboratory  testing.
The parti cipant shoul d sit quietly for 5 minutes before vital signs measurements are 
taken.
For each parameter, 2 measurements will be taken using the same arm, preferably the 
nondo minant arm.
The recordings should be taken at least 1 minute apart. Each measurement of sitting pulse 
and BP needs to be recorded in the eCRF.
BP m ust be taken with an automated BP instrument.
If BPand pul se measurements are taken separately, pulse should be taken prior to BP.
Note: In the event pulse measurement cannot be taken via an automated BPi[INVESTIGATOR_226368], the 
preferred l ocati on for measurement of pulse is the radial artery .
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
[ZIP_CODE].8. Appendix 8: Diet and Physical Activity Suggestions for Sites without 
Programs
10.8.1. Diet
Diet recommendat ions are b ased on the Worl d Heal th Organizat ion (WHO 2020) f or every one 
which is based on a Mediterranean eat ing pattern.
The Mediterranean eating pattern for a healthy diet consist sof
legumes ( for example , lentils and beans)
nuts
whole grains ( for example , unprocessed wheat, maize, millet, oats, and brown rice)
at least 5 porti ons of fruit and vegetables per day  (excluding potatoes, sweet potatoes, 
cassava, and other starchy  roots)
less than 10% of total energy  intake fro m free sugars (equivalent to 50 g or 12 level 
teaspoons), but ideally less than 5% of total energy intake. Free sugars are sugars 
added to foods and drinks, as well as sugars present in honey, syrups, fruit juices, and 
fruit juice concentrates
less than 30% of total energy  intake fro m fats. Unsaturated fats are preferred over 
saturated fats. Unsaturated fats are found in fish, avocado, nuts, sunflower, cano la, 
and o live oils. Consumpt ion of saturated fats, which are fats in fatty  meat, butter, 
palm and coconut oil, cream cheese, ghee, and lard , should be reduced to less than 
10% of total energy  intake. Trans fats, which are found in industrially  produced 
foods, shoul d be avoi ded, and
salt intake should not be more than 5 g (about 1 teaspoon) per day  and shoul d be 
iodized.
10.8.2. Physical Activity
Regular physical act ivity can improve a pa rticipant ’s healt h. Moving more and sitting less 
benefit severy one, regardless of age, sex, race, ethnicit y, or current fi tness l evel. Benefit s 
accumulate with even small amounts and start immediately.
To safely en gage in physical act ivity, types of  physical  activity appropriate for the participant ’s 
current fitness should be chosen. Furthermore, the amount and duration of physical act ivity 
shoul d be gradually increased over time. Pa rticipant s with chronic condit ions and symptoms 
shoul d be under the care of a healt h care provider about the ty pes and amounts of physical 
activit y that are appropri ate for the participant .
Physical act ivity recommendat ions are based on WHO recommendat ions (WHO 20 20) and wi th 
the US Healt h and Human Services (HHS 2020) recommendat ions.
Any physical act ivity is better than none. Adults should move more and sit less.
Adults should do 150 minutes (2 hours 30 minutes) to 300 minutes (5 hours) of 
moderate -intensit y aerobi c physical  activity throughout the week or 75 minutes (1 hour 
15 minutes) to 150 minutes (2 hours and 30 minutes) a week of vigorous -intensit y 
aerobi c physical act ivity, or an equivalent combination of moderate -and 
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
101vigorous -intensit y aerobi c act ivity. Pref erably, aerobi c act ivity shoul d be spread 
throughout the week.
Aerobic act ivity shoul d be performed in bouts of at least 10 minutes duration.
For addi tional heal th benefits, adults should increase their moderate -intensit y aerobic 
physical act ivity to [ADDRESS_272266] ivity per week, or an equivalent combinat ion of moderate -and 
vigorous -intensit y activi ty. Addi tional heal th benefits are gained by  [CONTACT_226431] y beyond the equivalent of 300 minu tes (5 hours) of moderate -intensit y physical 
activit y a week.
Muscle -strengthening act ivities shoul d be done involving major muscle groups on 2 or 
more days a week.
Older adul ts, wi th poor m obility, shoul d perform  physical act ivity to enhance balance and 
prevent falls on [ADDRESS_272267] ive as their abilit ies and 
condi tions all ow.
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
[ZIP_CODE].9. Appendix 9: Patient -Reported Outcomes
Short Form -36 Version 2 Health Survey Acute Form, 1 Week Recall Version
The Short Form -36 Versi on 2Health Survey acute form  (SF-36v2 acute), 1 -week recall versio n 
is a 36 -item generic, parti cipant -administered measure designed to assess the fo llowing 
8domains :
Physical Funct ioning 
Role Physical
Bodily Pain
General Healt h
Vitality
Social Functioning 
Role Em otional, and 
Mental Heal th.
The Physical Funct ioning domain assesses limitations due to health “now” while the remaining 
domains assess funct ioning “in the past week.” Each do main is scored individually  and 
inform ation from these 8 dom ains isfurth er aggregated into 2 health component summary  
scores: Physical Component Summary  and Mental Com ponent Summary . Items are answered on 
Likert scales of varying lengths (3 -point, 5 -point, or 6- point scales). Scoring of each domain and 
both summary  scores are norm  based and presented in the form of T -scores, with a mean of [ADDRESS_272268] deviat ion of 10; higher scores indicate better levels o f function and/or better health 
(Marui sh 2011).
Impact of Weight on Quality of Life -Lite Clinical Trials Version
TheIWQOL -Lite-CT (Ko lotkin et al. 2017, 2019 ) is a [ADDRESS_272269] assesses 2 primary domains of obesit y-related healt h-related quali ty oflife 
(HRQoL): Phy sical (7 i tems) and Psychosocial (13 items). A 5 -item subset of the Phy sical 
domain –the Physical Funct ion composite –is also supported. Items in the Physical Funct ion 
composite describe physical impacts related to general and specific physical  activi ties. All i tems 
are rated on either a 5 -point frequency (“never” to “always”) scale or a 5 -point truth (“not at all 
true” to “completely true”) scale.
Patient Global Impression of Status for Physical Activity
The Pati ent Gl obal Impressi on ofStatus for Physical Act ivityis designed to assess the 
participant ’s overall assessment of current limitat ion on physical act ivity due to health . This i s a 
single glo bal item that asks participants to rate the limitation o f their heal th on physical  activi ty 
in the past week on a 5 -point scale ranging fro m 1 =not at all limited to 5=extremely limited.
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
103Participant Survey
The Parti cipant Survey  is a parti cipant -completed form , which includes quest ions to understand 
participant experience with study  treatm entand the factors influencing their preferences.
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
[ZIP_CODE].10. Appendix 10: Country-S pecific Requirements
Discontinuation of Study Drug in Inadvertently Enrolled Participants in Canada
If the Sponsor or Invest igator ident ifies a participant who did not meet en rollment cri teria and 
was inadvertently enrolled, then the participant should be discontinued from study  treatm ent and 
safet y follow-up shoul d be perform ed as outlined in Section 1.3(Schedule of Act ivities), Secti on 
8.3(Adverse Events , Seri ous Adverse Events, and P roduct Complaint s), and Secti on 8.2(Safet y) 
of the protocol.
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
[ZIP_CODE].11. Appendix 11: Provisions for Changes in Study Conduct during 
Exceptional Circumstances
Implementation of This Appendix
The changes to procedures described in this appendix are temporary measures intended to be 
used only during specific time periods as directed by [CONTACT_226432].
Exceptional Circumstances
Exceptional circumstances are rare events that may cause di srupt ions to the conduct of the study . 
Examples include pandemics or natural disasters. These disrupt ions may limit the abilit y of the 
Invest igators, participants, or both to attend on- site visi ts or to conduct planned study  procedures.
Implementing C hanges under Exceptional Circumstances
In an except ional circumstance, after receiving the Sponsor’s written approval, sites may 
implement changes if permitted by [CONTACT_24550].
After approval by [CONTACT_31086], regulatory  bodi es,and any other relevant local 
authori ties, implementation of these except ional circum stance changes will not ty pi[INVESTIGATOR_31078], unless they  have specific requirements in whic h 
notification is required (for example, upon implementation and suspensio n of changes). All 
approval s and notificat ions must be retained in the study  records.
If the Sponsor grants written approval for changes in study  conduct, the Sponsor will also 
provi de addi tional wri tten gui dance, if needed.
Considerations for Making a C hange
The prevailing considerat ion for making a change is ensuring the safet y of study  parti cipants. 
Addit ional important considerat ions for making a change are compliance with G CP, enabling 
participants to continue safely in the study  and m aintaining the integrit y of the study .
Informed Consent
Addit ional consent fro m the parti cipant will  be obtained, if required, for:
participat ion in remote visits, as defined in Section “Remote Visits”
dispensat ion of addit ional study  interventi on during an extended treatment period
alternate delivery  of study  interventi on and ancillary  supplies, and
provi sion of their personal  or medical  information requi red pri or to implementation of 
these acti vities.
Changes in Study Conduct during Exceptional Circumstances
Changes in study  conduct not described in this appendix, or not consistent with applicable local 
regul ations, are not allowed.
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
106The fo llowing changes in study  conduct will not be considered p rotocol  deviat ions.
Remote Visits
Types of remote visits
Telemedicine: Telephone or techno logy-assisted virtual  visit s, or both, are acceptable to 
complete appropri ate assessments. Assessments to be co mpleted in this manner include, but are 
not limited to, collect ion ofAEs, SMBG values ,andconcomitant medicat ions.
Mobile healthcare: Healthcare visi ts may  be perform ed by a m obile heal thcare provi der at 
locations other than the study site when participants cannot travel to the site due to an 
exceptional circumstance if written approval is provided by [CONTACT_1034] . Procedures performed 
at such visits include, but are not limited to, concomitant medications, SMBG values, vital signs 
(BPandPR), body  weight, collection o f blood samples, physical assessments, administration of 
PROs if validated for these ty pes o f visits, administrati on of  study  intervent ion, and collection of 
healt h informat ion.
Other alternative locations: During except ional circumstances, l aboratory  samples may  be 
drawn locally, if needed outside of mobile hea lthcare visi ts.
Data capture
In source documents and the CRF, the study  site shoul d capture the visit method, with a specific 
explanat ion for any  data missing beca use of missed in -person site visits.
Safety reporting
Regardless of the ty pe of  remote visi ts implemented, the protocol requirements regarding the 
reporting of AEs, SAEs, and PCs remain unchanged.
Return to on -site visits
Every effort shoul d be made to enable part icipants to return to on -site visi ts as soon as 
reasonably  possible, while ensuring the safet y of both the parti cipants and the site staff.
Local Laboratory Testing Option
Local  laboratory  testing m ay be conducted in lieu of central laboratory  testing. However, central
laboratory  testing must be retained for: Visits 3, 10, and 15.The l ocal laboratory  must be 
qualified in accordance wit h applicable local regulations.
Study Intervention and Ancillary Supplies ( Including Participant Diaries)
When a participant i s unable to go to the site to receive study  supplies during norm al on-site 
visits, the site should work with the Sponsor to determine appropriate actions. These act ions may 
include
asking the participant to go to the site and receive study  supplies from  site staff 
without com pletion of a full study  visit
asking the participant’s designee to go to the site and receive study  supplies on a 
participant’s behalf, and
arranging delivery  of study  supplies .
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
107These requirements must be met before action is taken:
Alternate delivery  of study  interventi on shoul d be perform ed in a manner that does 
not com promise treatm ent blinding and ensures product integrit y. The exist ing 
protocol  requi rements for product accountabilit y remain unchanged, including 
verific ation of  parti cipant’s receipt of study  supplies.
When delivering supplies to a locat ion other than the study  site (for exam ple, 
participant’s ho me), the Invest igator, Sponsor, or both should ensure oversight of the 
shippi[INVESTIGATOR_226369] y and product qualit y (that i s, storage 
condi tions maintained and intact packaging upon receipt).
Instructi ons may  be provi ded to the parti cipant or designee on the final disposit ion of 
any unused or completed study  supplies .
Screening Period Guidance
To ensure safet y of study  participants, l aboratory  values and other eligibilit y assessments taken 
at screening visit are valid for a maximum o f [ADDRESS_272270] be paused due to 
exceptional circumstances:
If screening is paused for less than 30 days from  screening visits to randomizat ion 
visit:the parti cipant will proceed to the next study  visit per the usual  Schedule of 
Activities, provided that randomizat ion visit must be conducted within 30days fro m 
first screening/lead -in visit.
oThe site should conduct the next visit if the participant’s eligibilit y criteria are 
confirmed, and the site should document the reason for delay.
oDue to the pause in screening, sites should also reconfirm the impacted 
participant’s consent and document this confirmat ion in the source 
docum entati on.
If screening is paused for more than 30 days from screening visit s to randomizat ion 
visit: The participant must be discont inued because of screening interruption due to 
an except ional circumstance. This is docum ented as a screen failure in the CRF. The 
participant can reconsent and be rescreened as a new participant. The screening 
procedures per the usual Schedule of A ctivities should be fo llowed, starting at 
screening visit to ensure participant eligibilit y by [CONTACT_226433].
Adjustments to V isit Windows
Whenever possible and safe to do so, as determined by [CONTACT_24342]’s discret ion, parti cipants 
shoul d com plete the usual Schedule of Act ivities. To maximize the possibilit y that these visits 
can be conducted as on -site visi ts, the windows for visits may  be adjusted, upon further guidance 
from the Sponsor. Thi s minimizes missing data and preserves the intended co nduct of the study .
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
108This table describes the allowed adjust ments to visit windows.
Visit Number Tolerance
Visit [ADDRESS_272271] extended windows, additional study  interventi on may  need to 
be provided to avoid interruption and maintain overall integrit y of the study .
Documentation
Changes to study conduc t will be documented
Sites will ident ify and document the details o f how participants, visit types, and conducted 
activit ies were affected by [CONTACT_31087]. Di spensing/shipment records of study  
intervent ion and relevant communicat ions, includin g delegat ion, should be filed with site study  
records.
Source documents at alternate locations
Source documents generated at a location other than the study site should be part of the 
Invest igator’s source documentation and should be transferred to the sit e in a secure and timely 
manner.
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
[ZIP_CODE].12. Appendix 12: Abbreviations and Definitions
Term Definition
ABPM ambulatory blood pressure monitoring
AC Assessment Committee
AE adverse event: any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relatio nship with this treatment. An adverse event can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease 
temporally  associated with the use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product.
ALP alkaline phosphatase
ALT alanine aminotransferase
AST aspartate aminotransferase
AUC area under curve
BG blood glucose
blinding/masking A double -blind study is one in which neither the participant nor any of the Investigator 
or Sponsor staff who are involved in the treatment or clinic al evaluation of the subjects 
isaware of the treatment received.
BMI body mass index
BP blood pressure
C-SSRS Columbia Suicide Severity Rating Scale
CEC clinical endpoint committee
CFR Code of Federal Regulations
CI confidence interval
CIOMS Council forInternational Organizations ofMedical Sciences
CK creatine kinase
CKD- EPI [INVESTIGATOR_226370] A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality , purity , durability , reliability , safety  or effectiveness, or 
performance of a drug or drug delivery system.
compliance Adherence to all study -related, good clinical practice (GCP), and applicable regulatory 
requirements.
CRF case report form
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
110CRP clinical research physician: Individual responsible for the medical conduct of the study. 
Responsibilities of the CRP may be performed by a physician, clinical research 
scientist, global safety physician ,or other medical officer.
CSR clinical study repor t
CV cardiovascular
EAS efficacy analysis set
ECG electrocardiogram
eCRF electronic case report form
eGFR estimated glomerular filtration rate
enroll The act of assigning a participant to a treatment. Participants who are enrolled in the 
study are those who have been assigned to a treatment.
enter Participants entered into a study are those who sign the informed consent form directly 
or through their legally acceptable representatives.
ET early termination
FAS full analy sis set
FBG fasting blood glucose
FSH follicle -stimulating hormone
GI gastrointestinal
GCP good clinical practice
GGT gamma -glutamyl transferase
GLP-[ADDRESS_272272]
HbA1c hemoglobin A1c
HBC hepatitis B virus
HCV hepatitis C virus
HIV human immunodeficiency virus
HR heart rate
IB Investigator’s Brochure
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
111ICF informed consent form
ICH International Council for Harmonization
informed consent A process by [CONTACT_9444] a participant voluntarily confirms his or her willingness to 
participate in a particular study, after having been informed of all aspects of the study 
that are relevant to the participant’s decision to participate. Informed consent is 
documented by [CONTACT_3553] a written, signed, and dated informed consent form .
interim analysis An interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created/locked.
IP Investigational p roduct is a pharmaceutical form of an active ingredient or placebo 
being tested or used as a reference in a clinical trial, including products already on the 
market when used or assembled (formulated or packaged) in a way different from the 
autho rized form , or marketed products used for an unauthorized indication, or marketed 
products used to gain further information about the authorized form.
IWRS interactive web -response sy stem
IWQOL -Lite- CTImpact of Weight on Quality of Life -Lite Clinical Trials Versi on
LY LY3502970
LS least squares
MAD multiple -ascending dose
MedDRA Medical Dictionary for Regulatory Activities
MDD Major Depressive Disorder
MMRM mixed-effect model repeated measures
NOAEL no-observed -adverse -effect level
P-gp/BCRP P-glycoprotein/breast cancer resistant protein
participant Equivalent to CDISC term “subject”: an individual who participates in a clinical trial, 
either as recipi[INVESTIGATOR_10930] a control
PC product complaint
PGIS Patient Global Impression of Status for Physical Activity
PHQ -9 Patient Health Questionnaire -9
PK/PD pharmacokinetics/pharmacodynamics
PR pulse rate
PRN “pro re nata ,” the administration of medication is not scheduled
PRO patient -reported outcomes
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
112PT prothrombin time
QD once-daily
QTc corrected QT interval
OTC over the counter
SS safety  analy sis set
SAD single -ascending dose
SAE serious adverse event
SAP statistical analysis plan
screen The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study. 
SF-36 v2 acute form Short Form -36 Version 2 health survey acute form
SMBG self-monitoring of blood glucose
SoA Schedule of Activities
T1DM Type 1 diabetes mellitus
T2DM Type 2 diabetes mellitus
TBL total bilirubin level
TE treatment -emergent
TEAE Treatment -emergent adverse event: An untoward medical occurrence that emerges 
during a defined treatment period, having been absent pretreatment, or worsens relative 
to the pretreatment state, and does not necessarily have to have a causal relationship 
with this treatment.
THC tetrahy drocannabinol
TXP treatment
UACR Urinary  albumin creatinine rat io
ULN Upper limit of normal
Wks weeks
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
[ZIP_CODE]. References
[ADA] American Diabetes Associat ion. 6. Glycemic targets: standards of medical care in 
diabetes -2020. Diabetes Care. 2020;43(suppl 1):S66 -S76. https://doi.org/10.2337/dc20 -S006
[AMA] American Medical Association. American Medical Association House of Delegates 
resolution: 420 (A -13): recognit ion of obesit y as a disease. May 2013. Accessed May 21, 
2020. https://media.npr.org/documents/2013/jun/ama -resolution-obesit y.pdf
Aroda VR, Ratner R. The safet y and tol erabilit y of GLP -1 receptor agonists in the treatment of 
type 2 di abetes: a review. Diabetes Metab Res Rev . 2011;27(6):528 -542. 
https://doi .org/10.1002/dmrr.1202
Baggi oLL, Drucker DJ. Bio logy of incretins: GLP -1 and GIP. Gastro enterology . 
2007;132(6):2131 –2157. https://doi.org/ 10.1053/j.gastro.2007.03.054
Banks PA, Freeman ML; Practice Parameters Committee of the American Co llege of 
Gastroenterology . Practi ce gui delines in acute pancreatit is. Am J Gastroenterol . 
2006;101(10):237 9-2400. 
Baylis s WM, Starling EH. The m echanism  of pancreati c secret ion.J Physiol. 1902 ;28:325 –353.
https://d oi.org/ 10.1113/jphysio l.1902.sp000920
Bharucha AE, Charkoudian N, Andrews CN, et al.Effects of glucagon -like peptide -1, 
yohimbine, and nitrergic modulat ion on sympathetic and parasympathet ic activit y in humans. 
Am J Physiol Regul Integr Comp Physiol. 2008;295(3):R874- R880.
https://doi .org/10.1152/ajpregu.[ZIP_CODE].2008
Council on Science and Public Heal th. Report of the Council on Science and Public Healt h: is 
obesit y a disease? (Reso lution 115 -A-12). Report number: 3-A-13. 2013. Accessed May 21, 
2020. https://www.ama -assn.org/si tes/ama -assn.org/files/corp/media -browser/public/about-
ama/counc ils/Council%20Reports/council -on-science -public -healt h/a13csaph3.pdf
Danne T, Philotheou A, Goldman D, et al. A randomized trial co mpar ing the rate of 
hypoglycemia –assessed using continuous glucose monitoring –in 125 preschool children 
with type 1 diabetes treated with insulin glargine or NPH insulin (the PRESCHOOL study ). 
Pediatr Diabetes . 2013;14(8):593 -601. https://doi.org/10.1111/pedi.[ADDRESS_272273] fro m clinical safet y to reducti on of  cardi ovascular 
complicat ions. Diabetes. 2018;67(9):1710 -1719. https://doi.org/10.2337/dbi18-[ADDRESS_272274] T, et al.Once -weekly dulaglutide versus once -daily liraglut ide 
in metformin-treated pati ents wi th type2 diabetes (AWARD -6): a randomised, open -label, 
phase 3, non -inferiorit y trial. Lancet . 2014;384(9951):1349 -1357 . 
https://doi .org/10.1016/S0140 -6736(14)[ZIP_CODE]-4
[FDA]. FDA requests the withdrawal o f the wei ght-loss drug Belviq, Belviq XR (lorcaserin) 
from the market: potenti al risk of cancer outweighs the benefit s. Published 14 January  2020. 
Accessed June 5,2020. https://www.fda.gov/media/135189/downl oad
[FDA]. Guidance for industry : devel opi[INVESTIGATOR_134072]. Published February 
2007. Accessed May 22, 2021. https://www.fda.gov/media/[ZIP_CODE]/download .
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
114Frias JP, Nauck MA, Van J, et al. Efficacy and safety  of LY3298176, a novel dual GIP and 
GLP -[ADDRESS_272275], in pat ients with type 2 di abetes: a randomized, placebo -controlled and 
active co mparator -controlled phase 2 trial. Lancet. 2018;392([ZIP_CODE]):2180- 2193. 
https://doi .org/10.1016/S0140 -6736(18)[ZIP_CODE]-8
Gerstein HC, Co lhoun HM, Dagenais GR, et al. Dulaglut ide and cardiovascular outcomes in type 
2 diabetes (REWIND): a double -blind, randomized placebo -controlled trial. Lancet. 
2019;394([ZIP_CODE]):121- 130. https://doi.org/10.1016/S0140 -6736(19)[ZIP_CODE] -3
Giorgino F, Benroubi  M, Sun JH, et al. Efficacy  and safet y of once weekly  dulaglut ide versus 
insulin glargine in pat ients with type2 diabetes on met formin and glimepi[INVESTIGATOR_14956] (AWARD -2). 
Diabetes Care . 2015;38(12):2241- 2249. https://doi.org/10.2337/dc14 -[ADDRESS_272276] . 
1992;16(6):397 -41.
[HHS] Hum an and Health Services. Physical Act ivity Guidelines for Am ericans. Published 16 
September 2020 . Accessed May 24, 2021 .https://www.hhs .gov/fi tness/be- active/physical -
activit y-guidelines -for-americans/index.ht ml.
Holman RR, Bethel MA, Mentz RJ, et al. , EXSCEL Study  Group. Effects of once -weekly  
exenatide on cardiovascular outcomes in t ype 2 diabetes. NEngl JMed.2017;377(13):1228 -
1239. https://doi.org/ 10.1056/NEJMoa1612917
Jendle J, Grunberger G, Blevins T, et al. Efficacy and safet y of dulagl utide in the treatment of 
type2 diabetes: a com prehensive review of the dulaglut ide clinical data focusing on the 
AWARD phase 3 clinical trial pro gram. Diabetes Metab Res Rev . 2016;32(8):776 -790. 
https://doi .org/10.1002/dmrr.2810
Koizumi M, Takada T, Kawarada Y, et al. JPN Guidelines for the management of acute 
pancreat itis: diagnostic criteria for acute pancreatitis. J Hepatobiliary Pancreat Surg . 
2006;13(1):25 -32. https://doi.org/10.1007/s00534 -005-[ADDRESS_272277] ionnaire (IWQOL -Lite clinical tri als versi on): 
resul ts from two qualitat ive studies. Clin Obes . 2017;7(5):290 -299. 
https://doi .org/10.1111/cob.[ZIP_CODE]
Kolotkin RL, Williams VSL, Ervin CM, et al. Validation of a new measure of qualit y of life in 
obesit y trials: impact of wei ght on qualit y of life-lite clinical trials versio n. Clin Obes . 
2019;9(3):e12310. https://doi.org/10.1111/cob.[ZIP_CODE]
Lau J, Bl och P, Schäffer L, et al. Discovery  of the once -weekly glucagon -like peptide -1 (GLP -1) 
analogue semaglutide. J Med Chem. 2015;58:73 70-7380.
https://doi .org/ 10.1021/acs.jmedchem.5b00726
Lauby -Secretan B, Scocci anti C, Loomis D, et al; Internat ional Agency for Research on Cancer 
Handbook Working Group. Body  fatness and cancer -viewpo int of the IARC Working Group. 
N Engl J Med. 2016;375(8 ):794 -798. https://doi.org/10.1056/NEJMsr1606602
Lorenz M, Lawson F, Owens D, et al. Different ial effects of glucagon -like peptide -1 receptor 
agonists on heart rate. Cardiovasc Diabetol. 2017;16(1):6. https://doi.org/ 10.1186/s12933-
017-0564 -0
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
115Luppi[INVESTIGATOR_4276], de Wit LM, Bouvy  PF, et al . Overweight, obesit y, and depressio n: a systemat ic 
review and meta -analysis of lo ngitudinal studies. Arch Gen Psychiatry. 2010;67(3):220 -229. 
https://doi .org/10.1001/archgenpsychiatry .2010.2
Marso SP, Bain SC, Conso li A, et al . Sem agluti de and cardi ovascular outcom es in pat ients with 
type 2 di abetes. N Engl J Med. 2016 a;375(19):1834 -1844. 
https://doi .org/ 10.1056/NEJMoa1607141
Marso SP, Daniels GH, Brown -Frandsen K, et al, LEADER Steering Co mmittee, LEADER Tri al 
Invest igators. Liraglut ide and cardiovascular outcomes in ty pe 2 diabetes. N Engl J Med.
2016b;375(4):311 -322. https://doi.org/ 10.1056/NEJMoa1603827
Maruish ME, ed. User’s Manual for the SF -36v2 Heal th Survey. 3rd ed. Linco ln, RI: Qualit y 
Metri c Incorporated; 2011.
Mendis B, Simpson E, MacDonald I, Mansell P. Investigation o f the haemodynamic effects of 
exenatide in healt hy male subjects. Br J Clin Pharmacol . 2012; 74(3) :437-444.
https://doi .org/ 10.1111/j.1365 -2125.2012.[ZIP_CODE].x
Nauck MA, Ni edereichho lz U, Ettler R, et al. Glucagon -like peptide 1 inhibit ion of gastri c 
emptying outweighs its insulinotropic effects in healthy humans .Am J Physiol . 1997 ;273(5 Pt 
1):E981 –988. https:// doi.org/10.1152/ajpendo.1997.273.5.E981
Nauck M, Frid A, Hermansen K, et al. for the and for the LEAD -2 Study  Group. Efficacy  and 
safet y compar ison of liraglut ide, glimepi[INVESTIGATOR_14956], and placebo, all in co mbinat ion with metformin, 
in type2 diabetes: the LEAD (liraglut ide effect and action in diabetes )-2 study . Diabetes Care . 
2009;32(1):84 -90. https://doi.org/10.2337/dc08 -1355
Nauck M. Incretin therapi[INVESTIGATOR_014]: highlight ing commo n features and differences in the modes of 
action of  glucagon -like peptide -1 receptor agoni sts and di peptidyl peptidase -4 inhibitor s. 
Diabetes Obes Metab . 2016;18(3):203 -216. https://doi.org/10.1111/dom.[ZIP_CODE]
Nauck MA, Meier JJ, Schmidt WE. Incretin -based glucose -lowering medicat ions and the risk o f 
acurte pancreatit is and/or pancreatic cancer: reassuring data from cardio -vascular out come 
trials. Diabetes Obes Metab . 2017;19(9):1327- 1328. https://doi.org/10.1111/dom.[ADDRESS_272278] of  semaglut ide on liver enzymes and markers 
of inflammation in subjects with ty pe 2 di abetes and/or obesit y. Aliment Pharmacol Ther . 
2019;50(2):193 -203. https ://doi.org/10.1111/apt.[ZIP_CODE]
OZEMPIC [package insert ].Bagsværd, Denmark: Novo Nordisk; 2017.
Ryan DH, Yockey  SR. Weight l oss and improvement in co morbidity: differences at 5%, 10%, 
15%, and over. Curr Obes Rep. 2017;6(2):187 -194. https://doi.org/10.1007/s13679 -017-0262 -y
SAXENDA [package insert]. Bagsværd, Denmark: Novo Nordisk; 2014.
Scheen AJ. Dulaglut ide for the treatm ent of  type 2 di abetes. Expert Opin Biol 
Ther .2017;17(4):485 -496. https://doi.org/ 10.1080/1 4712598.2017.1296131
Smits MM, Tonneijck L, Muskiet MH et al. Heart rate accel eration with GLP -1 receptor agoni sts 
in type 2 diabetes patients: an acute and [ADDRESS_272279] acebo -
controlled trial. Eur J Endocrinol. 2017;176(1):77 -86.https ://doi.org/10.1530/EJE -16-0507
CONFIDENTIAL Protocol  J2A-MC-GZGI (a)
116Srivastava G, Apovian CM. Current pharmacotherapy  for obesi ty.Nat Rev Endocrinol. 
2018;14(1):12 -24. https://doi.org/10.1038/nrendo.2017.122
Steinberg WM, Buse JB, Ghorbani MLM, et al. LEADER Steering Committee; LEADER Trial 
Invest igators. Amylase, lipase, and acute pancreatitis in people wit h type 2 di abetes treated 
with liraglut ide: results from the LEADER rando mized trial. Diabetes Care.
2017 a;40(7):966-972. https://doi.org/10.2337/dc16 -[ADDRESS_272280] of liraglut ide on amylase, lipase, and 
acute pancreatit is in part icipants wi th overwei ght/obesi ty and norm oglycemia, predi abetes, or 
type 2 di abetes: secondary  analyses of pooled data fro m the SCALE clinical development 
program. Diabetes Care. 2017b;40(7):839 -848. https://doi.org/10.2337/dc16 -[ADDRESS_272281] of  GLP -1 receptor agonists on blood pressure, heart rate and 
hypertensio n amo ng patients with t ype 2 diabetes: a systemat ic review and network meta -
analysis. Diabetes Res Clin Pract. 2015;110(1):26 -37.
https://doi.org/10.1016/j.diabres.2015.07.015
van Bloemendaal L, Ten Kulve JS, la Fleur SE, et al. Effects of glucagon -like pept ide 1 on 
appeti te and body  weight: focus on the CNS. J Endocrinol . 2014;221(1):T1 -T16. 
https://doi .org/10.1530/JOE -13-0414
VICTOZA [package insert]. Bagsvaerd, Denmark, Novo Nordisk, 2017.
WEGOVY [package inser t]. Bagsvaerd, Denmark, Novo Nordisk; 2021.
Werner U, Haschke G, Herling AW, Kramer W. Pharmaco logical profile of lixisenat ide. A new 
GLP -[ADDRESS_272282] for the treatment of ty pe 2 di abetes. Regul Pept. 2010;164:58 -64.
https://doi. org/10.1016/j.regpep.2010.05.008
Weinberg ME, Bac chetti  P, Rushakoff RJ. Frequent ly repeated glucose measurements 
overestimate the incidence of inpatient hy poglycemia and severe hyperglycemia. J Diabetes 
Sci Technol . 2010;4(3):577 -582. https://doi.org/10.1177/193229681000400311
[WHO] World Healt h Organiz ation. WHO STEPS surveillance manual: the WHO STEPwise 
approach to noncommunicable disease risk factor surveillance. Updated January  26, 2017. 
Accessed May  04, 2020. https://www.who.int/ncds/surveillance/steps/STEPS_Manual.pdf
[WHO] World Healt h Organizat ion. Healthy diet. Published 29 April  2020. Accessed 24 May  
2021. https://www.who.int/news -room /fact-sheets/detail/healt hy-diet
[WHO] World Healt h Organizat ion. Physical act ivity and adul ts.Published 26 November 2020.
Accessed 24 May  2021 .https://www.who.int/news -room /fact-sheets/detail/physical -activity
Wing RR, Lang W, Wadden TA, et al.; Look AHEAD Research Group. Benefit s of m odest 
weight loss in improving cardiovascular risk factors in overweight and obese individuals with 
type 2 di abetes . Diabetes Care . 2011; 34(7):1481‐1486. https://doi.org/ 10.2337/dc10-2415
Leo Document ID = 2c5219df-278a-4d71-8c80-d8183086e23c
Approver:
Approval Date & Time: 27-Sep-2021 17:15:04 GMT
Signature [CONTACT_32869]: Approved
Approver: 
Approval Date & Time: 27-Sep-2021 18:31:49 GMT
Signature [CONTACT_32869]: Approved
[COMPANY_003]
[COMPANY_003]